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I n  v i t r o  S u s c e p t i b i l i t y  T e s t i n g  o f  F i l a m e n t o u s  F u n g i  a n d  
D R U G  IN T E R A C T IO N  M O D E L IN G  O F A N T IF U N G A L  D R U G S
J o s e p h  M e l e t i a d i s 1, J o h a n  W . M o u t o n 2, J a c q u e s  F. G. M . M e is 2, a n d  P a u l  E. V e r w e i j 1
Department o f  Medical Microbiology, University Medical Center Nijmegen1, and Department o f  Medical Microbiology and
Infectious Diseases, Canisius- Wilhelmina Hospitaf, The Netherlands
G iven th e  high m o rta lity  of invasive infections caused by filam entous fungi and  the  
lim itations of cu rre n t an tifungal th e rap ies , th e  in te re st in com bination  th e ra p y  is increasing . 
H ow ever, assessm ent of the  n a tu re  and  the  in tensity  of an tifungal in terac tions depend  on th e  in 
v itro  m ethodology used as well as on th e  ap p ro ach  chosen to  analyze th e  data . R eg ard in g  th e  in 
v itro  m ethodology m any  variab les in an tifungal susceptib ility  testing  of filam entous fungi such 
as the  inoculum , incubation  conditions, m edium , and  m in im al in h ib ito ry  concen tra tion  (M IC ) 
endpo in ts rem ain  u n stan d ard ized . T he p roposed  s ta n d a rd  m edium  R P M I 1640, a lthough  it 
p rovides rep ro d u cib le  resu lts, inadequate ly  su pports  th e  grow th of m any  fungi and  is considered 
less op tim al fo r detection of am pho teric in  B resistance. V isual d e term ina tion  of th e  M IC s is 
subjective and  does no t allow precise quan tifica tion  of fungal grow th. D eterm ination  of the  
M IC s could be facilita ted  using co lorim etric  assays based  on th e  conversion of te trazo lium  salts. 
These salts a re  converted  to  colored  fo rm azan  derivatives by enzym es w ith  dehydrogenase 
activ ity  and  th e re fo re  can be used as ind icato rs of reducing  system s. R egard ing  th e  assessm ent 
of d ru g  in teractions, th e  s ta n d a rd  ap p ro ach  in m edical m icrobiology is the  calculation  of the  
frac tio n al in h ib ito ry  concen tra tion  index despite its d raw backs. A lterna tive  app roaches of d ru g  
in terac tio n  m odeling consist of response su rface  app roaches an d  fully p a ram e tric  m odels w hich 
in co rp o ra te  m o d ern  concepts of statistica l an d  regression analysis an d  p rov ide an  objective and  
q u an tita tiv e  tool fo r th e  study of d ru g  in teraction .
Systemic infections caused by filamentous fungi 
can be differentiated to two groups; endemic and 
opportunistic mycoses. True hum an pathogens 
(dimorphic fungi) are responsible for endemic mycoses, 
which are able to cause infections even in individuals 
with normal host defense and which have their habitat 
in specific geographical areas (71). Less virulent and 
less well-adapted organisms (opportunists) are 
responsible for opportunistic mycoses, which cause 
infections in debilitated and immunocompromised hosts 
and which are distributed worldwide. In the last two 
decades a dramatic increase in the latter infections has 
been observed and incidence rates up to 36% have been 
reported in particular patient populations such as bone 
m arrow transplant recipients (16, 21). This increase was 
associated with an increasing num ber o f  immuno­
compromised individuals mainly due to organ 
transplantation, HIV infection and cancer where 
cytotoxic and immunosuppressive therapies are used 
(19, 57, 78). Corticosteroid therapy, diabetes and other 
underlying diseases were also recognized as 
predisposing factors (58). The m ost commonly 
identified pathogens were A spergillus species, 
especially A spergillus fumigatus. A growing num ber o f  
uncom m on organisms have been implicated in invasive 
hum an infections including members o f  the 
Zygom ycota (Rhizopus spp., M ucor  spp., and A bsidia  
spp.), Fusarium  spp. and Scedosporium  spp. (28, 77).
Since the immune system o f  immunocompromised 
patients m ay be suppressed for long periods, antifungal 
therapy is employed to prevent and/or control invasive 
fungal infections (79). Am photericin B and itraconazole 
are licensed drugs to treat invasive infections caused by 
filamentous fungi although new drugs are under 
investigation (34). However, the m ortality rates o f  these 
infections remain as high as 95% despite the use o f 
aggressive antifungal chemotherapy (78). Furthermore, 
there are several drawbacks to the currently available 
antifungal agents such as the high toxicity, the low level 
o f  penetration into some tissues, the irregular 
pharmacokinetic profile, the drug interactions, and the 
emergence o f  resistance (35). Given these limitations, 
new approaches for the managem ent o f  invasive 
infections caused by filamentous fungi are warranted. 
Combination therapy m ight be an effective approach 
(49) since new azoles with better pharmacokinetic 
profiles (i.e. voriconazole and posaconazole) and drugs 
with novel antifungal actions (i.e. echinocandins, 
nikkomycin) are under investigation. The increased 
arsenal o f  antifungal agents facilitates the num ber o f  
possible combinations and the probability o f  synergistic 
interactions (47).
Combination therapy has been shown to be 
beneficial for several difficult-to-treat infections such as 
HIV (http//:www.hivatis.org) and mycobacterial 
infections (42) which do not respond well to single-
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Table 1. NCCLS guidelines for antifungal susceptibility testing of conidium forming filamentous fungi
Param eter NCCLS M-38P
Suitability
Format
Inoculum
Inoculum standardization
Incubation conditions 
Duration of incubation
Solvent 
T est medium 
Endpoint
Conidium- and spore forming fungi 
Microdilution, two-fold dilution scheme 
Conidial suspensions of 0.4 x 104 -  5 x 104 CFU/ml 
Spectrophotometric adjustment at 530 nm
68-70% transmittance (T) for Scedosporium spp. and Rhizopus spp.
78-80% T for the remaining fungi incl. Aspergillus spp.
35oC in ambient conditions
24 h (Rhizopus spp.), 72 h (Scedosporium spp.)
48 h (most fungi including Aspergillus spp. and Fusarium spp.)
Dimethylsulfoxid for amphotericin B and all azoles, 1% of final concentration 
RPMI 1640 buffered at pH 7.0 with 0.165 M 3-N-morpholinopropanesulfonic acid 
Lowest drug concentration with absence of visible growth (for amphotericin B) or 
with prominent growth reduction (50%) from control (for azoles)
drug therapy either due to lack o f  efficacy or rapid 
emergence o f  resistance. Combination therapy has also 
been proven to be beneficial in clinical mycology such 
as the combination o f amphotericin B and flucytosine 
for the treatm ent o f  cryptococcal meningitis (35, 62). 
However, adverse events can either eliminate or reverse 
the benefits o f  combination therapy by worsening the 
clinical outcome (43, 44). The problem with the testing 
o f  the toxicity and superior efficacy o f  a given 
combination compared to m onotherapy in the clinical 
setting is that large, time-consuming and expensive 
clinical trials are required in order to have sufficient 
pow er to show significant differences. Although animal 
models m ight predict efficacy and toxicity in humans, 
current models are often inappropriate since antifungal 
drugs exhibit different pharmacokinetic characteristics 
compared with humans (61). However, recently models 
have been published that help to characterize the 
pharmacodynamic profile o f  antifungal agents (2). 
Nevertheless, in vitro systems are needed in order to 
help to predict drug interaction in clinical practice using 
the fungal strain that caused the infection. Furthermore, 
in vitro data, although they are obtained from simplified 
systems, could be combined with in vivo data in order 
to design proper, feasible, and less costly clinical trials 
by optimizing for instance the dosing o f  regimens in 
combination (18, 22).
However, assessing the nature and the intensity 
o f  drug interactions in vitro depends both on the 
m ethodology used (50) as well as on the approach used 
to analyze the results (6). Although different 
methodologies, such as agar dilution, disc diffusion, 
and Etest have been used for testing the in vitro
interaction o f  antifungal drugs (4, 13, 47, 48, 53, 56, 60, 
72), the m ost common approach in antifungal 
susceptibility testing is the m icrodilution checkerboard 
technique. According to this technique a serial dilution 
o f  drug A is combined with a serial dilution o f drug B 
(including zero concentrations o f each drug) in small 
volumes o f  broth medium in m icrotiter plates in such a 
way to obtain a two-dimensional checkerboard (41). 
Conclusions are then inferred by comparing the growth 
in the wells containing single drugs with the growth in 
the wells where the drugs are combined.
1.1 I n  V it r o  Su s c e p t ib il it y  T e st in g  
o f  F il a m e n t o u s  F u n g i
Despite the considerable progress in in vitro 
antifungal susceptibility testing (AST) o f  moulds 
leading to the publication o f  the M -38P standard 
proposed by the USA National Committee o f  Clinical 
Laboratory Standards for antifungal susceptibility 
testing o f  conidium forming fungi (55), several 
variables remain unstandardized. The M-38P method 
specifies the inoculum size and preparation, incubation 
time and temperature, the format o f  the methodology, 
test medium, and assessment o f the minimal inhibitory 
concentration (MIC) endpoint for various drugs (Table 
1). Although the large differences between the different 
methodologies used previously, are now eliminated and 
more reproducible results are obtained with this method 
(24, 25), the appropriateness o f some parameters is 
questionable given the absence o f  clinical correlation o f 
the results.
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Although it is more convenient to use conidial 
suspensions as an inoculum for AST, the invasive forms 
o f  filamentous fungi are hyphae, w hich exhibit higher 
MICs compared to conidia (24, 38). An inoculum o f 
104 CFU/ml seems to be satisfactory although inoculum 
effects (increased MICs with higher inocula) suggest 
specific adjustments based on the organism tested and 
the drug. In addition higher inocula m ay facilitate the 
detection o f  resistant strains (20, 24, 30). According to 
the reference method, the incubation period required for 
obtaining the inoculum takes several days and the 
technique advocated to harvest the conidia or spores 
results in an inoculum that may contain also hyphal 
fragments which could give variable MIC results (15, 
54). Spectrophotometric adjustment o f  the inocula 
provides a fast and reproducible way to obtain inocula 
within a range o f  1 logi0 CFU/ml (27) but the 
transmittance measured m ight be affected by the 
proportion o f  hyphal fragments present in the inoculum 
(24, 54). Furthermore, differences in color and size (64) 
o f  conidia and fungal spores affect spectrophotometric 
reading resulting in a w ider range o f  CFU/ml compared 
to counting with a hem acytometer (59).
Regarding the incubation conditions o f  AST, 
although tem peratures o f  35-37oC correspond to body 
tem peratures and appear adequate for AST, filamentous 
fungi seem to grow better at lower tem peratures i.e. 25- 
30oC (66, 67). Incubation periods were established 
arbitrary based on the presence o f visual growth, which 
is different for various species, w ithout considering the 
dynamic nature o f fungal growth. Prolonged incubation 
results in higher MICs (3, 24, 30) and different levels o f 
reproducibility may be achieved with different 
incubation periods (51). The degree o f  differentiation 
between resistant and susceptible strains is variable 
with different incubation periods (20).
Although the microdilution format is less 
troublesome and generates similar results compared to 
the well-evaluated m acrodilution method (26, 65), it is 
more sensitive to evaporation and assessment o f 
fungicidal activities is problematic (67). The synthetic 
and fully defined medium RPM I 1640 buffered at pH
7.0 is used for AST, supports the growth o f  different 
fungal species and generates reproducible results. 
However, the inability o f  this medium to distinguish 
am photericin B-resistant A spergillus and Candida  
strains from susceptible ones (46, 68) and the poor 
growth o f  dermatophytes and Cryptoccoccus  
neoform ans (24, 32), raises questions concerning the 
appropriateness o f  this medium for susceptibility testing 
o f  filamentous fungi given that no extensive evaluation 
has been reported that addresses the suitability o f  this 
medium for these fungi. Better growth was achieved by 
supplementing RPM I 1640 with extra glucose for 
C andida  strains or by using alternative nutrient media 
such as yeast nitrogen base medium for C. neoformans.
O ther m edia used for fungi include Antibiotic M edium
3, Sabouraud’s medium, and SAAM-F. Although the 
use o f  one standard medium for in vitro susceptibility 
testing o f  all fungi is desirable, the diversity in growth 
rate and nutrient requirements among members o f  the 
fungal kingdom and the differences in properties o f 
various antifungal drugs suggest that the use o f 
different m edia will be inevitable. The medium pH  as 
well as the buffering capacity is also critical factors for 
AST since they may alter the action o f  some antifungal 
drugs (69).
The MIC determ ination based on visual 
observation simplifies the M -38P since special 
equipm ent is not required. However, this introduces 
subjectivity and variability in methodology and 
precludes the precise quantification o f  fungal growth. 
The latter is complicated by the non-homogenous 
growth o f  moulds in liquid m edia and the fungistatic 
activity o f  azoles, which inhibit the growth over a range 
o f  drug concentrations. Thus automation o f  AST for 
filamentous fungi is impossible and detailed 
information about the antifungal effect-drug 
concentration relationship is not obtained. In order to 
avoid these problems alternative methodologies have 
been proposed based on spectrophotometric, 
radiometric, direct microscopic, colorimetric, flow 
cytometric, and fluorescent assays (14, 69, 70). 
However, some o f  them  are semi-quantitative (Alamar 
blue oxidation-reduction indicator dye), lack sensitivity 
(spectrophotometric), are time-consuming (measuring 
the rate o f  elongation o f  germ tubes), potentially 
hazardous (use o f  radioactive substances), or require 
expensive equipment (flow cytometer) thus limiting 
their use in routine clinical laboratories. Colorimetric 
assays based on the reduction o f  tetrazolium  salts have 
many advantages and have found many applications in 
various fields including the susceptibility testing o f 
cancer cells (73), viruses (45), parasites (17), bacteria 
(29) as well as yeasts (40).
Tetrazolium salts are heterocyclic organic 
compounds that got their name from the four nitrogens 
o f  the five-mem ber unsaturated ring that contains a 
heteroatom. The m ost characteristic and important 
property o f  this class o f  dyes is that they are reduced 
into highly colored formazans with m ild reduction 
giving rapid and strong reactions. Formazans are 
produced when the tetrazolium  salts receive electrons 
from the hydrogen transport system, catalyzed by 
enzymes, substituting the natural final acceptor 
(oxygen) in the biological redox process or non- 
enzymatically from artificial electron transporters 
(phenazine methosulfate, menadione) (Fig. 1). This 
reaction takes place inside m itochondria or other 
intracellular sites with dehydrogenase activity o f  intact 
cells where tetrazolium  salts can penetrate rapidly 
depending on the molecular size. Since the tetrazolium -
13
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■ Biosynthetic pathway ...................................................................................................................................
D EH Y D RO G EN A SE------ ► N AD PH 2 hydrogen transport system ^  HYDROXYLATION
h ▼ ▼ t ▼
PMS or M enadione------ ► Tetrazolium salts ------ ► FORM AZAN
Figure 1. Generalized scheme showing the pathways leading to reduction of tetrazolium salts to their formazan 
derivatives. Dehydrogenases are cellular enzymes, which oxidize different biomolecules by reducing the cofactor 
NADP+ to NADPH2. From NADPH2, e" are transferred through the hydrogen transport system (cytochromes) to O2 
the oxidation of which causes the hydroxylation of other substrates. Tetrazolium salts can interact with components 
of hydrogen transport system and can be reduced to formazan derivatives by receiving e" from carriers of this 
system (flavins) but not directly from NADPH unless an electron-coupling agent (PMS; phenazine methosulfate or 
Menadione) is added. NADPH2 is oxidized back to NADP+ by cellular enzymes called diaphorases.
formazan reaction assesses dehydrogenase activity, 
tetrazolium  salts have been used as indicators o f 
reducing systems with a num ber o f  applications in 
chemistry and biology including susceptibility testing 
(1).
A lthough some o f  the above mentioned factors o f 
AST o f  filamentous fungi have little effect on the final 
results, their effect may increase when all these factors 
are combined simultaneously (67). This effect will be 
amplified when filamentous fungi are tested against 
combinations o f  antifungal drugs where the drug- 
fungus interaction becomes more complicated with the 
addition o f  one or more drugs. The analysis o f  such a 
system is difficult not only from a methodological point 
o f  view but also when the results are attempted to be 
evaluated in order to assess the nature and the degree o f 
interaction taking place among the antifungal drugs 
against the fungus.
1.2 Dr u g  In t e r a c t io n  M o d e l in g
Assessing the nature and the degree o f  drug 
interactions is a critical challenge and a debated area o f 
chemotherapy. The importance o f  drug interactions in 
chemotherapy is related with the clinical outcome that 
can be improved or worsened when positive or negative 
drug interactions, respectively take place (44, 52). Drug 
interactions are o f  great interest particularly in 
antifungal chemotherapy given that treatm ent is 
initiated in patients who simultaneously receive a 
variety o f  anticancer, immune-suppressive, antiviral or 
antibacterial drugs, which increases the possibility for 
such interactions to take place. Drug interactions may 
occur at different levels i.e. absorption, metabolism, 
excretion o f  drugs altering their pharmacokinetic and 
finally their pharmacodynamic profiles (8, 39, 53) 
before the drugs reach the site o f  infection and exhibit 
their antifungal effects (Table 2). Even then drug 
interactions m ay occur at the cellular (fungus) (33, 81) 
and molecular (receptors) level (4) before an antifungal
effect occurs and at the population level before growth 
is arrested. In vitro susceptibility tests attempt to assess 
the drug interactions at this level.
Although different term s and classifications can 
be found in the literature in order to describe drug 
interactions, three classes can be recognized; 1. positive 
interaction or synergy which originates from the Greek 
w o rd s  ctuv (p lu s) an d  epyo  (w o rk ) an d  m e an s  w o rk in g  
together (synonyms are potentiation, augmentation, 
sensitization, supradditiveness). 2 . negative interaction 
or antagonism, which means working against each other 
(synonyms are depotentiation, desensitization, infrad" 
ditiveness, negative synergy) and 3. zero-interaction, in 
which the drugs do neither of the above do not interact 
and therefore the effect of such a combination is 
precisely what is expected (synonyms are additivity, 
indifference, independence, autonomy). The definition 
of the latter has a central position in drug interaction 
theories since synergy or antagonism can be defined as 
departures of the zero interaction and thus a 
combination is deemed synergistic or antagonistic when 
its effect is greater or less, respectively than that 
expected from the zero interaction theory.
For the calculation of the expected effect of zero 
interaction various theories were developed based upon 
m echanistic and empirical models (7). The former 
models which are based on the mechanism o f  action o f 
drugs for calculating the expected effects (11, 12) 
require a full understanding o f  the mode o f  actions o f 
the drug, are dependent on the current state o f 
knowledge and exclude analysis o f  the interaction o f 
drugs which modes o f  action are not known. Even i f  the 
mechanisms were fully understood at the molecular 
level, the effect o f  a zero interactive combination might 
be different than expected based on these theories since 
the action o f  drugs m ight be different at the cellular 
level (7) and at the population level (5) as is the case for 
susceptibility tests. The empirical mechanism-free 
models rely on concentration-effect curves o f individual 
drugs on which based the effect o f zero interaction is 
calculated without making assumptions about the
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Table 2. Classification of drug interactions
I. Prior to administration
II. Drug absorption
Within the gut lumen 
By altering gut motility 
By altering gut flora 
Within the gut wall
III. Protein-binding
IV. Drug metabolism
Stimulation
Inhibition
V. Drug excretion
Changes in urine pH
Competition for active renal tubular excretion 
Fluid and electrolyte changes
VI. Interactions at the site of infection
Physical conditions (pH, oxygen concentration) 
Population level (heteroresistant strains)
Cellular level (influx pumps)
Molecular level (receptor sites)
Adapted from Breckenridge (8).
m echanism o f  action. Among all theories described in 
the literature two are distinguished as reference models, 
the Bliss independence and the Loewe additivity 
theories.
Bliss independence implies that two drugs do not 
cooperate physically or chemically or biologically i.e. 
each drug acts independently from the other (36). In 
this case the effect (S0) o f  a zero interactive 
combination would be equal with the product o f  the 
survival fractions SA and SB o f  its constituent doses o f 
drug A and B when acting alone, respectively giving 
the equation:
So = Sa x  Sb [1].
I f  the combination o f  a dose o f  drug A and a dose 
o f  drug B results in a survival fraction o f  SA+B greater 
than the S0 antagonism is deemed while i f  it is smaller 
than S0 synergy is claimed. The equation [1] can be 
derived from the probability theory. Given that the two 
drugs do not interact, their actions m ay be treated as 
statistically independent events (5). Thus, i f  P(A) and 
P(B) are the probabilities o f  independent event A and 
B, the probability o f  at least one o f  event A or B 
occurring P (A uB ) is
P (A uB ) = P(A) + P(B) - P(A) x  P(B) [2].
Now, let P(A) and P(B) be the action o f  two 
drugs A and B alone (which in case o f susceptibility 
tests corresponds with growth inhibition IA and IB 
caused by each drug, respectively) and the P (A uB ) the
action o f  a zero interactive combination (I0) the 
following equation is derived:
I0 = IA + IB + IA x  IB [3].
Since it holds that S = 1 - I [4] where S is the 
percentage o f  growth and I the percentage o f  inhibition, 
the equation [3] is rewritten as
1 - So = (1 - Sa) + (1 - Sb) + (1 - Sa) x  (1 - Sb)
which after resolution results in equation [1]. Equation 
[1] is also derived by the following paradigm. Let us 
consider a drug A  that inhibits the growth o f  a fungal 
population for 30% (= IA) and a drug B that inhibits the 
growth for 50% (= IB). I f  the growth o f the control is 
designated as 100%, the drug A alone would reduce the 
growth to 70% (= SA). If  the drug B now added the 
growth would be reduced further to 35% (= S0 and 
based on equation [4] I0 = 65%) i f  the first drug did not 
affect the action o f the second drug. Likewise i f  drug B 
is used alone, the growth would be reduced to 50% 
(= SB) and the addition o f  drug A would reduce it to 
35% again. Using the values in the brackets equation 
[1] and [3] come true (80).
The other candidate for the reference zero 
interaction theory is the Loewe additivity, which is 
based on the concept that a drug cannot interact with 
itself by definition. Therefore, the effect o f  a sham 
combination o f  one drug with itself in any arrangement 
o f  concentrations is what would be expected from the 
concentration effect curve o f  the drug selected, so such 
a combination is zero-interactive by construction. This 
m ust hold irrespective the shape o f the concentration- 
effect curve o f  the drug and the type o f  the effect 
measured. Loewe additivity is described by the 
following equation:
1 = dA/DA + dB/DB [5]
where dA and dB are the concentrations o f  the drugs A 
and B in a combination which elicits a certain effect 
and DA and DB the iso-effective concentrations o f  the 
drugs A and B when acting alone. W hen the right part 
o f  the equation [5] is less than 1, synergy is claimed 
while when it is greater than 1, antagonism is 
concluded. The pow er o f equation [5] is supported by 
the following paradigm. Lets consider a drug A, 1 mg 
o f  which inhibits the growth by 30% and 2 mg by 50%. 
If  the 2 mg powder is split into two portions o f  1 mg 
and labeled as drug A 1  and drug A2, the combination o f 
1 mg o f  drug A 1  plus 1 mg o f  drug A 2 would have the 
same effect as 2 mg o f  drug A 1  or drug A2 alone which 
actually is the effect o f  drug A i.e. 50% o f  inhibition 
based on the concentration-effect curve o f  drug A. Such 
a combination can only be zero interactive. Thus, for
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Figure 2. Layouts of the microdilution checkerboards (i) and isobolograms (ii) for a synergistic (A), additive/indifferent (B) 
and antagonistic (C) interaction between voriconazole and terbinafine. The percentages of growth at each combination of the 
two drugs are presented (shadow area indicates combination with higher than 50% of growth) together with the SFICs 
calculated for the iso-effective combinations (arrows). The underlined SFICs represent the minimum (for A and B) and 
maximum (for C) SFIC and correspond to the FIC indices. Isobolograms were also constructed (graphs on the right hand) by 
plotting the concentrations of the two drugs showing the same effects as the effect at the MICs. Dashed lines represent the 
cutoffs of 0.5 and 4 for synergy and antagonism respectively.
the zero-interactive combination o f 1 mg o f  drug Ai 
(= dA) and 1 mg o f  drug A 2 (= dB) iso-effective with 2 
mg o f  drug A 1 (DA) or drug A 2 (DB), the equation [5] is 
true.
The graphical representation o f  equation [5] is a 
straight line (additivity line) which in case o f  
susceptibility tests connects the individual MIC o f  drug 
A with the individual MIC o f  drug B as well as all iso­
effective combinations o f  the two drugs in a graph 
(isobologram) where the two axes are the concen­
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trations o f the two drugs arithmetically scaled. Synergy 
is indicated when the line which connects iso-effective 
concentrations (isobols) concave up (Fig. 2Aii) above 
the additivity line (Fig. 2Bii) and antagonism when the 
isobols concave down (Fig. 2Cii).
However, the validity o f  both theories is not 
undisputed. The equation o f  the drug actions with 
statistically defined events and their probabilities in 
Bliss independence theory is questioned particularly for 
com plex systems like cells or populations o f  cells given
INTRODUCTION
the high degree o f  integration and interaction. 
Therefore, it was suggested that Bliss independence 
should be applied only in simple systems like single 
enzymes and simple biochemical pathways. Further­
more, using the paradigm o f  the sham combination o f 
two doses o f  the same drug, equation [1] holds only 
when the concentration-effect curves o f  the individual 
drugs follow log-linear pattern, otherwise paradoxical 
results are obtained (5, 7). On the other side, Loewe 
additivity implies that drugs act similarly at the same 
biochemical site, which is a rare phenomenon, or that 
the concentration-effect curves o f  the drugs are the 
same and therefore it should not be applied when two 
drugs have different concentration-effect curves. Since 
neither model can be invalidated based on mechanistic 
explanations in com plex systems such as cells or 
populations o f cells, both models are used to assess 
drug interactions (36).
Although various approaches have been used for 
assessing the in vitro interaction o f  antimicrobials, the 
m ost common approach in m edical m icrobiology and 
particularly for antifungal drug interaction studies is the 
calculation o f  the fractional inhibitory concentration 
index (FICi). The FICi model is a Loewe additivity 
based model, which is described by the following 
equation:
C comb p combA '■^B
SFIC = FICa + FICb = ----A------- + — B--------
MICAalone MICBalone
where CAcomb and CBcomb are the concentrations o f  the
drugs A and B at the iso-efective combinations and 
M ICAalone and MICBalone represent the concentrations o f 
the drugs A and B when acting alone (41). Given that in 
antimicrobial susceptibility testing a two-fold dilution 
scheme is followed, combinations are assess as 
synergistic when the SFIC<0.5, additive when 
SFIC>0.5 and <1, indifferent when SFIC>1 and <4 and 
antagonistic when SFIC>4 (23) (Fig. 2). Among all 
SFICs calculated for a data set, the FICi corresponds to 
the lowest SFIC when synergy is present or to the 
highest SFIC when antagonism is pre-sent and 
expresses the degree o f  bowing o f  the isobols.
The majority o f  in vitro antifungal combinations 
published in the literature were analyzed with this 
model. However, controversial results can be obtained 
depending on the parameters used to assess the 
antifungal interaction, even when the same m ethodo­
logy was employed. Factors such as the level o f  
antifungal effect (MIC endpoint), the way o f  reading 
the MICs, the analysis o f  the results o f  individual data 
sets or replicates, experimental errors, and interpre­
tation o f  FIC indices (FIC endpoints) can influence the 
final conclusions (62).
Experimental response surface
Theoretical Bliss independence response; surCace
Itra c o n a z o le  (m g/l)
Figure 3. Three-dimensional analysis of interaction between 
amphotericin B and itraconazole based on the model of 
Prichard et al. (63). The subtraction of the experimental 
response surface from the theoretical Bliss independence 
response surface (the latter was calculated based on the 
concentration-effect relationships of the single drugs and 
the equation [1]) yields an interaction surface with a mosaic 
of statistically significant (as evaluated using replicates) 
synergistic and antagonistic combinations above and below 
the 0 plane (independent combinations), respectively.
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Alternative models for assessing drug inter­
actions have been developed based on response surface 
approaches that emphasize the three dimensional nature 
o f  drug interactions in contrast with the m ono­
dimensional FICi (9, 10, 31, 64, 74-76). W ith these 
approaches, the dependent variable such as the drug 
effect (i.e. m easured % o f  growth) is related to any drug 
combination, thus generating a surface when this 
relationship is plotted three dimensionally (Fig. 3). This 
so called response surface is then compared with the 
zero interaction surface obtained based on the 
concentration-effect curves o f  the single drugs. Synergy 
is recognized when the experimental response surface is 
below the zero interaction surface and antagonism is 
recognized when the response surface is above the zero 
interaction surface. These approaches were further 
developed incorporating regression analysis for 
modeling the concentration-effect relationships and 
statistical analysis for the estimation o f  the significance 
o f  the departure from the zero interaction. Such a model 
is developed by Prichard et al. (62) based on the Bliss 
independence zero interaction theory. The observed 
effect (% o f  growth) o f a particular combination o f  the 
two drugs is subtracted from the effect o f  the zero 
interaction, estimated for this combination, using 
equation [1] where EA and EB are the observed effects 
(or fitted effects, i f  regression analysis is used for 
modeling the concentration-effect curves) o f  the two 
drugs alone. This difference is calculated for all 
combinations o f  the two drugs and plotted three 
dim ensionally where the volumes above and below the 
0 plane (zero interaction) indicate the synergistic or 
antagonistic combinations, respectively. W hen 
replicates are performed the results can be evaluated 
statistically (64) (Fig. 3).
M odern approaches o f  drug interaction modeling 
relying on fully param etric response surface models that 
are fitted to the entire experimental response surface 
(Fig. 4). These models incorporate interaction para­
meters, which indicate both the nature and the intensity 
o f  the interaction for all combinations o f  two drugs over 
the concentration range o f  both drugs and importantly 
include the uncertainty o f  the estimates taking into 
account the variation o f the data. Such a model is 
developed by Greco et al. (37) based on the Loewe 
additivity zero interaction theory and is described by 
the following equation:
1 = -
dA dB
IC- i  e  y /mA TP /  e  y /mBV Econ - E )  IC-B ^  Econ - E )
[6]
dA dB
+ a
/  E \  0-5(1/mA+ 1/m-  
IC50,A 1 C5 0,B ( E  _ E )
Figure 4. Modeling the interaction between voriconazole and 
terbinafine based on the fully parametric response surface 
model described by Greco et al. (37). The panels A, B, and C 
show the effect of the interaction parameter a  relative to zero 
interaction response surface. In each of the three panels the 
gray surfaces represent the zero interaction response surfaces 
as obtained with the equation [6] using values for Econ=100, 
IC5o,a=4, IC50,b=4, mA= -1 , mB= -1. The white balls indicate 
the data obtained with a=50 (synergy, panel A), a=0 (no 
interaction, panel B) and a= -0.2 (antagonism, panel C).
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where dA and dB are the concentrations o f  drug A and 
drug B, respectively in a combination (independent 
variables), E  is the percentage growth at this 
combination (dependent variable), IC50,A and IC50,B are 
the concentrations o f  the drug A and drug B result in 
50%  o f  the growth control Econ when acting alone and 
mA and mB are the slopes (Hill coefficients) o f the Emax 
model [sigmoid curve that is described by the equation 
E = Emax x  (D/IC50)m/(1 + D/IC5o)m]. The equation [6] is 
derived from equation [5] where DA and DB are 
obtained from the Emax model assuming that this model 
is an appropriate model o f  the concentration-effect 
curves o f  each drug alone. The third term  in the right 
part o f  the equation [6] includes the interaction 
param eter a . In contrast with equation [5], which 
describes only additive interactions, equation [6] 
describes all types o f  interactions. The drug interaction 
is synergistic when a  is positive, antagonistic when a  is 
negative, and additive when a  is 0. Equation [6] is not 
derived from a biological theory but is rather an 
empirical equation that often matches the shape o f  the 
response surface o f  experimental data. All estimates o f 
the parameters o f  equation [6] are obtained with a 
measure o f  uncertainty, usually the 95% confidence 
interval deriving from the results o f  regression analysis. 
M oreover, by using the variation in measurem ent as 
input in the fitting procedure, the errors o f  the estimates 
are taken into account as well.
Fig. 5 represents a schematic diagram proposed 
as the general approach to assess the nature and the 
intensity o f  drug interactions (36). After choosing the 
m ost appropriate model (sigmoid, exponential, 
exponential with shoulder curve) to describe the 
concentration-effect curves o f  each drug alone (Step 1), 
and a data variation model (i.e. normal or poisson 
distribution) in order to take into account random 
variation caused for instance by biological variability or 
experimental errors (Step 2), the experimental data are 
compared with the predicted data o f  jo in t action from 
the zero interaction theory (left side o f  Fig. 5) or a full 
combined action model is fitted to all experimental data 
at once and interaction parameters are estimated (right 
side o f  Fig. 5). The FICi model and the responses 
surface approach developed by Prichard et al. (62) 
follows strategy on the strategy on left-hand side while 
the fully param etric model developed by Greco et al. 
(37) follows the strategy on the right-hand side.
1.3 O u t l in e  o f  t h e  T h e sis
Given the great interest o f  combination therapy 
for treating invasive infections caused by filamentous 
fungi, objective and reliable analysis tools are required 
for assessing the in vitro interaction o f  antifungal drugs. 
However, before sophisticated and m odern approaches
S tra tegy  and  T actics for  
A ssessin g  A g en t In tera ctio n s
Figure 5. Schematic diagram of general approach to 
assessment of the nature and intensity of agent 
interactions, which include all specific approaches 
[adapted from Greco et al. (36)].
o f  drug interaction modeling can be applied to anti­
fungal susceptibility testing o f  filamentous fungi, 
precise quantification o f  fungal growth and accurate 
estimation o f antifungal effects are required. Due to the 
inability o f  the current proposed standard to determine 
these variables, further optimization is required.
Therefore, Chapter 2 is focused on different 
variables o f  A ST o f  filamentous fungi. Since the 
nutrient medium is an im portant factor o f  susceptibility 
tests in this chapter different m edia were evaluated for 
the growth o f  various filamentous fungi. For this 
purpose a kinetic in vitro system was developed to 
m onitor the growth o f  fungi and to describe the 
characteristics o f  their growth curves. In the remaining 
three studies, a spectrophotometric m ethodology and 
colorimetric assays based on tetrazolium  salts are 
developed and optimized in order to overcome the 
limitations arising from the visual determination o f  the 
MICs and to provide detailed information o f  the 
concentration-effect relationships o f  antifungal drugs 
for filamentous fungi.
These methods were then used in Chapter 3 for 
the assessment o f  in vitro interaction o f  antifungal 
drugs for various fungi. Data were analyzed based on
19
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conventional and m odem  approaches o f  drug 
interaction modeling using two different zero 
interaction theories. Thus, in vitro combinations were 
assessed with the standard approach o f the FIC index 
model. Response surface m odeling was applied and 
interactions were evaluated with fully parametric 
models incorporating m odern concepts o f  statistical and 
non-linear regression analysis.
Finally, in Chapter 4, after summarizing the 
highlights o f  this thesis as described in the previous 
chapters, the future perspectives o f  antifungal 
susceptibility testing and drug interaction modeling 
together with their applications are explored and new 
directions in these fields are addressed.
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A n a l y s i s  o f  G r o w t h  C h a r a c t e r i s t i c s  o f  F i l a m e n t o u s  F u n g i  
i n  D i f f e r e n t  N u t r i e n t  M e d i a
J o s e p h  M e l e t i a d i s 1, J a c q u e s  F. G. M . M e is 1,2, J o h a n  W . M o u t o n 2, a n d  P a u l  E. V e r w e i j 1
Department o f  Medical Microbiology, University Medical Center Nijmegen1, and Department o f  Medical Microbiology and 
Infectious Diseases, Canisius- Wilhelmina Hospitaf, Nijmegen, The Netherlands
A m icro b ro th  k inetic m odel based  on tu rb id ity  m easu rem en ts was developed in o rd e r to 
analyze the  grow th  ch arac te ristic s  of th re e  species of filam entous fungi (R h izopu s m icrosporus, 
A sperg illu s fum igatus, and  S cedosporiu m  prolificans) ch arac te rized  by d iffe ren t g row th  ra te s  in 
five n u trien t m edia (an tib io tic m edium  3, yeast n itrogen  base m edium , S ab o u rau d  b ro th , R PM I 
1640 alone, an d  R P M I 1640 w ith  2 %  glucose). In  general, five d istinct phases in th e  grow th  of 
filam entous fungi could be d istinguished , nam ely , the  lag phase , th e  firs t tran s itio n  period , the  
log phase , the  second tran s itio n  period , and  th e  s ta tio n ary  phase. The grow th  curves w ere 
sm ooth an d  w ere  ch a rac te rized  by the  presence of long tran sitio n  periods. A m ong th e  d ifferen t 
g row th  phases d istinguished, th e  sm allest v a riab ility  in grow th ra te s  am ong th e  stra in s  of each 
species w as found  d u rin g  th e  log phase  in all n u trien t m edia. T he d iffe ren t grow th  phases of 
filam entous fungi w ere  b are ly  d istinguishable  in R P M I 1640, in w hich th e  poorest g row th was 
observed  fo r all fungi even w hen th e  m edium  w as supp lem ented  w ith  2 %  glucose. R. m icrosporu s  
an d  A. fu m iga tu s  grew  b e tte r  in S ab o u rau d  an d  yeast n itrogen  base m edium  th an  in R PM I 
1640, w ith  grow th  ra te s  th ree  to  fo u r tim es h igher. None of th e  m edia p rov ided  optim al grow th 
of S. pro lifican s. T he germ ination  of R h izopu s  spores and  A sperg illu s  and  Scedosporium  conidia 
com m enced a fte r 2 an d  5 h of incubation , respectively. T he elongation ra te s  ran g ed  from  39.6 to 
26.7, 25.4 to  20.2, an d  16.9 to  9.9 ^m /h  fo r R hizopus, A spergillus, an d  Scedoporium  hyphae, 
respectively. T he germ ination  of conidia an d  spores and  th e  elongation ra te s  of hyphae w ere 
enhanced  in an tib io tic  m edium  3 an d  delayed in yeast n itrogen  base m edium . In  conclusion, the 
grow th  curves p rov ide  a useful tool to  gain insight in to  the  grow th  ch arac te ristic s  of filam entous 
fungi in d iffe ren t n u trien t m edia and  m ay  help to  optim ize th e  m ethodology fo r an tifungal 
susceptib ility  testing.
In vitro susceptibility testing o f  filamentous fungi 
is becoming increasingly im portant because o f  the 
frequency and diversity o f  infections caused by them 
(24, 31, 37). In addition, more antifungal agents have 
been introduced for clinical use and other new drugs are 
undergoing clinical evaluation (34). Hence, 
standardized in vitro susceptibility tests that give 
reproducible results, predict the resistance o f moulds, 
and correlate with clinical outcome are required (2, 3, 
9). Better inter- and intralaboratory agreem ent has been 
achieved by standardizing various factors involved in 
testing filamentous fungi for their susceptibilities such 
as the inoculum preparation, the incubation conditions 
(time and tem perature), the MIC determination (reading 
time and end points), and the nutrient medium (4, 5, 18, 
27).
The influence o f  medium on antifungal 
susceptibility tests o f  yeasts is well established (3, 11, 
15, 25, 28). Although there is no consensus as to the 
optimal nutrient medium, by definition the nutrient 
medium m ust be able to support adequate growth o f the 
fungus without interfering with the action o f  the 
antifungal agents and m ust result in reproducible results 
that have clinical value (19). M any studies have shown
that synthetic medium RPM I 1640 gives reproducible 
results for the in vitro testing o f  the susceptibility o f 
yeasts to various antifungal drugs (25, 28). This 
medium was also selected by the subcom m ittee for 
Antifungal susceptibility Testing o f  the National 
Committee for Clinical Laboratory Standards (NCCLS) 
for the in vitro susceptibility testing o f  conidium- 
forming filamentous fungi (23) although there was no 
evidence that this medium was suitable for filamentous 
fungi (3). RPM I 1640 has a num ber o f  advantages (28), 
but its suitability for the susceptibility testing o f 
nonfermentative yeasts such as C ryptococcus 
neoform ans has been questioned (10, 15, 33, 35). 
Therefore, the appropriateness o f this medium for 
filamentous fungi should not be implicitly postulated.
Given the greater variability in the growth rate, 
mechanisms o f  sporulation, and nutrient requirements 
among the filamentous fungi than among yeasts, growth 
characteristics o f  moulds in relation to the medium 
should be studied in detail. Due to the filamentous and 
non-homogenous growth o f  moulds, the analysis o f 
growth characteristics by growth curves is difficult. In 
the present study we developed a m icrobroth kinetic 
system in order to investigate the growth characteristics
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o f  filamentous fungi in different nutrient media. Such a 
system would help to select the medium that optimally 
supports the growth o f these fungi and to establish the 
optimal reading time o f  susceptibility testing o f 
filamentous fungi.
M a t e r ia l s  a n d  M e t h o d s
Isolates. Fifteen clinical isolates of filamentous fungi 
belonging to three species were selected based on their 
growth rates. Rhizopus microsporus var. rhizopodiformis was 
chosen as representative of fast-growing moulds, Aspergillus 
fumigatus was chosen as intermediate in growth rate, and 
Scedosporium prolificans was chosen as representative of 
slow-growing fungi. For each species five strains from our 
private collection were tested: R. microsporus var. 
rhizopodiformis, AZN190, AZN410, AZN5816, AZN5805, 
and AZN1185; A. fumigatus, AZN9618, AZN9619, 
AZN9620, AZN9621, and AZN9625; S. prolificans, 
AZN7898, AZN7901, AZN7902, AZN7906, and AZN7918.
Isolates had been frozen in 50% glycerol at -70°C and 
were revived by subculturing onto Sabouraud glucose agar 
(SGA) tubes supplemented with 0.5% chloramphenicol and 
incubated at 29°C for 7 days. The isolates were subcultured 
again on SGA tubes and incubated for another 5 to 7 days at 
37°C.
Nutrient media. The following five nutrient media 
were used: RPMI 1640 medium with L-glutamine but 
without bicarbonate (GIBCO BRL, Life Technologies, 
Woerden, The Netherlands) prepared alone (RPMI) or 
supplemented with 2% glucose (RPMI+); yeast nitrogen base 
(YNB; Difco Laboratories, Amsterdam, The Netherlands); 
antibiotic medium 3 (AM3; Oxoid, Hampshire, United 
Kingdom), and Sabouraud broth (SAB; Oxoid).
All media were prepared according to the 
manufacturer's instructions and buffered to pH 7.0 with
0.165 M 3-N-morpholinopropanesulfonic acid (MOPS) 
(Sigma-Aldrich Chemie GmbH, Steinheim, Germany). 
Double-strength media were prepared and sterilized by 
filtration (RPMI, RPMI+, and YNB) or by autoclavation 
(SAB and AM3).
Growth curves. Conidia and spores were collected 
using a cotton swab from 7- to 10-day-old cultures and 
suspended in 0.1% Tween 80. The suspensions were adjusted 
to 2 x 104 spores/ml by counting the cells in a hemacytometer 
cell counting chamber. Viability was confirmed by plating 
serial dilutions on SGA plates. One hundred microliters of 
each suspension containing 0.1% Tween 80 was inoculated 
into 100 ^l of double-strength medium in 96-well flat-bottom 
microtitration plates. Tween 80 was used in order to prevent 
the growth of fungi on the surfaces of the media inside the 
wells. The plates were sealed and incubated at 37°C for 100 h 
inside a plate reader (Rosys Anthos ht3; Anthos Labtec 
Instruments GmbH, Salzburg, Austria). The optical density 
(OD) at 405 nm was recorded for each well automatically 
every 15 min without shaking. The reader can detect changes 
of 0.001 in OD. Sequential OD measurements were used to 
generate growth curves for each fungus and medium in 
triplicate. All studies were conducted two times.
Microscopic examination. In order to correlate OD 
changes with the morphology of the fungi, conidia and spores 
were observed microscopically in microtitration plates by a 
reverse microscope at hourly intervals. At each time point, 
100 conidia and spores were counted and the percentage of 
germination in each medium was estimated in triplicate. The 
lengths of hyphae formed by 15 germinated conidia or spores 
were measured, and the average length was calculated in 
triplicate. Furthermore, the change in hyphal length over time 
was computed as (average length at t2 -  average length at 
t1)/(t2 -  t1), where t1 and t2 are the times at the beginning and 
end of the measurement period, respectively. The mean 
elongation rate was calculated by averaging the changes 
during sequential time periods of the growth.
Kinetic parameters. In order to compare the growth 
curves for each species in the five different nutrient media, 
various parameters were calculated based on the changes of 
the OD over time using the Micro Win, version 3, software 
(Mikrotek Laborsysteme GmbH, Overath, Germany). From 
the growth curve of each strain in each of the media the 
following parameters were calculated: the highest OD 
(ODmax), the average of all changes in OD (DOD) per minute, 
where DOD = ODfinal -  ODinitial in an interval of 15 min, the 
overall slope S obtained by linear regression analysis, and the 
maximal slope (Smax), which was the largest increase rate in 
OD repeated for 25 consecutive time points. Furthermore the 
following time-related parameters were recorded: the time of 
first detectable OD change, the time when 90% of the ODmax 
was reached (OD90), and the time at which Smax of the growth 
curve was reached.
In addition, the S values for the growth curves were 
calculated and were used as estimates of the growth rates of 
the species in each nutrient medium. To visualize small 
changes in the growth rates during the growth curve and to 
determine the time point after which the growth rate changed 
significantly, a calculation model based on the area under the 
kinetic curve (AUKC) was developed. With this model the 
relative AUKC (rAUKC) was estimated by dividing each 
AUKC for each time point every 3 h by the corresponding 
time period. The changes in rAUKC, DrAUKC, were 
calculated for each time point by subtracting the rAUKC for 
each time point from the corresponding rAUKC of the 
previous time point. The DrAUKC is an estimate of changes 
in the slope of the growth curve and thus an estimate of the 
growth rate of fungus. When the DrAUKC value increases 
linearly over time, the OD increases with a constant rate, and 
when the DrAUKC value decreases or goes to zero over time, 
the growth rate decreases or goes to zero, respectively. Thus, 
increasing DrAUKC values corresponded to high growth 
rates. The DrAUKC values were used in order to distinguish 
different phases in the growth of filamentous fungi and the 
time employed for each phase.
R e su l t s
A  total o f  225 growth curves based on 
90,000 time points were obtained. The shapes o f  the 
growth curves were different depending on the nutrient 
medium used and the species tested (Fig. 1A, 2A , and
28
GROWTH OF FILAMENTOUS FUNGI IN DIFFERENT MEDIA
2. 00- |  .  
1. 251 A
Time (h)
Time (h)
Time (h)
Time (h)
AM 3 — RPM I RPM I+ YNB SAB
Figure 1. Graphical representation of the growth of R. microsporus var. rhizopodiformis in five nutrient media. 
(A) Changes in OD over time. (B) Changes in DrAUKC over time. (C) Percentages of germination of conidia over 
time. (D) Extension of hyphae over time. Bars, SE.
3A). However they were very reproducible among the 
replicates and the strains tested. Since the results o f  the 
two experim ents were sim ilar, the data of the first 
experim ent were used for analysis.
The growth curves were fragmented and were 
analyzed. In general the following phases in the growth 
o f  each o f  the tested genera could be distinguished 
based on OD changes and DrAUKC values (Table 1). 
The first phase was the lag phase in which no changes 
in OD were measured and the DrAUKC values were 
lower than 5% o f the maximal DrAUKC. Microscopic 
examination revealed that during this phase germination 
o f  spores and conidia took place followed by elongation 
o f  hyphae to a maximal length o f  60 ^m  (Fig. 1D, 2D, 
and 3D).
Further elongation o f  hyphae was detected 
spectrophotometrically and resulted in a rapid increase 
in OD (first transition period) until 30% o f  the maximal 
DrAUKC was reached. After this phase, the DrAUKC 
increased and the growth curve reached the maximal 
slope, the maximal DrAUKC (log phase). Afterwards a 
second transition period, in which the slope o f  the 
growth curve decreased continuously until the DrAUKC 
reached 70% o f  its maximum and the OD tended to 
reach a plateau, was apparent (second transition period).
The last phase was the stationary phase, where no 
changes in OD or negative slopes o f  the growth curve 
were observed and where values for DrAUKC were 
lower than 70% o f  the maximum DrAUKC (Fig. 1A and 
B, 2A and B, and 3A and B).
R. m icrosporus. The strains o f  R. m icrosporus  
var. rhizopodiform is showed the shortest lag phase, 
with the first significant change in OD after 4.8 to 6.5 h 
o f  incubation at 37°C, and the OD90s for the five strains 
ranged between 20 and 40 h (Table 2). The OD90 was 
reached earlier (after 20 h) when RPM I was used as the 
nutrient medium; however in this medium the growth 
rate was very low, with an ODmax o f  0.29 and a slope o f 
0.61 x 10-4 (Table 2). Supplementation o f RPM I with 
2%  glucose resulted in a slight increase o f  the growth 
rate o f  the fungus. By contrast the growth rates in SAB 
and YNB m edia were the highest, with ODmaxs o f
1.01 and 1.02 and slopes o f 2.28 x 10-4 and 2.17 x  10-4, 
respectively. The 5maxs in these m edia were observed 
after 15.75 and 18.60 h, respectively. After 66 h o f 
incubation a decrease in the OD was observed in AM3 
but not in the other m edia (Fig. 1A). The microscopical 
observations showed that the germination o f spores 
started after 2 h in AM3 and SAB, after 4 h in RPMI 
and RPMI+, and after 5 h in YNB (Fig. 1C). The highest
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Tim e (h)
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Time (h )
T im e(h)
RPMI+ —•— YNB —♦— SAB
Figure 2. Graphical representation of the growth of A. fumigatus in five nutrient media. (A) Changes in OD 
over time. (B) Changes in DrAUKC over time. (C) Percentages of germination of conidia over time. (D) 
Extension of hyphae over time. Bars, SE.
2.00-, A  
0 .75 -L  H
Time (h)
Time (h) 
«-A M 3
Time (h)
RPMI RPMI+ YNB
Time(h)
-S A B
Figure. 3. Graphical representation of the growth of S. prolificans in five nutrient media. (A) Changes in 
OD over time. (B) Changes in DrAUKC over time. (C) Percentages of germination of conidia over time. (D) 
Extension of hyphae over time. Bars, SE.
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elongation rates o f hyphae were observed in AM3 
(39.6 ^m /h), and the lowest were observed in YNB 
(26.7 ^m/h) (Fig. 1D). The highest rate o f increase in 
OD (DOD per minute) was observed during the log 
phase (0.5 to 3 times higher than those in the other 
growth phases (Table 1). Based on the DrAUKC model 
the log phase was from 9 to 15.6 h in RM PI and 
RPMI+, from 12 to 25.2 h in YNB, from 9 to 23.3 h in 
SAB, and from 6.6 to 27 h in AM3 (Fig. 1B and Table
1). Based on DOD-per-minute values the lowest 
interstrain variation for all m edia was found during the 
log phase. The mean variations ± standard errors (SE) 
o f  DOD-per-minute values in the five m edia were 
11% ± 2% for the log phase, 14% ± 1% for the first 
transition period, 33% ± 9% for the lag phase, 
38% ± 9% for the second transition period, and 
92% ± 26% for the stationary phase (Table 1).
A. fum igatus. The first detectable growth for the 
strains o f  A. fum igatus was after 9.65 h (Table 2) 
although the germination o f  conidia was completed after 
13 h (Fig. 2C). In Fig. 2A the differences in the shapes 
o f  the growth curves for each nutrient medium are 
shown. The slopes o f  the growth curves in RPMI 
medium, even when supplemented with 2% glucose, 
were fourfold lower than those in SAB and YNB (Table
2). By contrast to that o f  Rhizopus strains, the growth o f 
the A spergillus strains failed to reach the stationary 
phase within 100 h. 5max was reached after 30 h for all 
m edia except RPMI, in which 5max occurred after 17 h 
(Table 2). The germination o f  conidia started after 5 h 
o f  incubation in all m edia although it was delayed for 
1.5 h in YNB (Fig. 2C). Similar rates o f  elongation o f 
A spergillus  hyphae occurred in all m edia (»25 ^m/h) 
except in YNB, in which a lower elongation rate 
(20.2 ^m /h) was observed (Fig. 2D). The DOD-per- 
minute values in the log phase were higher than those in 
the other growth phases except in RPMI, where the 
DOD per minute was comparable to that in the first 
transition period. The log phase based on DrAUKC 
values was between 14.4 and 46.8 h in RPM I and 
RPMI+, between 24.6 and 56.4 h in SAB, between 
30 and 65.4 h in YNB, and between 16.2 and 54.6 h in 
AM3 (Fig. 2B and Table 1). The lowest variation in 
DOD per minute among the five strains and among the 
growth phases was found during the log phase. The 
mean variations ± SE o f  DOD per minute in the five 
m edia were 9% ± 2%  for the log phase, 15% ± 3% for 
the first transition period, 18% ± 3% for the second 
transition period, 22% ± 2% for the stationary phase, 
and 23%  ± 6% for the lag phase (Table 1).
S. pro lifican s. The growth o f  this fungus was the 
slowest among the species tested since after 100 h o f 
incubation the ODmax ranged from 0.27 in YNB to 
0.64 in AM3 (Table 2). The highest growth rate 
occurred in AM 3, and the lowest occurred in YNB, with
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CHAPTER 2.1
Table 2. Parameters calculated from the growth curves of the five strains from each fungal species in five nutrient
media based on changes of ODa
Species Medium ODmax S (10-4) Smax (1 0-4) ODob (h) OD90 (h) Time of Smax(h)
R. microsporus AM3 0.55 ± 0.05 1.17 ± 0.11 3.33 ± 0.74 4.80 ± 0.21 39.35 ± 5.10 12.06 ± 6.57
RPM I 0.29 ± 0.03 0.61 ± 0.08 4.44 ± 0.50 4.95 ± 0.33 20.30 ± 6.10 11.15 ± 0.93
RPMI+ 0.41 ± 0.06 0.84 ± 0.06 3.96 ± 0.38 5.15 ± 0.29 37.15 ± 8.86 10.65 ± 1.04
SAB 1.01 ± 0.10 2.28 ± 0.24 11.52 ± 4.76 5.38 ± 0.14 29.24 ± 6.04 15.75 ± 2.19
YNB 1.02 ± 0.24 2.17 ± 0.60 8.52 ± 2.04 6.50 ± 0.35 40.18 ± 9.47 18.60 ± 1.15
A. fumigatus AM3 1.17 ± 0.15 2.49 ± 0.32 4.68 ± 0.59 10.02 ± 0.78 73.33 ± 3.78 31.17 ± 0.76
RPM I 0.53 ± 0.06 1.08 ± 0.11 1.69 ± 0.37 9.65 ± 0.38 76.05 ± 2.33 17.30 ± 5.04
RPMI+ 0.65 ± 0.08 1.27 ± 0.15 1.64 ± 0.22 9.70 ± 0.27 81.21 ± 0.53 17.13 ± 4.61
SAB 2.00 ± 0.26 4.23 ± 0.53 6.69 ± 0.45 9.65 ± 0.76 72.80 ± 3.56 42.44 ± 4.79
YNB 2.01 ± 0.12 4.28 ± 0.31 7.66 ± 0.67 11.35 ± 0.34 80.90 ± 4.03 43.63 ± 0.48
S. prolificans AM3 0.64 ± 0.23 1.31 ± 0.45 2.63 ± 0.75 11.35 ± 0.89 71.49 ± 13.46 40.25 ± 14.15
RPM I 0.45 ± 0.08 0.97 ± 0.14 1.92 ± 0.80 13.30 ± 1.01 74.05 ± 3.45 43.69 ± 19.90
RPMI+ 0.44 ± 0.06 0.87 ± 0.14 1.64 ± 0.35 12.95 ± 0.93 75.44 ± 7.36 39.63 ± 23.43
SAB 0.47 ± 0.04 0.97 ± 0.06 1.82 ± 0.18 12.95 ± 0.72 69.10 ± 8.62 22.50 ± 1.62
YNB 0.24 ± 0.04 0.53 ± 0.10 1.59 ± 0.16 17.75 ± 2.28 45.21 ± 5.41 26.31 ± 3.37
a Values are means
b
: standard deviations.
OD0, Time of the first significant change in OD.
slopes o f  the growth curves o f  1.31 * 10-4 and 
0.53 * 10-4, respectively. The 5max in these m edia 
occurred after 40 and 26 h, respectively (Table 2). In all 
the nutrient m edia the fungus continued to grow until 
100 h, except for YNB, in which the plateau was 
reached within 50 h (Fig. 3A). The germination o f 
Scedosporium  conidia started after 4 h o f  incubation in 
AM3 and SAB, after 5 h o f  incubation in RPM I and 
RPMI+, and after 7 h o f incubation in YNB, in which 
the delay in germination increased during the 
incubation. Complete germination was not achieved in 
any o f  the m edia after 20 h o f  incubation (Fig. 3C). The 
elongation rates ranged from 16.9 to 9.9 ^m/h, with the 
highest in AM3 and the lowest in YNB (Fig. 3D). The 
DOD-per-minute values were higher during the log 
phase but were comparable to those o f  the first 
transition period (Fig. 3B and Table 1). The log phase 
based on the DrAUKC model was between 17.4 and 
49.8 h in RPM I and RPMI+, between 18 and 55.8 h in 
AM 3, between 18.6 and 37.2 h in SAB, and between 
21 and 41.3 h in YNB. The lowest interstrain variation 
was found during the log phase, with a mean ± SE o f 
14% ± 3% compared with those during the first 
transition period (28% ± 5%), the second transition 
period (39% ± 8%), the lag phase (44% ± 8%), and the 
stationary phase (82% ± 31%) (Table 1).
D isc u s sio n
The nutrient medium is a m ajor factor that 
influences the results o f  susceptibility tests (3, 30).
According to clinical laboratory standards an optimal 
nutrient medium should provide good or adequate 
growth o f  the microorganisms (19). The relativity o f 
this definition is clear since all the m edia tested here 
supported the growth o f  filamentous fungi to various 
degrees. M oreover the definition o f an adequate 
medium is really a minimal requirem ent that has to be 
fulfilled in order for a medium to be considered as a 
candidate for the susceptibility tests. An optimal 
nutrient medium should provide not simply adequate 
growth but the best possible growth in order to allow 
moulds to grow without restriction and express all 
phenotypes. U nder these growth conditions, any failure 
o f  the fungus to grow in the presence o f  antifungal 
drugs should be considered as a true inability, i.e., lack 
o f  proper genetic predisposition to resist the antifungal 
drugs or interaction o f  the drug with the target.
The importance o f  the nutrient medium and the 
growth rate o f  the fungus in relation to in vitro 
susceptibility testing has been shown previously. The in 
vitro susceptibility o f  Candida albicans to fluconazole 
and miconazole depends on the stage o f  the growth o f 
the fungus and the nutrient medium used (6, 17, 36). 
Yeasts in the exponential growth phase were more 
susceptible to fluconazole than those in the lag phase 
when they were cultivated in YNB-2%  glucose medium 
(6, 17), and the in vitro activity o f  miconazole in CYG 
(0.5% casein gydrolase, 0.5% yeast extract, 0.5% 
glucose), N G  (1% neopeptone, 0.5% glucose), and 
YNB-4%  glucose m edia was greater when richer m edia 
were used (36). Differences in MICs for filamentous 
fungi were also observed when conidia (fungus in the
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lag phase) and hyphae (fungus in the log or stationary 
phase) were cultivated in RPM I 1640 (12). In another 
study where RPM I and YNB were employed the 
interaction between antimicrobial agents and fungi 
depended on the type o f  medium used (22).
The previous findings can be correlated with the 
results o f  this study. Figures 1A, 2A, and 3A show that 
RPM I poorly supports the growth o f the three species o f 
filamentous fungi tested. Supplementation with glucose 
essentially had little effect, despite being proposed as a 
means o f  improving the characteristics o f  this medium 
(32), and resulted only in a slight increase in the fungal 
growth even after incubation for 100 h. SAB and YNB 
were the more nutritious m edia and provided the highest 
growth for R. m icrosporus and A. fumigatus, with 
growth rates three to four times higher than those 
achieved in RPMI. None o f  the m edia supported the 
growth o f  S. pro lificans  sufficiently. Apparent were 
other effects o f  the media, such as the delay o f 
germination o f  spores and conidia as well as the lower 
elongation rates o f  hyphae o f  all species in YNB 
medium, processes which were enhanced in AM3. By 
contrast with the growth o f  yeasts, where the stationary 
phase is reached within 30 h (15, 36), the growth o f 
filamentous fungi is characterized by sm oother curves 
and long transition periods although it depended on the 
medium and species. Interestingly, during the growth o f 
R. m icrosporus  in AM 3, an OD decrease after 66 h o f 
incubation, which could be correlated with the death 
phase o f  bacterial growth, occurred (20).
The use o f  a poor medium such as RPMI, in 
which fungi grow slowly, m ight result in erroneous 
MICs. In an extreme situation a fungus unable to grow 
in a certain medium would seem to be susceptible 
despite the fact that the inhibition o f growth is not due 
to the action o f the antifungal agent but due to the 
medium. There m ight be other situations, which are 
difficult to prove experimentally, in which a poor 
medium, although it supports fungal growth, acts 
synergistically with the drug in inhibiting growth, 
resulting in an appearance o f  better activity. The 
discrepancy in the interaction o f  a fluoroquinolone with 
am photericin B against A. fum igatus in YNB 
(synergistic) and in RPM I (antagonistic) (22), as well as 
the higher activity o f  miconazole in richer m edia (36), 
could be explained by the growth curves. The high 
growth in YNB and the poor growth in RPM I correlate 
with different levels o f  m etabolic activity. Thus, in 
YNB the drugs m ight penetrate better into the 
intracellular site o f  action in sufficient concentrations to 
exhibit an effect.
RPM I has been evaluated extensively for in vitro 
susceptibility testing o f  yeasts and has been shown to 
provide reproducible results (2, 25, 28, 30). Therefore, 
the NCCLS has proposed to use this medium as the 
standard medium for antifungal susceptibility testing o f
filamentous fungi (23). Like YNB, RPM I is a synthetic 
and completely defined medium and is characterized by 
small lot-to-lot variation, resulting in high 
reproducibility o f  susceptibility tests, unlike AM3, 
which has considerable variation from lot to lot and 
source to source. By contrast the use o f  chemically 
com plex undefined m edia such as SAB medium is not 
recommended (19, 28) since undefined components that 
they may contain m ight interact with antifungal drugs 
(13, 14, 19, 26). Furthermore, acidic m edia such as 
YNB and SAB, i f  they were used unbuffered, may 
inactivate amphotericin B, which is not stable at low pH 
(16, 21).
A nother important variable in susceptibility 
testing o f  filamentous fungi is the reading time. It is 
well known that prolonged incubation elevates the 
MICs o f  antifungal drugs (8, 29). The NCCLS 
addressed this by recommending different incubation 
periods for each species based on visual growth. 
Although the growth curves o f  filamentous fungi have 
not been previously studied in order to characterize the 
growth over time, the NCCLS recommended incubation 
periods o f  24 h for the fast-growing species, usually 
belonging to the Zygomycetes, 72 h for the slow- 
growing species such as the black fungi, and 48 h for 
the other species (23).
In the field o f  antibacterial susceptibility testing, 
the MICs should be read when the growth control is in 
the log phase and not in the transition periods, i.e., 
between lag phase and log phase or between log phase 
and stationary phase, where unbalanced growth exists 
(20). Since the growth curves o f  filamentous fungi are 
characterized by long transition periods, the precise 
determination o f these periods is a crucial param eter in 
order to obtain balanced growth. The same conclusion 
was made by Galgiani and Stevens (7) in terms o f 
variability o f  MICs, when they observed that yeasts 
showed increased variation in the concentration o f  a 
drug producing 50% o f  the growth seen in a drug-free 
well when the MIC determination was made beyond 
48 h o f  incubation. Beyond this incubation period, the 
drug-free culture reached the stationary phase and 
stopped growing resulting in higher variation in MICs 
(7). This effect is more obvious for fungistatic drugs 
since in the stationary phase the fungi in the drug-free 
control stop growing but those in drug-containing wells 
do not, which increases the difference in optical density 
between these two wells (unpublished observations). 
These findings could be correlated with our finding o f 
high variation in the stationary phase compared with 
that in the other growth phases. That the growth phase is 
an im portant variable is supported by the findings that 
the inhibitory effects o f ketoconazole and miconazole 
against C. albicans  were indistinguishable when the 
yeasts were tested in the stationary phase (1).
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Based on the results o f  this study (Table 1), the 
growth curves for filamentous fungi during the 
transition periods were characterized by rapid changes 
in slope and high variation compared with other parts o f  
the growth curve. The slopes in the transition periods 
were either continuously decreasing until a plateau was 
reached (second transition period) or increasing until 
the log phase was reached (first transition period). Since 
the log phase is located between these two transition 
periods, precise determination o f  these periods is 
required in order to determine the boundaries o f  this 
growth phase. Due to long and smooth transition 
periods o f  the growth curves o f  filamentous fungi, the 
visualization o f  the start and end points o f  these periods 
by using the OD changes is difficult. Therefore, a 
calculation model based on DrAUKC was developed. 
W ith the DrAUKC model even small changes o f  the 
slopes, which might be an indication o f  transition 
between phases, can be observed. The log phase o f  the 
growth curve is that part o f the curve where DrAUKC 
values increase linearly over time and the growth rate is 
constant at its highest value. This model can be used to 
describe the different growth phases o f  filamentous 
fungi and to determine the boundaries o f  each phase. 
The level o f  30% (increase until 30% and decrease until 
70%) o f  the maximal DrAUKC seems to be the crucial 
breakpoint o f  the growth curves o f  filamentous fungi 
indicating the presence o f symmetry.
In summary, the above-mentioned studies 
indicate that during the log phase balanced growth takes 
place (20) and a greater distribution o f  MICs is obtained 
(1) and the reproducibility o f  MICs is higher (7) than in 
the other growth phases. In addition, this study shows 
that the lowest interstrain variation was observed during 
the log phase o f  the growth curve. Thus, the optimal 
reading time o f  antifungal susceptibility testing o f  
filamentous fungi could be during the log phase. 
Therefore the precise knowledge o f  the growth phases 
during the growth o f  filamentous fungi would help to 
find the optimal reading time o f  the MICs.
Nevertheless, many factors are involved in the 
standardization o f  antifungal susceptibility testing. 
Unequivocally intercenter and intracenter 
reproducibility, as underlined by NCCLS, is a m ajor 
issue for antifungal susceptibility testing o f  filamentous 
fungi. However another primary goal o f  susceptibility 
tests is the correlation o f  in vitro results with clinical 
response, and this does not favor necessarily and 
absolutely simplified methodologies.
Although an ultimate challenge would be to find 
a common medium that would be suitable for as many 
fungi as possible, this study indicates that the 
standardization o f  susceptibility testing o f  filamentous 
fungi may require different nutrient m edia for each 
species and consequently different reading times o f  the
MICs o f  antifungal drugs. Furthermore, findings for one 
species are not readily extrapolated to others, 
particularly for filamentous fungi, where significant 
morphological and physiological variations exist. 
Therefore, based on the results obtained from the 
growth curves further studies are required to investigate 
the effect o f nutrient m edia and growth phases on MICs 
and ultim ately to determine w hich approach correlates 
best with the clinical outcome.
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Comparison of NCCLS and 3-(4,5-Dimethyl-2-Thiazyl)-2,5- 
Diphenyl-2H-Tetrazolium Bromide (MTT) Methods of In 
Vitro Susceptibility Testing of Filamentous Fungi and 
Development of a New Simplified Method
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C o m p a r i s o n  o f  N C C L S  a n d  3 - ( 4 ,5 - D i m e t h y l - 2 - T h i a z y l ) - 2 ,5 - D i p h e n y l - 2 H -  
T e t r a z o l i u m  B r o m i d e  ( M T T )  M e t h o d s  o f  I n  V i t r o  S u s c e p t i b i l i t y  T e s t i n g  o f  
F i l a m e n t o u s  F u n g i  a n d  D e v e l o p m e n t  o f  a  N e w  S i m p l i f i e d  M e t h o d
1 1 2  2 3
J o s e p h  M e l e t i a d i s 1, J a c q u e s  F. G. M . M e i s ,  J o h a n  W . M o u t o n 2, J. P e t e r  D o n n e l l y 3,
a n d  P a u l  E. V e r w e i j 1
Departments o f  Medical Microbiology1 and Hematology3, University Medical Center Nijmegen, and Department o f  Medical 
Microbiology and Infectious Diseases, Canisius- Wilhelmina Hospitaf, Nijmegen, The Netherlands
The susceptib ility  of 30 clinical isolates belonging to  six d iffe ren t species of filam entous 
fungi (A sperg illu s fum igatus, A sperg illu s flavus, S cedosporium  prolifican s, Scedosporium  
apiosperm um , F u sariu m  solani, an d  F u sariu m  oxysporum ) w as tested  against six an tifungal drugs 
(m iconazole, voriconazole, itraconazole, UR9825, te rb in a fin e , and  am pho teric in  B) w ith  the 
m icrod ilu tion  m ethod  recom m ended  by th e  N ational C om m ittee fo r C linical L ab o ra to ry  
S tan d a rd s  (N C C LS) (M 38-P). T he M IC s w ere com pared  w ith  th e  M IC s ob ta ined  by a 
co lorim etric  m ethod  m easu rin g  th e  reduction  of the  dye 3-(4,5-dim ethyl-2-thiazyl)-2,5-diphenyl- 
2H -te trazo lium  b rom ide (M TT) to  fo rm azan  by  viable fungi. T he levels of ag reem en t betw een 
th e  tw o m ethods w ere 96 and  9 2 %  fo r M IC -0  (clear wells) and  M IC -1 (75%  grow th  reduction), 
respectively. T he levels of ag reem en t w ere always h igher fo r A sperg illu s  spp. (97%  ± 2 .5% ), 
followed by Scedosporium  spp. (87%  ± 10.3% ) and  F u sariu m  spp. (78%  ± 7.8% ). T he N C C LS 
m ethod  was m ore rep roducib le  th an  the  M T T  m ethod: 98 versus 9 5 %  fo r M IC -0  an d  97 versus 
9 0 %  fo r M IC -1. H ow ever, th e  percen tage of hyphal g row th  as determ ined  visually  by  the  
N C C L S m ethod  show ed several d iscrepancies w hen they  w ere com pared  w ith  th e  percen tages of 
M T T  reduction . A new  sim plified assay th a t  in co rp o ra tes  th e  dye M T T  w ith  th e  in itial inoculum  
an d  in w hich th e  fungi a re  in cu b ated  w ith  th e  dye fo r 48 h o r m ore  was developed, showing 
com parab le  levels of ag reem ent and  rep roducib ility  w ith  th e  o th er tw o m ethods. F u rth e rm o re , 
th e  new  assay w as easier to  p erfo rm  and  m ore sensitive th an  th e  M T T  m ethod.
Filamentous fungi m ay cause invasive mycoses 
in both im munocomprom ised and non-immuno- 
compromised individuals. These infections require 
prom pt systemic antifungal therapy, the effectiveness o f 
which depends, among other things, on the in vitro 
susceptibility o f  the fungus to antifungal drugs. 
Therefore, there is a demand for reproducible and 
reliable methods o f  antifungal susceptibility testing o f 
filamentous fungi. M any variables that decrease the 
inter- and intralaboratory agreement are now defined (2,
4, 5, 16, 19). Broth m acrodilution methods are tim e­
consuming and labor-intensive (1), and therefore, 
efforts have focused on m icrodilution methods that are 
more practical and more user-friendly in the clinical 
laboratory (18). Based on these principles, the 
Subcommittee on Antifungal Susceptibility Testing o f 
the National Committee for Clinical Laboratory 
Standards (NCCLS) has proposed the M38-P standard 
for the antifungal susceptibility testing o f  conidium- 
forming fungi (14).
The determination o f  MICs for filamentous fungi 
can be facilitated with a method which overcomes 
observer bias and quantifies the hyphal growth o f 
moulds. Because turbidity measurements and colony 
counts (9) are not useful in the case o f  filamentous
fungi, colorimetric methods based on the measurem ent 
o f  metabolic activity m ay facilitate determination o f  the 
MIC (17). One o f  these is an assay using the dye 3-(4,5- 
dimethyl-2-thiazyl)-2,5 -diphenyl-2H-tetrazolium brom i­
de (MTT). This yellow tetrazolium  salt is cleaved by 
dehydrogenases inside mitochondria or in other cellular 
locations possessing dehydrogenase activity (7) to form 
its purple formazan derivative (11), which can be 
measured spectrophotometrically at 550 nm. M TT is 
cleaved by all living, m etabolically active fungi 
independent o f proliferation and irrespective o f 
unicellular or multicellular growth and thus is a measure 
o f  metabolic activity.
A method based on M TT has been used for 
susceptibility testing o f  fungi. The M TT method 
demonstrated excellent agreem ent with the standard 
m acrodilution m ethod for the antifungal susceptibility 
testing o f  yeasts (1, 9). For filamentous fungi, the MTT 
method has been used for A spergillus fumigatus, 
resulting in interpretable data (10). In order to overcome 
the shortcomings o f  visual MIC determination for 
filamentous fungi and to develop a reliable, subjective, 
and less variable method for the antifungal 
susceptibility testing o f  filamentous fungi, we evaluated 
the performance o f a method using M TT and compared
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the results with those obtained with the proposed 
standard o f  the NCCLS. The correlation between the 
m etabolic activity and the growth o f  fungi was 
examined. Furthermore, a simplified method using 
M TT was developed and compared with the previous 
methods.
M a t e r ia l s  a n d  M e t h o d s
Test isolates. Thirty clinical isolates of filamentous 
fungi (part of our private collection) were tested. These 
included five isolates of each of the following species: 
A. fumigatus (AZN7151, AZN7275, AZN8249, AZN8248, 
and AZN7272), Aspergillus ilavus (AZN501, AZN6837, 
AZN6803, AZN6686, and AZN6578), Scedosporium 
prolificans (AZN7886, AZN7903, AZN7946, AZN7921, and 
AZN7895), Scedosporium apiospermum (AZN1252, 
AZN7309, AZN7110, AZN7111, and AZN6474), Fusarium 
solani (AZN729, AZN646, AZN2106, AZN7844, and 
AZN2784), and Fusarium oxysporum (AZN685, AZN441, 
AZN1859, AZN8263, and AZN1188). Candida parapsilosis 
(ATCC 22019) and Candida krusei (ATCC 6258) were used 
for quality controls.
Isolates were passaged twice at an interval of 5 to
7 days at 30 to 37°C. All isolates were tested three times on 
three different days. All the solutions were prepared ex novo 
with powders from the same lot. Conidia of the isolates were 
obtained from fresh cultures each time.
NCCLS method. A broth microdilution method was 
performed according to NCCLS guidelines (M38-P) (14). 
The drugs that were used included miconazole (Janssen 
Research Foundation, Beerse, Belgium), terbinafine 
(Novartis, Basel, Switzerland), itraconazole (Janssen 
Research Foundation), UR9825 (Ureach, Madrid, Spain), 
voriconazole (Pfizer Central Research, Sandwich, United 
Kingdom), and amphotericin B (Bristol-Myers Squibb, 
Woerden, The Netherlands). The drug dilutions were made in 
RPMI 1640 medium (with L-glutamine, without bicarbonate) 
(GIBCO BRL, Life Technologies, Woerden, The 
Netherlands) buffered to pH 7.0 with 0.165 M 3-N- 
morpholinopropanesulfonic acid (MOPS) (Sigma-Aldrich 
Chemie GmbH, Steinheim, Germany). The final 
concentrations of the antifungal agents ranged from 0.015 to 
16 mg of amphotericin B/liter, 0.06 to 64 mg of 
miconazole/liter, and 0.03 to 32 mg of itraconazole, 
terbinafine, UR9825, and voriconazole per liter.
The tests were performed in 96-well flat-bottom 
microtitration plates, which were kept at —70°C until the day 
of testing. Spores were collected with a cotton stick and 
suspended in sterile water. After the heavy particles were 
allowed to settle, the turbidity of the supernatants were 
measured spectrophotometrically (Spectronic 20D; Milton 
Roy, Rochester, N.Y.) at 530 nm and transmission was 
adjusted to 68 to 70% (Scedosporium spp. and Fusarium 
spp.) or to 80 to 82% (Aspergillus spp.). Each suspension was 
diluted 1:50 in RPMI 1640 to obtain two times the desired 
inoculum. The inoculum size was confirmed by plating serial 
dilutions on Sabouraud dextrose agar (SDA) plates, with final 
inocula ranging from 1 x 104 to 5 x 104 CFU/ml. After 
agitation, the plates were incubated at 37°C for 48 h
(Aspergillus spp. and Fusarium spp.) and 72 h (Scedosporium 
spp.). The growth was assessed by visual observation with 
the aid of a concave mirror. Growth was scaled according to 
the NCCLS guidelines as follows: 4, no reduction in growth;
3, slight reduction in growth, or approximately 75% of the 
growth control; 2, prominent reduction in growth, or 
approximately 50% of the growth control; 1, slight growth, or 
approximately 25% of growth control; and 0, optically clear, 
or the absence of growth. MIC-1 and MIC-0 were determined 
to be the lowest concentrations of drug showing slight growth 
(25%) and absence of growth (100% visible-growth 
inhibition) compared with that of the drug-free control, 
respectively. For amphotericin B, only the MIC-0 was 
determined.
MTT method (MTT-3h). The MICs were also 
determined by a colorimetric method using the dye MTT 
(Sigma Chemical, St. Louis, Mo.). After the MICs were 
visually determined on each of the microtitration plates, 25 ^l 
of RPMI 1640 containing 5 mg of MTT/ml was added to 
each well. Incubation was continued at 37°C for 3 h. The 
content of each well was removed (centrifugation is not 
required for filamentous fungi due their adherence to the 
wells), and 200 ^l of isopropanol containing 5% 1 M HCl 
was added to extract the dye. After 30 min of incubation at 
room temperature and gentle agitation, the optical density 
(OD) was measured with a microtitration plate 
spectrophotometer (MS2 reader, Titertekplus; ICN 
Biomedical Ltd., B.V., Zoetermeer, The Netherlands) at 
550 nm. The OD of the blank, which consisted of an 
uninoculated plate incubated together with the inoculated 
plates, was subtracted from the ODs of the inoculated plates. 
The percentage of MTT conversion to its formazan derivative 
for each well was calculated by comparing the OD at 550 nm 
(OD550) of the wells with that of the drug-free control based 
on the following equation: (OD550 of wells that contained the 
drug/OD550 of the drug-free well) x 100%. MIC-0 and MIC-1 
were considered to be the lowest concentrations of drug 
showing at least 95 and 75% reductions in the OD compared 
with that of the drug-free well, respectively.
Toxicity test. The dye MTT was tested for possible 
inhibitory effects on the growth of filamentous fungi. The 
isolates were incubated in RPMI 1640 with different 
concentrations of MTT ranging from 4 to 0.06 mg/ml, for 
72 h at 37°C. A final inoculum of 104 CFU/ml was used. 
Growth inhibition was assessed by visual observation of the 
wells containing MTT and compared with the MTT-free 
wells. The level of inhibition of the fungal growth was 
assessed and scored as described above.
Modified MTT method. The MICs for each of the 
isolates were also determined by a modification of the MTT 
method previously described. For this method, conidia 
suspensions were prepared as described above. Each 
suspension was diluted 1:50 in RPMI 1640 containing 0.2 mg 
of MTT/ml to obtain two times the desired inoculum. Then, 
the inoculum that contained MTT was added to microtitration 
plates, which resulted in a final concentration of MTT of
0.1 mg/ml, and the microtitration plates were incubated for 
72 h (Scedosporium spp.) and 48 h (other species). After 
incubation, the formed formazan was extracted and the MICs 
were determined as described above.
Analysis of results. Each of the 30 isolates was tested
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Table 1. The MICs of six antifungal drugs against 30 clinical isolates of filamentous fungi obtained by NCCLS method for the
two endpoints
Speciesa MIC
Endpointb
MIC (mg/liter) range (median) of the following drugs:
Miconazole Terbinafine Itraconazole UR9825 Voriconazole Amphotericin B
A. fumigatus MIC-0 4-16 (4) 2-4 (4) 0.5-2 (1) 0.25-1 (0.5) 0.25-1 (0.5) 0.5-1 (0.5)
MIC-1 4-16 (4) 0.5-4 (1) 0.5-1 (0.5) 0.13-0.25 (0.25) 0.13-0.5 (0.25) NDc
A. flavus MIC-0 1-16 (4) 0.03-0.5 (0.06) 0.13-1 (1) 0.13-0.25 (0.25) 0.25-1 (0.5) 0.5-1 (1)
MIC-1 0.13-8 (2) 0.03-0.13 (0.03) 0.06-1 (0.5) 0.06-0.13 (0.13) 0.06-0.5 (0.25) ND
S. apiospermum MIC-0 1-8 (2) >32 2->32 (32) 1-8 (2) 0.5-2 (0.5) 2-4 (2)
MIC-1 0.5-2 (1) >32 0.5-4 (1) 0.25-2 (1) 0.13-1 (0.25) ND
S. prolificans MIC-0 16->64 (>64) >32 >32 8-32 (16) 16->32 (32) 0.5->16 (16)
MIC-1 4->64 (64) >32 >32 1-8 (2) 1-8 (4) ND
F. oxysporum MIC-0 1 ->64 (16) 0.13->32 (8) 0.5->32 (32) 0.5->32 (8) 0.5-16 (4) 0.25-2 (1)
MIC-1 0.25->64 (8) 0.03-8 (2) 2)(323>-30. 0.13-16 (4) 0.13-8 (2) ND
F. solani MIC-0 4->64 (16) 1 ->32 (4) 4->32 (32) 4->32 (8) 2-32 (4) 0.5-2 (1)
MIC-1 2->64 (8) 0.5-8 (2) 2->32 (16) 2->32 (4) 1-16 (2) ND
a There were five isolates per species.
b MIC-0, the lowest concentration of drug showing completely inhibition of growth (NCCLS method); MIC-1, the lowest concentration of 
drug showing slight growth (25%) (NCCLS method). 
c ND, not determined.
three times by the three methods against the six drugs. For 
each isolate, there was one reading per test. The MICs 
derived from the three readings by the NCCLS method and 
the two MTT methods were compared for each drug-isolate 
combination.
(i) Agreement between NCCLS and MTT methods.
The percentage of agreement between the NCCLS method 
and the MTT methods was defined as the proportion of MIC-
0 and MIC-1 determined by MTT methods which fell within
1 dilution of the MIC-0 and MIC-1 determined by the 
NCCLS method, respectively, for each reading. The high and 
low off-scale MICs were included in the analysis by 
converting to the next higher or lower drug concentration, 
respectively. The differences were analyzed by two-way 
analysis of variance and were considered not statistically 
significant when the probability (P) exceeded 0.05.
(ii) Correlation of visual reading of growth with 
OD reduction. The correlation of the visual reading of 
growth with the OD reduction was estimated for each MIC 
endpoint by comparing the MIC-0 and MIC-1, as these were 
determined visually by the NCCLS method and 
spectrophotometrically by the MTT method (MTT-3h). The 
frequency of visual MICs, which fulfilled the criteria defined 
above for the MIC endpoints of the MTT method (at least 
95 and 75% reductions of the OD for MIC-0 and MIC-1, 
respectively) as well as the average of percentage of OD 
reduction compared with the visual MIC endpoints were 
calculated.
(iii) Reproducibility of methods. For each method, 
the median of the three MICs measured was calculated and 
the proportion of the MICs that fell within 1 dilution of the
median was estimated. Based on these calculations, the 
reproducibility of each method for determining the drug-MIC 
endpoint was determined.
R e su l t s
A total o f  1,620 MICs obtained by the three 
methods were evaluated in this study. All the isolates 
produced detectable growth at 48 and 72 h. The MICs 
o f  quality control strains were within the reference 
ranges for the three replicates.
M IC  d ata . The MIC ranges for both MIC 
endpoints obtained by the NCCLS method for six 
antifungal drugs against the six fungal species are 
summarized in Table 1. Table 1 also provides the 
m edian MIC o f  the three readings. In m ost o f  the 
endpoint-drug-species combinations, the MIC range and 
the m edian MIC were the same for the two methods, 
with very few exceptions with the Fusarium  spp. The 
MICs were distributed over all the drug concentrations 
used.
Toxicity of M T T . M TT did not have any effect 
on the growth o f  the fungi at concentrations o f 
0.125 mg/ml and lower (Fig. 1). A t the higher 
concentrations, M TT was toxic for Scedosporium  spp. 
and Fusarium  spp. since the growth was completely 
inhibited. By contrast, A spergillus  spp. appeared 
resistant to M TT even at higher concentrations.
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Figure 1. Toxicity of MTT for six species of filamentous fungi. The bars for each species represent each 
of five individual strains tested and indicate the lowest concentration of MTT at which no inhibition of 
growth was observed. The dotted line shows the concentration of MTT used for MIC determination 
(0.1 mg/ml) by the modified MTT method.
A greem ent betw een m ethods. The percentages 
o f  agreem ent within 1 dilution between MICs obtained 
by the NCCLS and M TT methods for each species- 
drug-M IC endpoint combination are presented in Table 
2. The results were stratified by antifungal agents and 
MIC endpoint. High levels o f  agreem ent (96% for MIC-
0 and 92% for M IC-1) were found for the comparison 
o f the NCCLS m ethod with the M TT method. Lower 
levels o f  agreem ent were found when results o f  the 
m odified M TT method were compared with those o f the 
NCCLS method and the M TT method (MTT-3h). The 
agreem ent for MIC-0 was always higher than that for 
MIC-1. The observed differences among the methods 
were not statistically significant except for those derived 
from the comparison o f the m odified M TT method with 
the other two methods for both MIC endpoints o f 
voriconazole and for MIC-1 o f  UR9825.
The levels o f agreem ent for each drug-MIC 
endpoint combination between the methods were
always the highest for the A spergillus  spp. 
(97% ± 2.5%), followed by Scedosporium  spp. 
(87% ± 10.3%). For Fusarium  spp., the levels o f 
agreem ent were relatively low (78% ± 7.8%) (data not 
shown).
Representative curves o f  the OD  and percentage 
o f M TT conversion o f miconazole against
S. apiosperm um  are presented in Fig. 2. MIC-0 and 
MIC-1 determined visually by the NCCLS m ethod were
1 and 0.5 mg/liter, respectively.
C o rre la tio n  betw een visual read in g  of grow th 
and  OD reduction . Visual reading o f growth was 
correlated with the colorimetric assessment o f m eta­
bolic activity o f fungi by comparing the results o f the 
NCCLS method with the results o f  the M TT method 
(MTT-3h) (Table 3). The off-scale MICs were excluded 
from the analysis. For the MIC-0 endpoint, 84.7% o f  the 
M IC-0s o f all drugs determined by the NCCLS method 
corresponded to a 95% or greater reduction o f the OD.
1
........... ! ! ........... P n d i .
A. fum igatus A. flavus S. prolificans S. apiosperm um  F. so lani F. oxysporum
Table 2. Agreement between NCCLS- and MTT- derived MICs
% Agreement within ±  1 dilution (P-value)
Drug NCCLS-MTT NCCLS-modified MTT MTT-modified MTT
MIC-0 MIC-1 MIC-0 MIC-1 MIC-0 MIC-1
Miconazole 99 (0.94) 93 (0.79) 89 (0.36) 88 (0.66) 86 (0.36) 83 (0.48)
Terbinafine 92 (0.82) 84 (0.45) 93 (0.85) 78 (0.36) 94 (0.96) 75 (0.89)
Itraconazole 97 (1) 95 (0.43) 90 (0.66) 81 (0.18) 91 (0.66) 82 (0.46)
UR9825 99 (0.98) 96 (0.53) 76 (0.04) 77 (0.09) 86 (0.03) 76 (0.25)
Voriconazole 94 (0.91) 94 (0.21) 83 (0.006) 69 (0.003) 86 (0.01) 81 (0.05)
Amphotericin B 94 (0.60) 88 (0.16) 87 (0.35)
Overall agreement 95.8 92.3 86.6 78.5 88.4 79.4
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Figure 2. Testing of susceptibility of a S. apiospermum strain to miconazole. Representative curves generated by 
the MTT method (MTT-3h) and its modification (mod. MTT). The curves with the circles represent the percentage 
of OD reduction compared with the OD of drug-free well, and the curves with the squares represent the absorption 
of formed formazan at 550 nm. The MIC-0 and MIC-1 determined by the NCCLS method were 1 and 0.5 mg/l, 
respectively.
For the MIC-1 endpoint, 63.9% o f the MIC-1s obtained 
by the NCCLS method corresponded to a 75% or 
greater reduction o f the OD.
R eproducib ility  of m ethods. Overall, the three 
methods were very reproducible, since the levels o f  the 
reproducibility were higher than 89% for both MIC 
endpoints. The NCCLS m ethod was more reproducible 
than the M TT methods, since the reproducibility for 
M IC-0 and MIC-1 were 94.8 and 93.4% for the NCCLS 
m ethod compared with 94.8 and 89.5% for the MTT 
m ethod and 92.8 and 89.6% for the modified MTT 
method, respectively. Between the two MIC endpoints, 
M IC-0 was more reproducible than MIC-1. For all 
drugs tested, the reproducibility o f  MIC-0 ranged from 
90 to 100% and that o f  MIC-1 ranged from 82 to 99%. 
The lowest reproducibility among the drug-MIC
endpoint-method combinations was exhibited by MIC-1 
o f  terbinafine determined by the M TT method and the 
m odified M TT m ethod (82 and 84%, respectively).
D isc u s sio n
There are several problems in the determination 
o f  the MICs o f  antifungal agents, such as trailing effect 
caused by partial inhibition o f  fungal growth (8) and the 
subjectivity o f  visual reading with the aid o f  a 
magnifying m irror (16). These shortcomings are 
increased for filamentous fungi, which produce hyphae, 
making quantification o f  growth difficult. M oreover, the 
unequal growth, clumping, and adherence (13) o f 
moulds in assay tubes makes establishing a clear
Table 3. Correlation of visually determined MICs (NCCLS MICs) with the percentages of MTT conversion, as
calculated by MTT methoda
MTT conversion of isolates with 
NCCLS MIC-0 MTT conversion of isolates with NCCLS MIC-1
Drug
% of isolates with %  Conversion % of isolates with: % Conversion
<5 % conversion [median (range)]b <25 % 26-50 % 51-75 % [median (range)]
Miconazole 89.5 0 (0-36) 74.7 21.5 3.8 13 (0-75)
T erbinafine 76.9 2 (0-24) 53.6 31.9 14.5 24 (0-75)
Itraconazole 84.9 1 (0-30) 68.8 25.0 6.2 15.5 (0-75)
UR9825 83.3 1 (0-36) 61.3 31.2 7.5 21 (0-75)
Voriconazole 87.8 1 (0-35) 61.7 27.7 10.6 21 (0-71)
Amphotericin B 84.3 0 (0-28)
Overall 84.7 1 (0-36) 63.9 27.6 8.5 20 (0-75)
a Percentage of MTT conversion was calculated by comparing the OD of the drug containing well with that of the drug-free 
well.
b The median and range of percentage of MTT conversion calculated by the MTT method were corresponded to MIC 
endpoints determined by the NCCLS method.
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endpoint impossible both by visual reading as well as by 
spectrophotometer.
The colorimetric m ethod using the dye M TT has 
been investigated as an alternative method for the 
NCCLS method for in vitro susceptibility testing of 
fungi. Its applicability was investigated for the MIC o f 
fluconazole against 101 yeast isolates, and high levels 
o f  agreement with the NCCLS m ethod were reported 
(1). In the same study, the authors found that the MICs 
could be determined 24 h earlier with the M TT method. 
A lthough previous studies have shown that the M TT 
m ethod resulted in interpretable dose-response curves 
with both amphotericin B  and itraconazole against 
A. fum igatus (9, 10), the applicability o f  the MTT 
m ethod for the antifungal susceptibility testing o f 
various filamentous fungi against different antifungal 
drugs and the comparison o f  this m ethod with the 
NCCLS m ethod (M-38P) had not been studied.
Overall, the levels o f  agreement between the 
M TT and NCCLS methods within 1 dilution were 
95.8% based on MIC-0 and 92.3% based on MIC-1 
(Table 2). The M TT method relies on metabolic activity 
o f  mycelia (6, 11) and, thus, not directly on growth. 
Any factor which influences the metabolic rate m ight 
have an effect on reduction o f  M TT even i f  the biomass 
remains the same. The high levels o f  agreement with the 
NCCLS method m ight indicate that growth corresponds 
directly with the metabolic status o f  fungi. However, 
different levels o f  agreem ent were found between the 
genera, with A spergillus spp. showing higher levels o f  
agreem ent (97% ± 2.5%) than Scedosporium  spp. 
(87%  ± 10.3%) and Fusarium  spp. (78% ± 7.8%). This 
could be explained by the different rates and m anner o f 
sporulation and, i f  true, indicates potential difficulties in 
developing a general, accurate, comprehensive assay for 
testing the susceptibility o f  conidium-forming 
filamentous fungi in vitro.
Although the m icrotitration plates were prepared 
ex novo, the two methods showed high reproducibility 
since the levels o f agreem ent among the replicates were 
97.6 and 96.7% (NCCLS) and 94.8 and 89.5% (MTT) 
based on MIC-0 and MIC-1, respectively. The lower 
reproducibility o f  MIC-1 compared with that o f  MIC-0 
in the M TT m ethod could be explained by the high 
sensitivity o f  the assay. D ifferent variables in the 
conditions o f incubation, such as batch o f  medium, 
tem perature, and evaporation, m ight have an effect in 
the reduction o f  M TT influencing the less-stable MIC-1 
endpoint to a higher degree.
The correlation o f  the MIC endpoints in two m e­
thods showed some discrepancies since only 84.7% o f 
the MIC-0s determined by the NCCLS method 
corresponded with metabolic activity low er than 5%, as 
assessed by M TT conversion, and 63.9% o f visually 
determined MIC-1s by the NCCLS m ethod corre­
sponded to M TT conversion lower than 25%  (Table 3).
The discrepancies that occurred from the comparison o f 
MIC endpoints were expected since the accurate 
method o f  M TT precisely quantifies the growth in each 
well, which is very difficult to achieve by visual 
reading.
In order to increase the reduction o f  M TT and 
diminish the incubation period required for the MIC 
determination, it has been suggested to use menadione, 
an electron-coupling agent that increases the reduction 
o f  M TT (3, 6, 9, 10). However, we were able to increase 
the reduction o f  M TT just by adding the dye to the 
inoculum and by incubating the fungi with the dye for 
48 and 72 h. This resulted in a 1.5- to 5-fold increase o f 
absorption due to the higher production o f  formazan 
(Fig. 2). To ensure that M TT does not inhibit the growth 
o f  fungi, we incubated the fungi with different 
concentrations o f  MTT. All fungi were inhibited by a 
high concentration o f  MTT, although the susceptibility 
varied among the species. No inhibition was observed at 
a concentration o f 0.125 mg/ml or lower when all the 
isolates were incubated for 72 h with the dye (Fig. 1). 
Therefore, a final concentration o f  0.1 mg o f  MTT/ml 
was used in the m odified M TT assay.
The agreement o f  this new assay with the NCCLS 
method was lower than that o f  the M TT method (86.6% 
for MIC-0 and 78.5% for MIC-1), probably due to 
interexperimental variability (different plates) and its 
higher sensitivity, since small differences in the growth 
rate can result in large differences in the am ount o f 
formazan that is produced. The discrepancies for 
UR9825 and voriconazole were statistically significant. 
This could be related to the trailing effect, which might 
influence the results obtained by the m odified MTT 
method more than those derived by the M TT assay. 
However, the modified assay was very reproducible 
(92.8% for MIC-0 and 89.6% for MIC-1), compared to 
the M TT method.
The M TT m ethod incorporates several 
advantages. It is easy to perform and objective (1). The 
MICs o f  antifungal drugs can be determined rapidly 
since it can produce results after 24 h for Aspergillus  
spp. and 48 h for Scedosporium  spp., although the 
reduction o f  M TT increased during prolonged 
incubation (unpublished observations). The MTT 
method is reproducible and reliable. It provides good 
agreem ent with the NCCLS method while overcoming 
some o f  its drawbacks. The main advantage o f  the MTT 
method is that it enables precise quantification o f 
hyphal proliferation o f  moulds and can assess even very 
small differences. This property is very im portant in 
cases that interactions between combinations o f 
antifungal agents are studied (12).
A  drawback o f  the M TT m ethod is the 
requirem ent o f  high numbers o f cells, especially i f  they 
have low  m etabolic activity (6), in order to achieve 
measurable M TT reduction. Furthermore, the high
44
MTT METHOD FOR IN VITRO TESTING OF FILAMENTOUS FUNGI
sensitivity can decrease the reproducibility in some 
experimental designs. The extraction o f  formazan 
crystals is perform ed by dissolution in organic solvents 
(15), which precludes direct spectrophotometric 
measurem ent o f  absorption (20) and prevents the 
assessm ent o f  fungicidal concentration o f the drugs. 
Furthermore, an additional extraction step is required to 
visualize the reduction o f  M TT (20). Alternatively, 2,3- 
{bis(2-methoxy-4-nitro-5-[(sulfophenylamino)carbonyl] 
-2H-tetrazolium-hydroxide} (XTT) could be considered 
an alternative since it is reduced to a water-soluble 
formazan product (8, 20; J. M eletiadis, unpublished 
observations).
In conclusion, the M TT method can be used as an 
alternative m ethod to the NCCLS method since it 
shows high levels o f  agreem ent with the NCCLS 
method. The spectrophotometric reading provides more 
detailed information on the antifungal activity in each 
well. Furthermore, optimalization o f  the M TT method 
m ay overcome the above-mentioned drawbacks. The 
m odified assay we described in this study could be the 
starting point for further optimization o f  the M TT 
method.
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C o l o r i m e t r i c  A s s a y  f o r  A n t i f u n g a l  S u s c e p t i b i l i t y  T e s t i n g
o f  A s p e r g i l l u s  S p e c i e s
J o s e p h  M e l e t i a d i s 1, J o h a n  W . M o u t o n 2, J a c q u e s  F. G. M . M e is 2, B i a n c a  A. B o u m a n 1,
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Microbiology and Infectious Diseases, Canisius- Wilhelmina Hospitaf, Nijmegen, The Netherlands
A co lorim etric  assay fo r an tifungal susceptib ility  testing  of A sperg illu s  species (A sperg illu s  
fum igatus, A sperg illu s flavus, A sperg illu s terreus , A sperg illu s n idu lans, an d  A sperg illu s ustus) is 
described  based  on th e  reduction  of the  te trazo lium  salt 2,3-bis{2-m ethoxy-4-nitro-5- 
[(sulphenylam ino) carbonyl]-2H -tetrazo lium -hydroxide} (X TT) in th e  presence of m enad ione as 
an  electron-coupling  agent. T he com bination  of 200 ^ g  of X T T /m l w ith  25 ^ M  m enadione 
resu lted  in a high p ro d u c tio n  of fo rm azan  w ith in  2 h of exposure, allowing th e  detection of 
h yphae fo rm ed  by low inocula of 102 C FU /m l a fte r 24 h of incubation . U nder these settings, the  
fo rm azan  p ro d u c tio n  co rre la ted  linearly  w ith  th e  fungal biom ass an d  less-variable concen tra tion  
effect curves fo r am photeric in  B an d  itraconazo le  w ere obtained .
Tetrazolium salts are heterocyclic organic 
compounds that substitute the natural final acceptor 
(oxygen) in the biological redox process and are reduced 
to formazan derivatives by receiving electrons 
enzymically from substances of the hydrogen transport 
system or nonenzymically from artificial electron 
transporters (phenazine methosulfate and menadione), 
which enhance the reaction. Tetrazolium salts can 
penetrate rapidly into intact cells and directly into 
subcellular membranes with dehydrogenase activity, 
where they are converted to colored formazan 
derivatives (1, 14). Therefore, they were used as 
indicators o f  reducing systems. The tetrazolium  salt 
M TT has been used for antifungal susceptibility testing 
o f  various yeasts and filamentous fungi, and testing was 
in agreement with the corresponding standard methods 
recommended by the National Committee for Clinical 
Laboratory Standards (NCCLS) (2, 7, 11). The 
disadvantage o f  MTT, however, is that the process 
includes the solubilization o f  formazan derivatives. As 
an alternative, a new tetrazolium  salt, 2,3-bis{2- 
methoxy-4-nitro-5-[(sulphenylamino) carbonyl]-2H-tet- 
razolium-hydroxide} (XTT) (10), has been employed for 
antifungal susceptibility testing o f  yeasts and resulted in
*EC-TMR-EUROFUNG network (ERBFMRXCT97- 
0145). The Eurofung Network consists of the following 
participants: Emmanuel Roilides and Nicos Maglaveras, 
Aristotle University, Thessaloniki, Greece; Tore 
Abrahamsen and Peter Gaustad, Rikshospitalet National 
Hospital, Oslo, Norway; David W. Denning, University of 
Manchester, Manchester, United Kingdom; Paul 
E. Verweij and Jacques F. G. M. Meis, University of 
Nijmegen, Nijmegen, The Netherlands; Juan L. Rodriguez- 
Tudela, Instituto de Salud Carlos III, Madrid, Spain; and 
George Petrikkos, Athens University, Athens, Greece.
clear-cut endpoints for various antifungal agents (4, 15). 
XTT is converted into a water-soluble formazan, thereby 
avoiding the additional steps for the solubilization o f 
formazan derivatives (8, 12), but needs the presence o f 
an electron-coupling agent. The nature and the 
concentration o f  this agent are critical in order to obtain 
a good correlation between the formazan production and 
the num ber o f  viable fungi and less-variable 
concentration effect curves (1, 15).
We developed a colorimetric assay for the 
quantification o f  fungal growth o f  five different 
A spergillus species based on the tetrazolium  salt XTT 
by standardizing various factors that influence XTT 
conversion. This assay was also tested in the presence 
o f  antifungal drugs in order to ascertain its potential for 
antifungal susceptibility testing o f  filamentous fungi.
M a t e r ia l s  an d  M e t h o d s
Isolates. Two clinical isolates of Aspergillus 
fumigatus [AZN5161 (S) and AZN 5241 (R)] and one each of 
Aspergillus flavus (AZN 510), Aspergillus terreus (AZN 
7320), Aspergillus nidulans (AZN 8933), and Aspergillus 
ustus (AZN 9420) from our private collection was selected, 
and Candida parapsilosis (ATCC 22019) and Candida krusei 
(ATCC 6258) were used for quality control. Isolates were 
revived by subculturing them twice onto sabouraud glucose 
agar (SAB) plates with chloramphenicol first at 30°C and 
then at 37°C for 5 to 7 days. Conidia were collected with a 
swab and suspended in sterile saline containing 0.05% Tween
20. After the heavy particles were allowed to settle for 5 to 
10 min, the turbidity of the supernatants were measured 
spectrophotometrically (Spectronic 20D; Milton Roy, 
Rochester, N.Y.) at 530 nm and transmission was adjusted to 
80 to 82%, corresponding to an inoculum size of 1 x 106 to 
5 x 106 CFU/ml. The inoculum size was confirmed by plating 
serial dilutions of conidia suspensions on SAB plates.
49
CHAPTER 2.3
Medium. RPMI 1640 medium (with L-glutamine; 
without bicarbonate) (GIBCO BRL, Life Technologies, 
Woerden, The Netherlands) buffered to pH 7.0 with 0.165 M 
3-A/-morpholinopropanesulfonic acid (MOPS) (Sigma- 
Aldrich Chemie GmbH, Steinheim, Germany) was used 
throughout.
XTT. XTT (Sigma Chemical, St. Louis, Mo.) was 
dissolved in saline at a final concentration of 1 mg/ml. The 
solution was filtered through a 0.22 ^m-pore-size filter.
Electron-coupling agents. Two electron acceptors 
were evaluated, menadione (Sigma-Aldrich Chemie GmbH) 
and phenazine methosulfate (PMS) (Sigma-Aldrich Chemie 
GmbH). Menadione was first dissolved in acetone at a 
concentration of 10 mM and was then diluted 1:10 in saline. 
PMS was directly dissolved in saline at a final concentration 
of 1 mM. Further dilutions of both agents were made in 
saline.
Antifungal drugs. Itraconazole (Janssen-Cilag, 
Beerse, Belgium) and amphotericin B (Bristol-Myers Squibb, 
Woerden, The Netherlands) were dissolved in dimethyl 
sulfoxide (DMSO) at final concentrations of 3,200 and 
1,600 mg/liter, respectively.
XTT assay. Conidia suspensions of each species were 
diluted 1: 100 in the medium, and 200 ^l was inoculated in 
96-well flat-bottom microtitration plates (Costar, Corning, 
N.Y.). After 24 or 48 h of incubation at 37°C, 50-^l aliquots 
of various concentrations of XTT with either menadione or 
PMS were added to the wells in order to obtain final 
concentrations of 200, 100, and 50 ^g of XTT/ml and 
100, 25, 6.25, 1.56, and 0.39 ^M menadione or PMS. The 
microtitration plates were incubated further for 6 h at 37°C 
and the optical density at 450 nm (OD450) was measured at 
hourly intervals by spectrophotometer (Rosys Anthos ht3; 
Anthos Labtec Instruments GmbH, Salzburg, Austria). The 
XTT assay was performed for each species in triplicate and 
the ODs after 1, 2, and 4 h of exposure to various 
concentrations of XTT and the two electron coupling agents 
of fungi incubated for 24 and 48 h were plotted.
Quantitative assay of fungal viability. The 
relationship between the number of viable fungi and the 
amount of XTT reduction was tested by incubating various 
inocula of Aspergillus conidia (102 to 106 CFU/ml) with XTT 
and various concentrations of menadione. Conidia 
suspensions were diluted 1:10 serially in the medium to up to 
102 CFU/ml. Then, 96-well flat-bottom microtitration plates 
were inoculated with 200 ^l of each conidia dilution. After 
24 h of incubation at 37°C, 50-^l aliquots of XTT and various 
concentrations of menadione were added to each well in order 
to obtain final concentrations of 200 ^g/ml for XTT and 
100, 25, 6.25, 1.56, and 0.39 ^M for menadione. The 
microtitration plates were then incubated for another 2 h, after 
which 100 ^l of the supernatant of each well was transferred 
in clean wells. The OD450 was measured spectropho- 
tometrically. This experiment was performed in triplicate for 
each species, and the data were analyzed by linear regression 
analysis. Regression lines were plotted for each concentration 
of menadione and for each species, together with the 95% 
confidence intervals. The slopes and the r 2 of each regression 
line were reported as an estimation of steepness of the line 
and the goodness of fit, respectively. An r2 value of
1 indicates perfect correlation. The nonlinearity of the curves 
was checked by a runs test following the linear regression.
Antifungal susceptibility assay. Stock solutions of 
antifungal drugs were serially diluted twofold in DMSO, and 
then each drug concentration was diluted 1:50 in the medium 
in order to obtain twofold final concentrations which ranged 
from 0.015 to 16 mg of amphotericin B/liter and 0.03 to 
32 mg of itraconazole/liter. Wells of 96-well flat-bottom 
microtitration plates were filled with 100 ^l of each drug 
concentration. A drug-free well containing 2% DMSO in the 
medium served as the growth control. Each well was 
inoculated with 100 ^l of conidia suspensions diluted 1:50 in 
medium in order to obtain a final inoculum of 1 x 104 to 
5 x 104 CFU/ml. The plates were incubated for 24 or 48 h at 
37°C, and the MIC-0 was determined visually by four 
different observers to be the lowest drug concentration 
showing no visible growth (NCCLS) (9). Afterwards, the OD 
of each well at 405 nm was measured in order to quantify the 
biomass of fungal growth (spectrophotometric method). 
Then, 50 ^l of XTT-menadione was added to each well in 
order to obtain final concentrations of 200 ^g/ml and 25 ^M, 
respectively. After 2 h of further incubation, the OD of each 
well at 450 nm was measured in order to quantify the 
formazan production (colorimetric method). Background OD 
was obtained by spectrophotometric measurements of 
noninoculated wells processed in the same way as the 
inoculated wells. The relative ODs for each well based on 
both measurements at 405 and 450 nm were calculated (in 
percent) based on the following equation: [(OD of drug 
containing well — background OD)/(OD of drug-free 
well — background OD of drug-free well)] x 100%. The tests 
were carried out in triplicate in three independent 
experiments for each strain. Results from each experiment 
were analyzed by nonlinear regression analysis by using a 
four parameter logistic model (sigmoid curve with variable 
slope) known as the Emax model, which is described by the 
following equation: E = Emax x (D/EC50)m/[1 + (D/EC50)m], 
where E is the relative OD (dependent variable), Emax is the 
maximum relative OD, D  is the drug concentration 
(independent variable), EC50 is the drug concentration 
producing 50% of the Emax, and m is the slope that describes 
the steepness of the curve (3). Since data were normalized by 
using the relative ODs, the top and the bottom of the Emax 
model corresponded to 100 and 0%, respectively. Analysis 
was carried out using the GraphPad Prism Software (San 
Diego, Calif.). Deviation from the model was tested by the 
runs test, and goodness of fit was checked by the r2 values. In 
order to compare the concentration effect curves generated by 
the spectrophotometric and colorimetric methods, the best-fit 
values of EC50 and slope (m) obtained by the regression 
analysis were used. The differences between the best-fit 
values of the concentration effect curves for all species were 
analyzed by analysis of variance followed by a Bonferroni 
post test. The significance level of 0.05 was chosen.
R e su l t s
X T T  assay. The tetrazolium  salt XTT was not 
m etabolized by any o f  the A spergillus species until an
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24h 1h 24h 2h 24h 4h
Electron-coupling Agent ( mM)
48h 2h
Electron-coupling Agent ( mM) Electron-coupling Agent ( mM)
- 200mg/ml X T T  + menad ione
- 200 mg/ml X T T  + PMS
- 100 mg/ml X TT  + menad ione
- 100 mg/ml X T T  + PMS
- 50 mg/ml X T T  + m enad ione
- 50 mg/ml X T T  + PMS
Figure 1. XTT reduction by Aspergillus species. The Aspergillus strains were incubated for 24 or 48 h and were 
then exposed for 1, 2, and 4 h to various concentrations of XTT, 200 (squares), 100 (triangles) and 50 (circles) ^g/ml, 
combined with menadione (close symbols) or PMS (open symbols) at various concentrations (0.39, 1.56, 6.25, 25, 
and 100 ^M). Each data point represents the average of all strains tested in triplicate.
electron-coupling agent was added. Conversion o f XTT 
by a certain amount o f  hyphae depended on the 
concentration o f  XTT and the exposure time as well as 
the electron-coupling agent and its concentration (Fig. 
1). Between the three concentrations o f  XTT used, 
200 ^g/m l resulted in two-tim es-higher formazan 
production than 100 and 50 ^g/ml, for which the 
formazan production was similar. Among the two 
electron-coupling agents, m enadione was eight times 
more potent than PMS for all A spergillus species. The 
use o f  PMS resulted in a background absorbance higher 
than that o f  menadione, especially at the concentration 
o f  100 ^M , where the OD o f  the blank after 6 h o f 
exposure was 0.805 for PMS and 0.347 for menadione. 
Relatively lower background absorbances (»0.2) were 
observed at maximal concentrations o f  25 ^M  
m enadione and 1.56 ^M  PMS (data not shown). Any 
increase o f  m enadione concentration beyond 25 ^M  did 
not have any effect in formazan production when XTT 
was exposed for longer than 2 h to fungi which were 
incubated for 48 h.
Q u an tita tiv e  assay of fungal viability . The 
relationship between the XTT conversion and 
increasing inocula o f  A spergillus species was tested 
using 200 ^g o f  XTT/ml with 25 ^M  menadione after
2 h o f  exposure. The analysis o f  results showed a linear 
relationship between the Od  and log CFU (Fig. 2). The
slopes and the coefficients obtained by the regression 
analysis depended on the concentration o f menadione 
used for each species.
A general pattern o f  concentration dependence 
was observed for all five species. A t menadione 
concentrations lower than 1.56 ^M , low XTT 
conversion rates were apparent (slopes ranged between 
0.01 and 0.13) for all species. For A. nidulans and 
A. flavus, low conversion rates were also observed at a 
m enadione concentration o f  6.25 ^M  (Table 1). The 
conversion rates increased at higher concentrations o f 
menadione, generating higher slopes, up to 0.65, as in 
the case o f  A. terreus w ith 100 ^M  menadione. 
However, at this concentration o f menadione, larger 
deviations from linearity were observed for all species 
(except A. ustus) and very low slopes were obtained for 
A. fum igatus (R) and A. flavus (0.05 and 0.22, respe­
ctively). In addition, at the concentration o f 100 ^M  
menadione, formazan production exceeded an OD o f
3 after 4  h o f  exposure o f  XTT, which was the detection 
limit o f  the spectrophotometer, especially when hyphae 
were exposed to XTT after 48 h o f  incubation.
Among the different concentrations o f menadione 
that were evaluated, relatively higher conversion rates 
and more linear relationships between formazan 
production and viable fungi were generated with the 
concentration o f  25 ^M  for all species (Table 1). In ad­
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A. fumigatus (R) A. flavus A. terreus
CFU/ml CFU/ml CFU/ml
A. nidulans A. ustus
CFU/ml CFU/ml
□ 100 mM
A 25 mM
V 6. 25 mM
O 1. 56 mM
O 0. 39 mM
Figure 2. Relationship between the amount of XTT and increasing inocula of each Aspergillus species. The reduction 
of 200 ^g of XTT/ml in the presence of various concentrations of menadione (0.39, 1.56, 6.25, 25, and 100 ^M) was 
tested in triplicate for each strain. The symbols are the means of the triplicates, and the lines were generated by linear 
regression analysis. Dotted lines represent the 95% confidence intervals of the regression lines.
dition, the formazan production at this concentration 
was high within 2 h o f  exposure without exceeding the 
detection limit o f  the spectrophotometer (OD o f  3) and 
low background absorbance was obtained.
A ntifungal susceptib ility  assay. For all 
A spergillus  species, the NCCLS MICs o f  amphotericin 
B ranged from 0.5 to 4 m g/liter and those o f 
itraconazole ranged from 0.25 to 0.5 m g/liter except for 
A. fum igatus (R) and for A. ustus, for which the MICs 
were higher than 2 m g/liter (Table 2). Concentration 
effect curves based on the conversion o f  XTT by 
hyphae are shown in Fig. 3 (right-hand). All curves 
show similar patterns and are characterized by two 
plateaus connected by a drop in relative OD. In the case 
o f  a resistant strain, significant XTT conversion was 
observed in higher concentrations [A. ustus and
A. fum igatus (R) against itraconazole; Fig. 3]. The three 
phases o f  XTT conversion were clearly distinguishable 
for amphotericin B, for which steep concentration effect 
curves were obtained. In contrast, for itraconazole, more 
shallow curves were generated.
The concentration effect curves obtained by the 
colorimetric and the spectrophotometric assessments o f 
fungal growth (Fig. 3) were analyzed by the Emax model 
with variable slope, and the best-fit values o f  the two 
variables EC50 and slope (m) were compared for each 
species, drug, and incubation period. The model fitted 
the data very well since the i2 ranged between 0.85 and 
0.99 (median, 0.95) and no statistically significant 
deviations from the model were found (P  > 0.1). No 
statistically significant differences were found by 
analysis o f  variance between the best-fit values o f  the
Table 1. Results of linear regression analysis of the relationship between the amount of XTT reduction in the presence of 
different concentrations of menadione and increasing inocula of each Aspergillus species after 24 h of incubationa
Relationship between menadione concentration and Aspergillus inoculum (log CFU/ml)
Species 10 0  mM 25 mM 6.25 mM 1.563 mM 0.39 mM
Slope 2r Slope 2r Slope 2r Slope 2r Slope 2r
A. fumigatus (R) 0.05 0.368 0.26 0.884 0.20 0.853 0.04 0.524 0.01 0.359
A. flavus 0.22 0.756 0.28 0.873 0.09 0.549 0.02 0.671 0.01 0.529
A. terreus 0.65 0.869 0.57 0.878 0.38 0.934 0.13 0.862 0.02 0.745
A. nidulans 0.42 0.894 0.35 0.929 0.07 0.635 0.03 0.787 0.02 0.462
A. ustus 0.52 0.994 0.49 0.936 0.30 0.926 0.08 0.908 0.02 0.802
a Each replicate was analyzed as a separate point. Data used for calculations were OD and log CFU.
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Table 2. Best-fit values and the 95% CIs obtained by non-linear regression analysis3
Drug and 
incubation 
period
Results of antifungal susceptibility assay
Species MICs-0
(NCCLS)b
EC50 ± 95% CI (mg/l) Slope m ± 95% CI
SP XTT SP XTT
AB, 24 h A. fumigatus (S) 0.5 (0.125-0.5) 0.20 ± 0.05 0.22 ± 0.04 -1.65 ± 0.63 -2.18 ± 0.78
A. fumigatus (R) 2 (1-4) 0.51 ± 0.06 0.38 ± 0.11 -7.04 ± 7.04 -1.33 ± 0.44
A. flavus 1 (0.5-1) 0.42 ± 0.19 0.65 ± 0.08 -1.27 ± 0.61 -7.33 ± 3.18
A. nidulans 1 (1-4) 0.21 ± 0.09 0.33 ± 0.03 -1.47 ± 0.72 -4.11 ± 1.09
A. terreus 1 (1-2) 0.27 ± 0.12 0.66 ± 0.10 -1.00 ± 0.41 -8.69 ± 4.71
A. ustus 2 (1-2) 0.47 ± 0.09 0.35 ± 0.12 -3.58 ± 2.56 -1.11 ± 0.34
AB, 48 h A. fumigatus (S) 1 0.41 ± 0.07 0.37 ± 0.05 -2.88 ± 1.25 -5.09 ± 2.14
A. fumigatus (R) 4 (2-4) 1.13 ± 0.93 1.00 ± 0.68 -6.42 ± 6.42 -1.22 ± 0.51
A. flavus 1 (1-2) 0.73 ± 0.18 1.23 ± 0.14 -2.94 ± 1.79 -8.41 ± 4.29
A. nidulans 2 (2-4) 0.25 ± 0.10 1.09 ± 0.12 -1.24 ± 0.51 -5.10 ± 3.98
A. terreus 4 (2-4) 0.63 ± 0.16 0.96 ± 0.09 -2.67 ± 1.54 -7.00 ± 7.00
A. ustus 2 (1-2) 0.27 ± -0.09 0.45 ± 0.13 -1.08 ± 0.37 -1.14 ± 0.31
ICZ, 24 h A. fumigatus (S) 0.5 (0.5-1) 0.15 ± 0.02 0.16 ± 0.04 -1.26 ± 0.23 -1.39 ± 0.42
A. fumigatus (R) >32 6.27 ± 5.80 > 32 -0.42 ± 0.17 -0.24 ± 0.12
A. flavus 0.25 (0.25-0.5) 0.07 ± 0.01 0.09 ± 0.02 -1.42 ± 0.25 -1.64 ± 0.54
A. nidulans 0.5 (0.25-0.5) 0.07 ± 0.01 0.10 ± 0.01 -2.54 ± 0.86 -1.86 ± 0.41
A. terreus 0.5 (0.25-0.5) 0.07 ± 0.02 0.05 ± 0.01 -1.46 ± 0.44 -1.32 ± 0.21
A. ustus 2 (0.5->32) 0.20 ± 0.08 0.37 ± 0.08 -0.89 ± 0.26 -1.83 ± 0.61
ICZ, 48 h A. fumigatus (S) 1 (0.5-1) 0.15 ± 0.03 0.17 ± 0.05 -1.26 ± 0.27 -1.33 ± 0.40
A. fumigatus (R) >32 > 32 > 32 -0.04 ± 0.04 0.00 ± 0.00
A. flavus 0.5 0.07 ± 0.01 0.21 ± 0.01 -1.17 ± 0.18 -6.06 ± 1.92
A. nidulans 0.5 (0.25-0.5) 0.08 ± 0.01 0.17 ± 0.02 -3.44 ± 1.44 -1.87 ± 0.43
A. terreus 0.5 (0.5-1) 0.11 ± 0.02 0.09 ± 0.02 -1.63 ± 0.53 -1.36 ± 0.33
A. ustus >32 0.48 ± 0.22 3.34 ± 1.41 -0.56 ± 0.16 -0.53 ± 0.12
Data were obtained by nonlinear regression analysis using the Emax model with variable slopes for the concentration effect curves 
obtained by spectrophotometric (SP) and colorimetric (XTT) methods after 24 and 48 h of incubation with serial twofold dilutions of 
amphotericin B (AB) and itraconazole (ICZ). 95% CI, 95% confidence intervals.
1 Data were the most frequently observed MIC and the range of MICs. MICs were determined visually by four different observers and 
three independent experiments.
two concentration effect curves for each drug and 
incubation period (P  > 0.05) with the exception o f  the 
concentration effect curves o f amphotericin B  after 
48 h, where statistically significantly steeper curves 
(higher absolute m  values) were obtained by the 
colorimetric m ethod than by the spectrophotometric 
m ethod (P  < 0.01). However, the slopes and the EC50s 
o f  the fitted model were similar for the concentration 
effect curves obtained by the two methods (Table 2). 
Overall, the m edian coefficient variation o f  the log 
EC50s and the slope m  o f  the fitted model for the six 
strains among the replicates was 22 and 25%, 
respectively, for the colorimetric method and 37 and 
38%, respectively, for the spectrophotometric method. 
Furthermore, the discrimination between the in vitro 
itraconazole-resistant strains and the other itraconazole- 
susceptible strains was clearer in concentration effect 
curves o f  the colorimetric m ethod than those o f 
spectrophotometric method (Fig. 3).
D isc u s sio n
The tetrazolium  salt XTT was converted by 
A spergillus species only in the presence o f  an electron- 
coupling agent, as was found with yeasts (14). As 
opposed to mam m alian cells (12) but similar to yeasts 
(15), among the two electron-coupling agents tested 
m enadione was more potent than PMS. Since PM S 
exhibited a background higher than that found in 
previous studies (12, 13) and inhibitory effects at 
elevated concentrations were reported previously (1), 
m enadione was chosen as the electron-coupling agent 
for the XTT assay o f  A spergillus  species.
The concentration o f  XTT is another important 
factor since it was found that high concentrations o f 
XTT result in inhibition o f  formazan production while 
very low concentrations can result in poor conversion 
(15). No inhibition was observed among the three 
concentrations tested in this study. Preliminary studies 
showed that XTT was not toxic for conidia (unpublished
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Spectrophotometric method 
AB after 24 h
Amphotericin B (mg/l) 
AB after 48 h
Amphotericin B (mg/l) 
ICZ after 24 h
Itraconazole (mg/l) 
ICZ after 48 h
Itraconazole (mg/l)
A. fumigatus (S) — A. fumigatus (R)
Colorimetric method 
AB after 24 h
Amphotericin B (mg/l) 
AB after 48 h
relativéHOD (%)
T0  c 2  c 2  ( 2  c
2
Amphotericin B (mg/l) 
ICZ after 24 h
Itraconazole (mg/l) 
ICZ after 48 h
Itraconazole (mg/l)
- A. flavus A. terreus — A. ustus A. nidulans
Figure 3. Concentration effect curves for amphotericin B (AB) and itraconazole (ICZ). Conidia of each Aspergillus spp. 
tested were incubated for 24 and 48 h and the OD of hyphal growth at 405 nm was measured for each well. Then, hyphae 
were exposed to 200 ^g of XTT/ml plus 25 of menadione for 2 h and the OD at 450 nm was measured. Concentration 
effect curves based on the spectrophotometric method (left-hand) and colorimetric method (right-hand) were constructed, 
and the relative ODs for each drug concentration represent the amount of formazan produced and the fungal biomass, 
respectively, for each method compared with the growth control. A. ustus and A. fumigatus (R) showed NCCLS MICs 
higher than 2 mg of itraconazole/liter. Means with the standard errors of triplicates are represented for each strain.
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observation). A t higher concentrations o f  XTT 
(200 ^g/m l), the rate o f  formazan production increased 
rapidly. Therefore, a concentration o f  200 ^g o f 
XTT/ml was used for further studies. XTT and 
m enadione at the above concentrations were stable 
when they were stored separately for up to 3 months at 
room tem perature and 4, -2 0 , and -70°C  (unpublished 
data).
The linear relationship between the formazan 
production using 200 ^g o f  XTT/ml and menadione 
with increasing inocula o f A spergillus  species indicates 
that the XTT assay is a reliable indicator o f  fungal 
biomass. The linearity and the slopes o f  this 
relationship depended on the concentration o f 
m enadione for each o f  the A spergillus  species. A t a 
concentration o f  25 ^M , high coefficients and slopes for 
all A spergillus species tested were found, unlike with 
yeasts, for which lower concentrations o f  menadione 
(1 ^M ) were required to generate a linear relation 
between XTT conversion and CFU (15). For 
A spergillus  species, m enadione concentrations higher 
than 25 ^M  generated a less linear CFU-OD 
relationship, which explains the conclusions o f  Jahn et 
al., who found that when XTT was used with 1,000 ^M  
menadione, a less-well-defined correlation was 
observed (5).
The XTT assay was applied in the presence o f 
antifungal drugs generating less-variable concentration 
effect curves. For amphotericin B, clear-cut endpoints 
were obtained since XTT conversion was absent once 
the MIC was exceeded, as was found previously (15). 
For itraconazole, shallow concentration effect curves 
were obtained due to a partial inhibition o f  growth and 
possible interference o f  the drug in the m etabolic status 
o f  fungi. Furthermore, as was found in a previous study 
(14), discrimination between susceptible and resistant 
strains may be facilitated by using the XTT assay since 
resistant strains converted XTT even at a high 
concentration o f  antifungal drugs.
The need for the use o f  m enadione in the XTT 
assay described here offers the possibility o f  increasing 
the sensitivity o f  this assay by adjusting the 
concentration o f  menadione. In this way, it would be 
possible to detect the metabolic capacity o f  slow- 
growing fungi. Also, incubation periods proposed by 
the NCCLS to determine the MICs m ay be shortened if  
conversion o f  XTT o f the growth control is sufficient. 
However, the developm ent o f  a tetrazolium  salt which 
m ight not require the addition o f  an electron-coupling 
agent would be a favorable step since the need o f  an 
electron-coupling agent complicates the assay more and 
m ay increase variability (13). Variability m ay also be 
increased by the lack o f  a step for the term ination o f 
XTT conversion since small variation in incubation time 
would influence the formazan production.
In conclusion, the XTT-menadione system 
described in this study provides an assay which enables 
the quantification o f  metabolic activity o f  A spergillus  
species and which could be applied for other 
filamentous fungi like it was shown with M TT (7).
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Departments of Medical Microbiology1 and Hematology3, University Medical Center Nijmegen, and Department of Medical 
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The susceptibilities of 25 clinical isolates of various Aspergillus species (Aspergillus 
fumigatus, A. flavus, A. terreus, A. ustus, and A. nidulans) to itraconazole (ICZ) and amphotericin 
B (AB) were determined using the standard proposed by NCCLS for antifungal susceptibility 
testing of filamentous fungi, a modification of this method using spectrophotometric readings, 
and a colorimetric method using the tetrazolium salt 2,3-bis{2-methoxy-4-nitro-5- 
[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide} (XTT). Five MIC end points for ICZ 
(MIC-0, no visible growth or £5%  the growth control value [GC]; MIC-1, slight growth or 6 to 
25% the GC; MIC-2, prominent reduction in growth or 26 to 50% the GC; MIC-3, slight 
reduction in growth or 51 to 75% the GC; and MIC-4, no reduction in growth or 76 to 100% the 
GC) and one for AB (MIC-0) were determined visually by four observers and 
spectrophotometrically. The intraexperimental (between the observers) and interexperimental 
(between the experiments) levels of agreement of the NCCLS and XTT methods exceeded 95%  
for MIC-0 of AB and MIC-0 and MIC-1 of ICZ. The MIC-2 of ICZ showed lower 
reproducibility, although spectrophotometric reading and/or incubation for 48 h increased the 
interexperimental reproducibility from 85 to >93%. Between visual and spectrophotometric 
readings, high levels of agreement were found for AB (»97%) and MIC-1 (»92%) and MIC-2 
(»88%) of ICZ. Poor agreement was found for MIC-0 of ICZ (51% after 24 h), since the 
spectrophotometric readings resulted in higher MIC-0 values than the visual readings. The 
agreement was increased to 98% by shifting the threshold level of MIC-0 from 5 to 10% relative 
optical density and by establishing an optical density of greater than 0.1 for the GC as the 
validation criterion. No statistically significant differences were found between the NCCLS 
method and the XTT method, with the levels of agreement exceeding 97% for MIC-0 of AB and 
83% for MIC-0, MIC-1, and MIC-2 of ICZ. The XTT method and spectrophotometric readings 
can increase the sensitivity and the precision, respectively, of in vitro susceptibility testing of 
Aspergillus species.
Opportunistic systemic mycoses caused by 
filamentous fungi occur more frequently now than 
before partly as a consequence o f the larger numbers of 
individuals receiving more potent immunosuppressive
*EC-TMR-EUROFUNG network (ERBFMRXCT97- 
0145). The Eurofung Network consists of the following 
participants: Emmanuel Roilides and Nicos Maglaveras, 
Aristotle University, Thessaloniki, Greece; Tore 
Abrahamsen and Peter Gaustad, Rikshospitalet National 
Hospital, Oslo, Norway; David W. Denning, University of 
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E. Verweij and Jacques F. G. M. Meis, University of 
Nijmegen, Nijmegen, The Netherlands; Juan L. Rodriguez- 
Tudela, Instituto de Salud Carlos III, Madrid, Spain; and 
George Petrikkos, Athens University, Athens, Greece.
therapy (1). The pathogens most frequently encountered 
belong to the genus Aspergillus, with Aspergillus 
fumigatus being responsible for over 90% of invasive 
infections in humans (10). Amphotericin B (AB) and 
itraconazole (ICZ) are the only licensed antifungal 
drugs available for treatment (4), although their efficacy 
is limited, perhaps partly because of drug resistance. 
Therefore, testing o f the susceptibility o f these 
pathogens may contribute to the management of 
patients. Such testing requires standardized and 
reproducible techniques (6, 7). Broth microdilution 
methods have been adopted, since they are less 
expensive and cumbersome than macrodilution methods 
and yield reproducible results (2, 5, 18). Fungal growth 
is assessed either visually by grading turbidity (16) or
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spectrophotometrically by measuring optical density 
(OD) (3, 12). Alternatively, biomass can be determined 
colorimetrically using indicator substances that are 
reduced to colored products by viable microorganisms. 
Thus, fungal biomass is estimated by the metabolic 
activity o f the fungus (7, 9, 13).
The hyphae and nonhomogeneous growth of 
filamentous fungi, together with a trailing effect of 
fungistatic drugs, complicate the determination o f MICs 
and do not allow for precise quantification o f fungal 
growth (13). Visual assessment o f fungal growth lacks 
objectivity and precision (13, 19), and the accuracy of 
spectrophotometric readings may be hampered by 
clumps o f mycelia (11, 15). Colorimetric methods may 
be an alternative, since precise quantification o f hyphal 
growth is achieved and clear-cut end points can be 
generated (8). Tetrazolium salts have been used as 
colorimetric indicators, since fungi convert them to 
colored formazan derivatives, which can be quantified 
(18). The tetrazolium salt 3-(4,5-dimethyl-2-thiazyl)- 
2,5-diphenyl-2H-tetrazolium bromide (MTT) has been 
used for antifungal susceptibility testing o f yeasts and 
has recently been shown to be useful for determining 
MICs for filamentous fungi (13, 14). However, the 
usefulness of this assay is limited, since dissolution of 
the formazan derivative is achieved in organic solvents 
and relatively large numbers o f fungi are required (11, 
15).
2,3-Bis{2-methoxy-4-nitro-5-[(sulfenylamino)car- 
bonyl]-2H-tetrazolium-hydroxide} (XTT) is a new 
yellow tetrazolium salt which is converted by 
mitochondrial dehydrogenases of viable fungi to an 
orange formazan product (8, 18, 24). Unlike MTT- 
derived formazan, the product of XTT conversion is a 
water-soluble formazan, which obviates the need for 
solubilization steps (15, 21, 22). The XTT assay has 
been used for testing o f the susceptibility o f yeasts to 
antifungal agents and has yielded a high level of 
agreement with the NCCLS method for various 
Candida species and Cryptococcus neoformans (8). The 
same assay has been used to determine MICs for a small 
collection o f filamentous fungi and has resulted in 
reproducible and comparable results relative to those 
obtained with the NCCLS method (23). A recently 
developed XTT assay for Aspergillus species resulted in 
well-defined dose-response curves for antifungal drugs 
(13a).
In this study, 25 clinical isolates o f five 
Aspergillus species were tested three times against AB 
and ICZ using the method proposed by NCCLS (M38- 
P), and five MIC end points were determined visually 
by four observers. Given the problems encountered 
with the visual observation and spectrophotometric 
assessment o f the hyphal growth of filamentous fungi, 
the results o f M38-P were compared with a 
modification of this method using spectrophotometric
readings at 405 nm. Furthermore, in order to facilitate 
the determination of MICs for filamentous fungi, the 
activities o f antifungal drugs were determined by a 
colorimetric method that uses the dye XTT as described 
previously (13a). The intraexperimental (between the 
observers) and interexperimental (between the 
experiments) agreements o f the methods as well as the 
agreements between the NCCLS and colorimetric 
methods and between visual and spectrophotometric 
readings were calculated.
M a ter ia ls  and  M ethods
Test isolates. Twenty-five clinical isolates of 
Aspergillus species (from our private collection) were 
selected for testing and included 5 isolates each of the 
following species: A. fumigatus (AZN5161, AZN5241, 
AZG7, AZN8248, and AZN8244), A. flavus (AZN137, 
AZN510, AZN2865, AZN4094, and AZN4132), A. nidulans 
(AZN2867, AZN8033, AZN8236, AZN8933, and AZN4606), 
A. terreus (AZN286, AZN515, AZN2868, AZN7320, and 
AZN9152), and A. ustus (AZN677, AZN2725, AZN6989, 
AZN9420, and AZN7843). Candida parapsilosis (ATCC 
22019) and C. krusei (ATCC 6258) were used for quality 
control.
Isolates were cultured twice on Sabouraud glucose 
agar at 30°C for 5 to 7 days. All isolates were tested on three 
different days. Conidia of the isolates were obtained from 
fresh cultures each time.
Medium. RPMI 1640 medium (with L-glutamine but 
without bicarbonate) (GIBCO BRL, Life Technologies, 
Woerden, The Netherlands) buffered to pH 7.0 with 0.165 M 
3-N-morpholinopropanesulfonic acid (MOPS) (Sigma- 
Aldrich Chemie GmbH, Steinheim, Germany) was used as 
the assay medium.
Inoculum. Conidia were collected with a cotton swab 
and suspended in sterile saline containing 0.05% Tween
20. After heavy particles were allowed to settle, the turbidity 
of the supernatants was measured spectrophotometrically 
(Spectronic 20D; Milton Roy, Rochester, N.Y.) at 530 nm, 
and the transmission was adjusted to 80 to 82% to yield an 
initial inoculum of 1 x 106 to 5 x 106 CFU/ml. Each 
suspension was diluted 1:50 in medium to obtain twice the 
desired inoculum. The inoculum size was confirmed by 
plating of serial dilutions on Sabouraud glucose agar plates, 
with final inocula ranging from 1 x 104 to 5 x 104 CFU/ml.
Antifungal susceptibility testing. The broth micro­
dilution method of the NCCLS (M38-P) (16) was performed 
using 96-well flat-bottom microtitration trays. ICZ (Janssen- 
Cilag, Beerse, Belgium) and AB (Bristol-Myers Squibb, 
Woerden, The Netherlands) were dissolved in dimethyl 
sulfoxide (DMSO) and diluted serially in medium to yield 
final concentrations of 0.015 to 16 mg of AB/liter and 0.03 to 
32 mg of ICZ/liter in a final volume of 200 ^l after the 
inoculation. A drug-free growth control that contained 0.5% 
DMSO in medium was included. Trays were kept at -70°C 
until the day of testing.
Incubation and MIC determination. After the 
microtitration trays were defrosted, they were inoculated with
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100 ^l of inoculum. The trays were agitated for 10 s and 
incubated at 37°C for 48 h. The MICs of the antifungal drugs 
were determined after 24 and 48 h of incubation by two 
methods (the NCCLS and XTT methods) and by two modes 
of reading (visual and spectrophotometric) as described 
below.
(i) NCCLS method. (a) Visual reading (NCCLSvis).
Fungal growth was assessed visually by four different 
observers with the aid of a concave mirror and graded 
according to NCCLS guidelines as follows: 4, no reduction in 
growth; 3, slight reduction in growth; 2, prominent reduction 
in growth; 1, slight growth; and 0, absence of visual growth 
compared with the growth in the drug-free well. Only score 
0 was recorded for AB. Four MIC end points (MIC-0, MIC-1, 
MIC-2, and MIC-3) were determined as the lowest drug 
concentrations showing growth scaled to the corresponding 
score (0, 1, 2, and 3, respectively). MIC-4 was determined as 
the highest drug concentration showing growth scaled to 
score 4.
(b) Spectrophotometric reading (NCCLSsp). After 
the MICs were determined visually, the OD of each well was 
measured at 405 nm with a spectrophotometer (Rosys Anthos 
ht3; Anthos Labtec Instruments GmbH, Salzburg, Austria). 
After subtraction of the ODs of the blank, which consisted of 
noninoculated wells that had been incubated together with the 
inoculated wells, from the ODs of the inoculated wells, the 
percentage of growth for each well was correlated with the 
relative OD estimated by the following equation: (OD405 of 
wells that contained the drug/OD405 of the drug-free 
well) x 100. Relative ODs after rounding were grouped in 
five levels: 4, 76 to 100% relative OD; 3, 51 to 75% relative 
OD; 2, 26 to 50% relative OD; 1, 6 to 25% relative OD; and
0, equal to or less than 5% relative OD. Five MIC end points 
were determined for ICZ based on the levels of relative ODs. 
MIC-0, MIC-1, MIC-2, and MIC-3 were determined as the 
lowest drug concentrations with relative ODs of levels
0, 1, 2, and 3, respectively. MIC-4 was determined as the 
highest drug concentration with a relative OD of level 4. Only 
MIC-0 was determined for AB.
Once these determinations were completed, the trays 
were returned to the incubator for another 24 h and read again 
visually and spectrophotometrically.
(ii) XTT method. The MICs were also determined 
colorimetrically using XTT (Sigma-Aldrich Chemie). 
Microtitration trays were prepared and incubated for 24 and 
48 h at 37°C according to NCCLS guidelines as described 
above. Then, 50 ^l of saline containing 1 mg of XTT/ml and
20.2 ^g of menadione (Sigma-Aldrich Chemie)/ml was added 
to each well in order to obtain final concentrations of 200 ^g 
of XTT/ml and 4.3 ^g of MEN/ml (25 ^M). MEN was first 
dissolved in acetone at a concentration of 430.5 ^g/ml and 
then diluted 1/10 in saline. Incubation was continued at 37°C 
for 2 h in the dark to allow conversion of XTT to its formazan 
derivative. The OD was measured at 450 nm, after shaking, 
with a microtitration tray spectrophotometer reader. The color 
was assessed first visually by the same four observers and 
graded according to NCCLS guidelines (XTTvis) and then 
spectrophotometerically based on relative ODs at 450 nm and 
grouped in five levels as described above (XTTsp). Five MIC 
end points were determined for ICZ as described above. For 
AB, only MIC-0 was determined.
Study design. A multifactorial panel of data was ge­
nerated based on five parameters studied, i.e., modes of 
reading, MIC end points, drugs, species, and incubation 
periods, in order to test the reproducibility of and the 
agreement between the NCCLS and XTT methods. Data from 
five readings (four observers and spectrophotometer), five 
MIC end points, two drugs, five species, five strains, two 
incubation periods, and three independent experiments were 
obtained for both methods. Four comparisons were done in 
order to find the levels of absolute and relative agreements 
within the observers and the experiments (intra- and 
interexperimental agreements, respectively), between the 
visual and the spectrophotometric readings for each method, 
and between the NCCLS and the XTT methods.
Analysis of results. The levels of agreement within 
the four observers and the three experiments as well as 
between the two methods and between the two modes of 
reading were calculated for each species-drug-MIC end point- 
incubation period combination. In order to approximate a 
normal distribution for statistical analysis, the drug 
concentrations were transformed by logarithmic 
transformation to log2 and the percentages of agreement were 
transformed by angular transformation (with the transformed 
value being the arcsine of the square root of the percentage). 
After the transformation, MIC end points were analyzed by 
two-way analysis of variance (ANOVA), which was applied 
to each drug-MIC end point-incubation period combination. 
P  values of less than 0.05 were considered significant. Any 
systematic differences between the methods and the species 
were controlled by the interaction factor of two-way 
ANOVA. A P  value of less than 0.05 indicated that the 
differences between the two methods are not the same for 
each species and therefore that the differences between the 
methods are species dependent. Discrepancies were analyzed 
by Fisher's exact test. The transformed percentages of 
agreement were used in order to estimate variations between 
the experiments, the species, and the strains and to analyze 
differences in intra- and interexperimental agreements 
between all MIC end points after 24 and 48 h by repeated- 
measures ANOVA. The 95% confidence intervals (95% CI) 
of the percentages of agreement were calculated using the 
Wald equation for proportions (Prism software; GraphPad: 
Software, Inc., San Diego, Calif.). The high and low off-scale 
MICs were included in the analysis by conversion to the next 
higher and lower drug concentrations, respectively.
(i) Intraexperimental agreement. For the visual 
readings (NCCLSvis and XTTvis), the percentage of absolute 
or relative agreement between the four observers for each 
strain was defined as the proportion of the MIC end points 
which were identical or which belonged to the largest subset 
of four observations with a range of which not more than 
3 dilutions, respectively. The levels of agreement between the 
four visual readings were calculated for each species and 
experiment, and the total percentage of agreement for all 
species and experiments was reported for each drug and MIC 
end point for the NCCLSvis and XTTvis methods after 24 and 
48 h of incubation.
(ii) Interexperimental agreement. For each method 
and mode of reading, the percentage of absolute and relative 
agreements between the three experiments was defined as the 
proportion of the MIC end points determined by the four
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Table 1. Susceptibilities of five strains of five Aspergillus spp. to AB and ICZ based on MIC-0 and MIC-2, respectively,
after 24 and 48 h of incubation
Geometric mean (range) MIC, in mg/liter, determined by the following method:
Drug Time Species
NCCLSv NCCLS., XTTv XTTS,
AB 24 h
48 h
ICZ 24 h
48 h
A. fumigatus 0.68 (0.125-4) 0.63 (0.5-2) 0.63 (0.25-2) 0.63 (0.5-2)
A. flavus 1.19 (0.5-4) 1.20 (0.5-2) 1.11 (0.5-2) 1.15 (0.5-2)
A. nidulans 0.74 (0.25-4) 0.72 (0.25-2) 0.68 (0.25-2) 0.66 (0.25-1)
A. terreus 1.11 (0.5-4) 0.95 (0.5-4) 1.07 (0.5-2) 1.10 (0.5-2)
A. ustus 1.11 (0.5-2) 0.88 (0.5-2) 0.92 (0.5-4) 1.12 (0.5-2)
A. fumigatus 1.50 (1-4) 1.26 (1-4) 1.14 (0.5-4) 1.15 (0.5-4)
A. flavus 1.64 (1-4) 1.38 (1-2) 1.57 (1-4) 1.45 (1-2)
A. nidulans 1.10 (0.25-4) 0.87 (0.25-4) 0.97 (0.25-4) 0.95 (0.25-4)
A. terreus 2.89 (2-4) 2.09 (2-4) 2.64 (2-4) 2.52 (2-4)
A. ustus 1.91 (1-4) 1.36 (1-2) 1.53 (1-4) 1.47 (1-2)
A. fumigatus 2.39 (0.015->32) 1.15 (0.125->32) 1.36 (0.125->32) 1.38 (0.125->32)
A. flavus 0.14 (0.063-0.25) 0.10 (0.063-0.125) 0.14 (0.0125-0.5) 0.14 (0.063-0.25)
A. nidulans 0.13 (0.031- 0.5) 0.13 (0.063-0.25) 0.13 (0.062-0.5) 0.10 (0.062-0.5)
A. terreus 0.09 (0.031-0.25) 0.09 (0.063-0.125) 0.12 (0.062-0.5) 0.11 (0.063-0.125)
A. ustus 0.40 (0.062-1) 0.35 (0.063-1) 0.54 (0.062-1) 0.46 (0.063-1)
A. fumigatus 2.89 (0.125->32) 2.41 (0.125->32) 2.96 (0.125->32) 2.10 (0.063->32)
A. flavus 0.19 (0.125-0.5) 0.12 (0.063-0.25) 0.26 (0.125-1) 0.24 (0.125-0.5)
A. nidulans 0.16 (0.062-0.25) 0.20 (0.063-2) 0.17 (0.031-0.5) 0.15 (0.031-0.5)
A. terreus 0.15 (0.062-0.5) 0.14 (0.063-0.25) 0.29 (0.062-0.5) 0.23 (0.125-0.5)
A. ustus 1.48 (0.125->32) 0.89 (0.5-1) 3.21 (0.125->32) 2.72 (0.25->32)
observers or the spectrophotometer which were identical or 
within 1 dilution of the median, respectively. The levels of 
agreement between the three experiments were calculated for 
each species, and the total percentage of agreement for all 
species was reported for each drug and MIC end point for the 
NCCLSvis, NCCLSsp, XTTvis, and XTTsp methods after 24 and 
48 h of incubation.
(iii) Agreement between visual and spectropho- 
tometric readings. For each method, the percentage of 
agreement between the visual and spectrophotometric 
readings was calculated as the proportion of the MIC end 
points determined visually by the four observers which fell 
within 1 dilution of the corresponding MIC end points 
determined spectrophotometrically. The total percentage of 
agreement for the three experiments and all species between 
NCCLSvis and NCCLSsp as well as between XTTvis and XTTsp 
was reported for each drug and MIC end point after 24 and 
48 h of incubation, and the approximate 95% CI of 
percentages of agreement were calculated as described above.
(iv) Agreement between NCCLS and XTT me­
thods. For each strain, the percentage of agreement between 
the NCCLS and XTT methods based on visual and 
spectrophotometric readings of each MIC end point was 
calculated as the proportion of the MIC end points 
determined by the NCCLS method, visually or 
spectrophotometrically, which fell within 1 dilution of the 
corresponding MIC end points of the XTT method, 
determined visually or spectrophotometrically, respectively. 
The total percentage of agreement between NCCLSvis and 
XTTvis and between NCCLSsp and XTTsp for the three experi­
ments was reported for each drug and MIC end point after 
24 and 48 h of incubation, and the approximate 95% CI of 
percentages of agreement were calculated as described above.
R esults
M ICs. The Aspergillus strains tested in this study 
had various susceptibilities to AB and ICZ, with MICs 
ranging between 0.125 and 4 mg/liter for AB and 
0.015 to >32 mg/liter for ICZ. Most o f the MICs o f ICZ 
were less than 1 mg/liter, except for those for two 
strains o f A. fumigatus (Table 1). For A. ustus strains, 
despite the fact that the MIC-2 values were less than
1 mg/liter, the MIC-0 values were higher than 2 mg/liter 
and up to >32 mg/liter (data not shown). The geometric 
means o f the MICs o f AB and for ICZ obtained by all 
methods after 24 and 48 h o f incubation were similar, as 
shown in Table 1. Differences were observed with
A. fumigatus and ICZ, for which the geometric mean of 
the MICs obtained by NCCLSvis after 24 h was slightly 
higher than the corresponding value obtained by the 
other methods (2.4 and 1.4 mg/liter, respectively), and 
with A. ustus and ICZ, for which the geometric means 
of the MICs obtained by NCCLSvis and NCCLSsp after 
48 h were lower than the values obtained by the 
corresponding XTT methods (1.5 and 0.9 mg/liter for 
NCCLSvis and NCCLSsp and 3.2 and 2.7 mg/liter for 
XTTvis and XTTsp, respectively).
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Table 2. Overall absolute and relative (within 0 and 1 dilution, respectively) agreement within the four observers and the three
experiments for all tested Aspergillus isolates
Agreement Groupa Drug Growthlevelb
Overall absolute (relative) %  agreement for the indicated method after 
the following h of incubation:
24 48
NCCLS XTT NCCLS XTT
Intraexperimental 1 ICZ 0 82.9 (99.1) 90.3 (97.7) 89.7 (99.4) 92.5 (99.5)
1 83.2 (98.6) 77.6 (99.1) 76.1 (99.5) 82.0 (98.8)
2 69.0 (88.8) 66.9 (87.6) 69.8 (95.3) 72.0 (94.9)
3 62.4 (80.2) 59.1 (73.6) 65.5 (78.2) 65.0 (86.7)
4 60.8 (71.7) 63.2 (71.8) 64.1 (77.0) 63.5 (70.3)
AB 0 91.0 (99.8) 96.1 (99.9) 90.6 ( 100) 95.8 ( 100)
Interexperimental 2 ICZ 0 78.3 (97.6) 75.3 (95.6) 83.7 (99.4) 85.6 (99.3)
1 69.6 (95.5) 74.5 (96.6) 78.3 (98.9) 77.0 (98.6)
2 65.8 (85.7) 64.6 (85.3) 71.5 (94.3) 68.8 (93.3)
3 62.8 (82.2) 57.7 (75.9) 67.7 (82.5) 69.1 (87.8)
4 61.9 (73.8) 58.5 (68.4) 66.0 (79.3) 66.8 (77.2)
AB 0 81.7 (99.0) 87.9 (99.7) 78.1 (99.7) 83.1 (99.7)
3 ICZ 0 54.7 (76.2) 64.4 (90.9) 75.4 (91.6) 87.3 (99.4)
1 71.2 (99.7) 74.8 (95.7) 84.7 (97.6) 81.0 (97.2)
2 65.6 (96.2) 63.4 (93.1) 72.3 (99.7) 67.0 (89.6)
3 58.8 (71.4) 56.0 (80.2) 62.9 (89.6) 49.3 (88.9)
4 61.7 (64.3) 61.7 (67.0) 59.5 (64.8) 56.1 (78.2
AB 0 78.9 (99.7) 88.2 ( 100) 92.4 ( 100) 89.6 ( 100)
a Groups 1 and 2, NCCLSvis and XTTvis, 95% confidence intervals of absolute agreement ranged from ± 3.6 to ± 5.6%; group 3, NCCLSsp 
and XTTsp, 95% confidence intervals of absolute agreement ranged from ± 2.6 to ± 11.3%. 
b 0, no visible growth or <5%; 1, slight growth or 5-25% of growth control; 2, prominent reduction of growth or 26-50% of growth control; 
3, slight reduction in growth or 51-75% of growth control; 4, no reduction in growth or 76-100% of growth control.
(i) In traexperim ental agreement. For AB, the
absolute agreement between the four observers was 
higher with the XTTvis method (96%) than with the 
NCCLSvis method (91%) after 24 and 48 h (Table 2). 
The lowest level of agreement was found for A. ustus 
with the NCCLSvis method (75%); the agreement was 
higher with the XTTvis method (>88%). For ICZ, the 
absolute agreement was higher for MIC-0 and MIC-1 
with both methods (>76%) than for the other MIC end 
points. Based on MIC-0 and MIC-1, A. ustus (67%) and
A. fumigatus (98%) showed the lowest and the highest 
levels o f absolute agreement, respectively, among the 
tested species. The coefficient o f variation of 
intraexperimental absolute agreement was always less 
than 10% among the experiments as well as among the 
species for both the NCCLSvis and the XTTvis methods. 
No statistically significant differences were found 
between the percentages of agreement o f the NCCLSvis 
and XTTvis methods after 24 and 48 h o f incubation.
(ii) Interexperim ental agreem ent. For AB, the 
absolute agreement between the experiments was 
slightly higher for the XTTvis method than for the 
NCCLSvis method and was lower after 48 h of 
incubation than after 24 h for both methods (Table 2). 
When spectrophotometric readings were used, the
interexperimental agreement for the XTTsp and 
NCCLSsp methods was higher after 48 h o f incubation 
than after 24 h. For ICZ, the reproducibility o f the 
NCCLSvis and XTTvis methods was high (>70%) with 
MIC-0 and MIC-1 and was always higher after 48 h. 
For these MIC end points, the lowest and highest levels 
o f absolute agreement among the different species were 
found with A. ustus (64%) and A. fumigatus (93%), 
respectively. For the NCCLSsp and XTTsp methods, the 
highest reproducibility was found for MIC-1 (71-85%) 
with both methods after 24 and 48 h, with the exception 
of the XTTsp method after 48 h, for which the MIC-0 
showed the highest reproducibility (87%).
The reproducibility o f MIC-0 with the NCCLSsp 
method was very low after 24 h (55%) but improved 
after 48 h (75%) and with the XTTsp method (87%). 
The coefficient o f variation o f interexperimental 
absolute agreement among the species was always less 
than 13% for visual readings, with an average 
coefficient o f variation o f 10%; for the spectro- 
photometric readings, the coefficient o f variation was 
always less than 19%, with an average coefficient of 
variation o f 13% for both methods. Unlike that o f the 
spectrophotometric readings, the relative agreement of 
the visual readings increased statistically significantly
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Table 3. Overall relative (within 1 dilution) agreement and 95% confidence intervals (95% CI) between the visual and 
spectrophotometric readings and between the NCCLS and XTT methods
______________ % Agreement ±  95% CI for the following comparisons:____________
Time (h) Drug Geow* Visual vs Spectrophotometric readings NCCLS vs XTT methods 
______________________NCCLSvis vs NCCLSspb XTTvis vs XTTspb NCCLSvis vs XTTvisb NCCLSsp vs XTTspc
24 ICZ 0 51.4 ± 5.7d 90.8 ± 3.3 88.0 ± 3.7 60.0 ± 11.1e
1 92.8 ± 3.0 91.1 ± 3.3 92.7 ± 3.0 94.7 ± 5.1
2 87.7 ± 3.8 86.0 ± 4.0 86.8 ± 3.9 82.7 ± 8.6
3 67.8 ± 5.4e 75.4 ± 4.9e 79.8 ± 4.6e 73.3 ± 10.0e
4 68.1 ± 22.6d 67.9 ± 5.3 68.3 ± 5.4 73.3 ± 10.0
AB 0 96.7 ± 2.0 99.3 ± 0.9 96.7 ± 2.0 98.7 ± 2.5
48 ICZ 0 81.5 ± 4.4 95.3 ± 2.4 94.0 ± 2.7 84.0 ± 8.3
1 91.6 ± 3.1 90.9 ± 3.3 85.1 ± 4.1 77.3 ± 9.5
2 87.2 ± 3.8 83.2 ± 4.2 82.8 ± 4.3 73.3 ± 10.0
3 72.5 ± 5.1 69.5 ± 5.2 78.0 ± 4.7 54.7 ± 11.3
4 58.1 ± 5.6 67.5 ± 5.5d 69.6 ± 5.2 48.0 ± 11.3
AB 0 98.7 ± 1.3 100.0 ± 0.0 97.0 ± 1.9 98.7 ± 2.6
a See Table 2, footnote b. 
b A total of 300 comparisons. 
c A total of 75 comparisons.
d The P value (obtained by the two way ANOVA of log2MIC-endpoints derived by the two methods) was <0.01. 
e The P value was <0.05.
after 48 h for both methods (P  < 0.05).
(iii) Agreem ent between visual and spectro­
photom etric readings. For AB, the relative agreements 
between the NCCLSViS and NCCLSsp methods as well as 
between the XTTVis and XTTsp methods were high after 
24 and 48 h (>96 and >99%, respectively) (Table 3). 
For ICZ, the levels o f agreement between the XTTVis 
and XTTsp methods for MIC-0, MIC-1, and MIC-2 
ranged from 83 to 95% after 24 and 48 h o f incubation. 
Between the NCCLSVis and NCCLSsp methods, the 
agreements were higher for MIC-1 and MIC-2 after 
24 h (93 and 88%, respectively) and 48 h (92 and 87%, 
respectively). Very low agreement was found for MIC-0 
after 24 h (51%; P  < 0.01), but it increased after 48 h 
(82%). Statistically significant differences were found 
for MIC-3 ( P < 0.01) and MIC-4 (P  < 0.05) o f ICZ after 
24 h with the NCCLS methods and for MIC-3 after 24 h 
(P  < 0.05) and MIC-4 after 48 h (P  < 0.01) o f ICZ with 
the XTT methods. No statistically significant systematic 
differences between the two methods and the species for 
both drugs after 24 and 48 h o f incubation for all MIC 
end points were found (P  > 0.15). For MIC-0 o f ICZ 
after 24 h o f incubation, in 42 (56%) out of 
75 comparisons (three experiments, five species, and 
five strains), the MIC-0 values o f the NCCLSsp method 
were higher than those o f the NCCLSvis method, and 
only six comparisons (8%) were the opposite. Further­
more, out o f 35 comparisons in which differences of 
higher than 1 dilution were observed, the MIC-0 values 
o f the spectrophotometric method were higher than 
those o f the NCCLS method in 33 and vice versa in 2.
In order to study further the low levels o f agre­
ement between the NCCLSvis and NCCLsp methods for 
MIC-0 o f ICZ after 24 h, the relative ODs of the 
NCCLSsp method which corresponded to the MIC-0 
values o f the NCCLSvis method were associated with 
the ODs o f their growth controls for all 75 comparisons 
in a cross-sectional study. Various contingency tables 
were constructed based on different cutoff values for 
relative ODs of MIC-0 (5 and 10%) and ODs o f the 
growth control as validation criteria (0, 0.05, and 0.1). 
The strongest association was found when a relative 
OD of 10% as a cutoff for MIC-0 was combined with an 
OD of 0.1 for the growth control as a validation 
criterion (P  < 0.0005). The Spearman correlation 
coefficient between these two parameters was -0.35 
(P  = 0.029). Using the 10% relative OD as a cutoff for 
MIC-0 instead o f 5% and an OD of 0.1 for the growth 
control as an evaluation criterion, the discrepancy 
between the NCCLSvis and NCCLSsp methods was 
reduced 10 times (from 28 to 2.7%) and the levels of 
agreement reached 98%. However, 27% of MIC-0 
values o f the NCCLSsp method will be in agreement 
with those o f the NCCLSvis method, although the ODs 
of their growth controls could be less than 0.1. The 
levels o f agreement between the XTTvis and XTTsp 
methods, especially for MIC-0, were higher after 24 and 
48 h (91% and 95%, respectively).
(iv) Agreem ent between NCCLS and XTT 
m ethods. For AB, the levels o f agreement between the 
NCCLSvis and XTTvis methods as well as between the 
NCCLSsp and XTTsp methods were higher than 97% 
(Table 3). For ICZ, the agreement between the 
NCCLSvis and XTTvis methods was higher than 83% for
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Figure 1. Results of susceptibility testing of an A. ustus strain against itraconazole in the NCCLS and XTT methods, 
with data determined visually and spectrophotometrically, after 24 h of incubation. The bars represent the growth levels 
obtained in the NCCLSvis (dark bars) and XTTvis (light bars) methods for each concentration on a scale of 0 (absence of 
growth or color) to 4 (no reduction of growth or color compared with the data for the drug-free control). The curves with 
the circles represent the OD at 450 nm (open symbols) and the relative OD (percentage) (closed symbols) obtained by the 
XTTsp method. The curves with the triangles represent the OD at 405 nm (open symbols) and the relative OD 
(percentage) (closed symbols) obtained by the NCCLSsp method.
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MIC-0, MIC-1, and MIC-2, with MIC-1 showing the 
highest agreement after 24 h (93%) and MIC-0 doing so 
after 48 h (94%). Among the species, A. ustus showed 
the lowest level o f agreement (82%). The levels of 
agreement between the NCCLSsp and XTTsp methods 
were lower with MIC-1 after 24 h and higher with MIC-
0 after 48 h (95 and 84%, respectively). Statistically 
significant differences were found for MIC-3 o f ICZ 
after 24 h between the NCCLSvis and XTTvis methods as 
well as between the NCCLSsp and XTTsp methods 
(P  < 0.05). The statistically significant differences for 
MIC-0 o f ICZ after 24 h between the NCCLSsp and 
XTTsp methods (P  < 0.05) were due to the erroneous 
higher MICs obtained by the NCCLSsp method. The 
discrepancies were reduced when the above-mentioned 
validation criteria were applied for the determination of 
MIC-0 by the NCCLSsp method. No statistically 
significant systematic differences between the two 
methods and the species were obtained for both drugs 
after 24 and 48 h of incubation for all MIC end points 
(P  > 0.25).
A representative graph is shown in Fig. 1, with
the results of NCCLSvis, NCCLSsp, XTTvis, and XTTsp 
for an A. ustus strain and ICZ. Growth at an OD at 
405 nm o f 0.047 with the NCCLSsp method 
corresponded to formazan production o f 2.0 OD units at 
450 nm with the XTTsp method.
Discussion
The selection o f an endpoint for MIC 
determination o f antifungal drugs is an important factor 
o f antifungal susceptibility testing o f filamentous fungi 
which may increase the variability o f these tests (5). 
This parameter is crucial especially for fungistatic drugs 
like ICZ since partial inhibition o f the growth due to the 
delayed action of the drug (trailing phenomenon) may 
result in limited growth over a range o f drug 
concentrations, which may elevate the MIC-0. 
Therefore, MIC-2 (prominent reduction of growth) was 
chosen for this drug (20). However, in previous studies 
MIC-1 (slight growth or 75% reduction o f growth) 
showed higher interlaboratory agreement and similar
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interexperimental agreement relative to MIC-2 (6, 12). 
In the present study, high levels o f intra- and 
interexperimental agreement were found for MIC-0 and 
MIC-1 (>95%) as was found in our previous study (13). 
For MIC-2, the levels of intra- and interexperimental 
agreement were lower after 24 h (89 and 86%, 
respectively) although they increased after 48 h of 
incubation (95 and 94%, respectively). The 
interexperimental agreement for MIC-2 was improved 
when the spectrophotometric reading was used (96% 
after 24 h and 99% after 48 h). Similar results were 
obtained when XTT was used.
For fungicidal drugs such as AB, growth ceases 
abruptly after exposure to the drug which results in 
clear-cut end points (20). Therefore, the MIC-0 was 
chosen as the end point. In this study, in agreement with 
previous studies, high levels o f inter- and 
intraexperimental agreement (>98%) were found after 
24 and 48 h o f incubation. Using the dye XTT, the 
absolute intra- and interexperimental agreements of 
visual determination were further increased.
It is assumed that spectrophotometric estimation 
o f the growth o f filamentous fungi is inaccurate because 
o f nonhomogeneity (4, 5). However, in previous studies, 
high levels o f agreement were found between visual and 
spectrophotometric readings at 405 and 570 nm for 
MIC-1 and MIC-2 for ICZ and MIC-0 for AB (3, 12). 
The same results were obtained in this study, since the 
levels o f agreement for MIC-1 and MIC-2 were 92 and 
87%, respectively, for ICZ and 97% for AB with MIC- 
0. However, the levels o f agreement between visual and 
spectrophotometric readings at 405 nm for MIC-0 of 
ICZ were very low, especially after 24 h (51%; 
P  < 0.01). In most cases, the MIC-0 values based on 
spectrophotometric readings were higher than those of 
visual readings. Further analysis o f the discrepancies 
showed that this disagreement depended on the cutoff of 
relative OD as well as the OD of the growth control 
(P  < 0.0005). In a previous study, an OD of 0.15 for the 
growth control was chosen as validation criterion for 
spectrophotometric readings o f susceptibility testing of 
Aspergillus species although no evidence for the choice 
o f threshold level was provided (17). Using a threshold 
level o f 10% relative OD for MIC-0 and as a validation 
criterion an OD of the growth control o f greater than 
0.1, the discrepancies were reduced 10-fold and the 
agreement between visual and spectrophotometric 
readings was increased to 98%.
Spectrophotometric readings are in general more 
precise and reproducible than visual reading. Since the 
hyphal growth o f Aspergillus species does not seem to 
present an obstacle, spectrophotometry can be used to 
determine the susceptibility o f these fungi to antifungal 
drugs resulting in more precise quantification o f hyphal 
growth than is attained by a visual reading. However, 
further optimization is required. The presence o f phenol
red in RPMI 1640 medium may pose problems as it 
might lower the sensitivity o f spectrophotometric 
readings. The absorbance of this medium is very high at 
405 nm (OD, 0.15 to 0.2), a wavelength at which 
hyphae have the highest absorbance. At lower 
wavelengths, the background absorbance is decreased 
(OD at 630 nm, 0.06), but the absorbance of hyphae is 
also decreased (unpublished observations). Thus, due to 
high background absorbance, limited fungal growth is 
not detectable by spectrophotometer. Studies using 
RPMI 1640 medium without phenol red for in vitro 
susceptibility testing show identical results compared 
with the standard medium (23). Since phenol red was 
originally used to allow contamination of the medium 
to be detected, in antifungal susceptibility testing it 
serves no useful purpose; therefore, phenol red should 
be omitted.
Although spectrophotometric reading resulted in 
higher accuracy and reproducibility, lack in sensitivity 
was observed since growth higher than 0.1 OD is 
required for precise hyphal quantification. The 
sensitivity o f spectrophotometric readings was 
increased with the colorimetric method, since ODs o f up 
to 2.0 were achieved compared with 0.047 using the 
noncolorimetric method. In a previous study, a 
colorimetric method based on the dye XTT was applied 
for antifungal susceptibility testing o f various yeasts 
against different azoles and flucytosine, resulting in 
high levels o f agreement with the standard NCCLS 
method (8). XTT was applied for the first time for 
filamentous fungi by Sugar and Liu (23), who found 
lower MICs compared with the NCCLS method. These 
discrepancies between the two methods may be due to 
the different MIC end points that were chosen, namely, 
the MIC-0 defined as the first well showing no growth 
for the NCCLS method and a decrease in OD of greater 
than 50% for the XTT method (23). Variation in the 
colorimetric method may be caused by the absence o f a 
step that stops the conversion, since extraction steps are 
not necessary. Since high levels o f agreements were 
found between the spectrophotometric and the visual 
readings o f the XTT method, the colorimetric method 
can be automated by using spectrophotometric readings. 
However, wells containing hyphae may interfere with 
OD measurements, since at 450 nm, where the 
formazan derivative is absorbed, hyphae also show high 
absorbance. These problems could be overcome by 
removing the formazan derivative from the wells where 
the fungi are growing, although it will increase the time 
required to generate results.
Strains for which MICs o f antifungal agents are 
high were detectable with the colorimetric method, in 
some cases 24 h earlier than it was possible with visual 
reading. Furthermore, it was possible to distinguish 
between metabolically active hyphae and dead hyphae, 
which would both produce turbidity, which would be
66
SPECTROPHOTOMETRIC vs VISUAL READINGS, XTT vs NCCLS METHODS
seen as growth when examined visually, possibly 
resulting in a trailing effect. Besides helping to alleviate 
this problem, the colorimetric method should allow 
detection o f small amounts o f growth, more precise 
quantification, and earlier MIC determination than is 
possible with the noncolorimetric method.
In conclusion, for AB high levels o f agreement 
were always obtained. For ICZ with both the NCCLS 
and the XTT methods, MIC-0 and MIC-1 showed the 
highest levels o f intra- and interexperimental agreement. 
For MIC-2, similar levels o f agreement were achieved 
either by prolonging the incubation period to 48 h or by 
using spectrophotometric reading after 24 h. The 
spectrophotometric readings can be used for antifungal 
susceptibility testing o f Aspergillus species, since high 
levels of agreement with the visual readings were 
achieved for MIC-0, MIC-1, and MIC-2. The low 
agreement was found between the visual readings and 
the spectrophotometric readings o f the NCCLS method 
for MIC-0 o f ICZ was improved by shifting the 
threshold level to 10% relative OD and establishing an 
OD of 0.1 for the growth control as a validation 
criterion for the spectrophotometric readings. The XTT 
method based on both visual and spectrophotometric 
readings used in this study showed high levels of 
agreement with the NCCLS method, and higher levels 
o f sensitivity and precision were achieved. Therefore, 
the colorimetric method could be used as an alternative 
method for antifungal susceptibility testing of 
Aspergillus species, although further work is required to 
study the robustness o f this colorimetric method.
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In Vitro Interaction of Terbinafine with Itraconazole against
Clinical Isolates of Scedosporium prolificans
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In o rder to develop new approaches for the chem otherapy of invasive infections caused by 
Scedosporium prolificans, the in vitro interaction between itraconazole and terbinafine against 
20 clinical isolates was studied using a checkerboard m icrodilution m ethod. Itraconazole and 
terbinafine alone were inactive against most isolates, bu t the combination was synergistic against 
95 and 85%  of isolates after 48 and 72 h of incubation, respectively. Antagonism was not 
observed. The M ICs obtained with the terbinafine-itraconazole combination were within levels 
th a t can be achieved in plasma.
Invasive infections caused by Scedosporium 
species are uncommon but are generally fatal in 
immunocompromised patients, especially when they are 
caused by Scedosporium prolificans (2, 13). Treatment 
includes surgical debridement, if  possible, and 
antifungal chemotherapy, although the optimal choice 
and duration of therapy are unknown. Azoles, such as 
miconazole and itraconazole, have been used with some 
success for the treatment o f invasive infections with 
Scedosporium apiospermum (6), but treatment failures 
have also been reported (15). S. prolificans is 
considered multiresistant since low in vitro activities 
have been reported for amphotericin B, flucytosine, and 
the azoles (3). Even novel antifungal agents such as the 
triazoles voriconazole, posaconazole (SCH56592), and 
Syn-2869 (5, 9) and the echinocandins LY303366 and 
caspofungin (MK-0991) show limited or no in vitro 
activity against this fungus (4, 5). We have previously 
reported a patient with pulmonary pseudallescheriosis 
who failed itraconazole therapy but responded after 
treatment was changed to terbinafine (15). The 
S. apiospermum isolate was resistant to either drug 
alone but was susceptible in vitro to the terbinafine- 
itraconazole combination (N. S. Ryder and I. Leitner, 
Abstr. 38th Intersci. Conf. Antimicrob. Agents 
Chemother., abstr. J-155, 1998). In the present study we 
investigated whether terbinafine and itraconazole act 
synergistically against 20 clinical S. prolificans isolates 
to determine if  this combination is a potentially useful 
combination in the treatment o f these infections.
Ma ter ia ls  and M ethods
All isolates were obtained from clinical specimens (3) 
and subcultured on Sabouraud glucose agar (SAB) plates 
with 0.5% chloramphenicol and incubated at room
temperature for 7 days. They were then subcultured again on 
SAB plates and incubated for another 5 to 7 days at 37°C, and 
spores were collected. Paecilomyces variotii (ATCC 22319) 
was used as a quality control strain, and all isolates were 
tested in duplicate.
MICs were determined by a broth microdilution 
method according to National Committee for Clinical 
Laboratory Standards guidelines (proposed standard M38-P) 
(11). Briefly, a suspension of spores was adjusted with a 
spectrophotometer (Spectronic 20D; Milton Roy, Rochester, 
N.Y.) to 68 to 70% transmission at a wavelength of 530 nm 
and diluted 10-fold to yield a final inoculum of 1 x 104 to 
5 x 104 CFU/ml. The spectrophotometer transmissions were 
verified by enumeration of colonies per milliliter of serial 
dilution on SAB plates that were incubated at 35°C for 48 h. 
These cultures showed that the final inoculum varied between
1.5 x 104 and 3.5 x 104 CFU/ml. Terbinafine (Novartis, 
Basel, Switzerland) and itraconazole (Janssen Research 
Foundation, Beerse, Belgium) were tested in RPMI 
1640 medium with L-glutamine and without bicarbonate 
(GIBCO BRL, Life Technologies, Breda, The Netherlands), 
buffered to pH 7.0 with 0.165 M MOPS (3-N-morpho- 
linepropanesulfonic acid). The final concentrations ranged 
from 0.5 to 32 ^g/ml for itraconazole and 0.06 to 64 ^g/ml 
for terbinafine. Growth was graded on a scale of 0 to 4 as 
follows: 4 indicated no reduction in growth, 3 indicated a 
25% reduction of growth, 2 indicated a 50% reduction of 
growth, 1 indicated a 75% reduction of growth, and
0 indicated an optically clear well. The MIC was defined as 
the lowest concentration of antifungal compound that 
inhibited growth by 50% or more.
A two-dimensional, two-agent broth microdilution 
checkerboard technique was used to study the interactions 
between itraconazole and terbinafine. Serial twofold dilutions 
of itraconazole and terbinafine, alone and in combination, 
were tested against final inocula of 1 x 104 to 5 x 104 
CFU/ml. In order to obtain an exact percentage of growth for 
each well, the dye 3-(4,5-dimethyl-2-thiazyl)-2,5-diphenyl- 
2H-tetrazolium bromide (MTT; Sigma Chemical, St. Louis, 
MO.) was added together with the inoculum to each well at a
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Table 1. MICs and SFICs of itraconazole (ICZ) and terbinafine (TB) alone and in combination against S. prolificans
after 48 and 72 h of incubation
Isolate MIC (mg/ml)
Lowest MIC of the MIC (mg/ml) Lowest MIC of the
ICZ TB 48 h (ICZ/ TB) ICZ TB 72 h (ICZ/ TB
7898 16 0.5 0.25 2/0.06 >32 4 0.14 1/0.5
7906 16 0.5 0.25 2/0.06 >32 4 0.25 8/0.5
7902 16 0.5 0.25 2/0.06 >32 4 0.31 4/1
7921 >32 0.5 0.18 4/0.06 >32 4 0.51 0.5/2
7946 16 1 0.19 2/0.06 >32 4 0.26 0.5/1
7891 >32 1 0.12 4/0.06 >32 4 0.16 1/0.5
7940 >32 0.5 0.52 1/0.25 >32 32 0.09 2/2
7886 >32 1 0.27 1/0.25 >32 >64 0.02 0.5/0.5
7901 >32 1 0.09 2/0.06 >32 >64 0.05 2/1
7924 >32 1 0.15 1/0.13 >32 >64 0.05 1/2
7920 >32 0.5 0.27 1/0.125 >32 >64 0.04 0.5/2
7894 >32 1 0.12 4/0.06 >32 4 0.38 8/1
7905 16 1 0.19 2/0.06 >32 8 0.52 1/4
7888 16 2 0.13 1/0.125 >32 >64 0.07 0.5/4
7908 >32 1 0.14 1/0.125 >32 >64 0.05 2/1
7913 >32 0.5 0.28 2/0.125 >32 >64 0.05 1/2
7930 16 1 0.12 1/0.06 >32 >64 0.05 1/2
7903 >32 8 0.09 2/05 >32 >64 2 >32/>64
7900 >32 2 0.10 2/0.13 >32 >64 0.25 16/1
7912 >32 >64 0.04 0.5/2 >32 >64 0.04 0.5/2
final concentration of 0.1 mg/ml (8). After 48 or 72 h of 
incubation, the content of each well was removed and 200 ^l 
of isopropanol containing 5% HCl (1 M) was added. After 
30 min of incubation at room temperature and gentle 
agitation, the optical density (OD) was measured with a 
spectrophotometer (MS2 reader, Titertekplus; ICN 
Biomedical Ltd., Basingstoke, United Kingdom) at 550 nm 
(8). The OD of the blank, to which a conidium-free inoculum 
had been added, was subtracted from the OD values. The 
percentage of growth for each well was calculated by 
comparing the OD of a well with that of the drug-free control. 
For each itraconazole-terbinafine combination which showed 
the same percentage of growth with the MICs, the summation 
of the fractional inhibitory concentrations (SFIC) of each 
drug was calculated for these combinations as follows: 
(concentration of itraconazole in the combination/MIC of 
itraconazole) + (concentration of terbinafine in the 
combination/MIC of terbinafine). The interpretation of the 
SFIC was as follows: the synergistic effect was <0.5, the 
indifferent effect was >0.5 but <4, and the antagonistic effect 
was >4 (7). The results of experiments with the two agents 
alone and in combination were analyzed separately as well as 
together by calculating the mean ODs. Since all analyses 
yielded identical results, we present the results based on the 
mean OD from both experiments.
R esults
The MICs o f terbinafine and itraconazole based 
on 50% reduction o f growth for P. variotii were 
0.125 and 0.25 ^g/ml, respectively. Itraconazole was
inactive in vitro against most isolates, with the MIC at 
which 90% of the isolates were inhibited being >32 
^g/ml after both 48 and 72 h o f incubation (Table 1). 
An attempt was made to establish the exact MIC of 
itraconazole by an agar dilution method. Serial dilutions 
ranging from 32 to 512 ^g o f itraconazole per ml were 
made in RPMI 1640 agar. The growth o f none o f the 
S. prolificans isolates was inhibited by any o f these 
concentrations after 48 h o f incubation. Therefore, a 
MIC of 64 ^g/ml was chosen for calculations for those 
isolates that grew in the wells that contained the highest 
concentration o f itraconazole. The MIC o f terbinafine at 
which 90% of the isolates were inhibited was 2 ^g/ml 
after 48 h but increased to 64 ^g/ml after 72 h. 
Synergism was found for 19 o f 20 (95%) of the 
S. prolificans isolates after 48 h and for 17 of 20 (85%) 
of the isolates after 72 h o f incubation (Table 1). For 
three isolates the effect o f the combination appeared to 
be indifferent after 72 h o f incubation, and antagonism 
was not observed.
Discussion
Although drug interactions in vitro are difficult to 
assess, we believe that the observed synergism is 
significant for several reasons. (i) Despite the fact that 
we selected a stringent criterion for the definition of 
synergism, almost all isolates showed synergism after 
both 48 and 72 h o f incubation. (ii) Because the MIC of
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itraconazole was set at 64 ^g/ml for most isolates, the 
calculated SFIC underestimates the actual level of 
synergism. Calculations with higher MICs o f single 
drugs would have resulted in even lower SFIC. (iii) 
Itraconazole and terbinafine block different steps o f the 
same pathway of fungal ergosterol biosynthesis, which 
supports the possibility o f synergistic action. The 
classic example o f proven synergism in this respect is 
the combination o f trimethoprim with sulfonamides, 
which also interacts with consecutive steps o f a 
common pathway. Furthermore, the combination of 
terbinafine with azoles has been shown to be synergistic 
in vitro for other fungi, including Candida albicans (1), 
Candida glabrata, and Cryptococcus neoformans 
(A. W. Fothergill, I. Leitner, J. G. Meingassner, 
N. S. Ryder, and M. G. Rinaldi, Abstr. 36th Intersci. 
Conf. Antimicrob. Agents Chemother., abstr. E53, 
1996), and for Pythium insidiosum (14). Synergism has 
been reported for combinations of amphotericin B with 
azoles against S. apiospermum but the synergistic 
activity was less pronounced than for the terbinafine- 
itraconazole combination and occurred only for a 
limited number o f isolates (16). In another study, the 
effect o f amphotericin B combined with terbinafine was 
indifferent against S. apiospermum, but terbinafine with 
fluconazole was synergistic against the same isolate 
(Ryder and Leitner, 38th ICAAC, abstr. J-155). 
Terbinafine appears to interact synergistically with the 
class o f azole antifungal drugs.
The MICs o f the terbinafine-itraconazole 
combination are within the range that can be achieved 
in blood. The achievable maximum concentrations of 
terbinafine are approximately 1.7 ^g/ml within 2 h of 
oral administration o f a dose o f 500 mg (10). Levels in 
serum above 3.0 ^g/ml can be achieved with 
itraconazole (12), and even higher levels may be 
achieved with the oral solution or the intravenous 
formulation that is now undergoing clinical evaluation.
Invasive infections caused by S. prolificans are 
generally fatal, and at present there is no antifungal 
regimen that has been shown to be effective. The in 
vitro synergism of itraconazole and terbinafine that we 
demonstrated may prove effective for the treatment of 
these infections. Animal-model and clinical studies are 
warranted to further elucidate the potential of 
terbinafine-itraconazole combination therapy in 
difficult-to-treat infections by filamentous fungi.
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Drug Interaction Modeling of in vitro Combination of Azoles
with Terbinafine against Clinical 
Scedosporium prolificans Isolates
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The in vitro interaction between terbinafine and the azoles, voriconazole, miconazole and 
itraconazole against 5 clinical Scedosporium prolificans isolates after 48 and 72 h of incubation 
was tested with a m icrodilution checkerboard (12x8) technique. The antifungal effects of the 
drugs alone and in combination on the fungal biomass as well as on the metabolic activity of 
fungi was m easured using a spectrophotom etric and two colorimetric m ethods, based on MIC-1 
and M IC-2 (the lowest drug concentration showing 75%  and 50%  growth inhibition, 
respectively). The natu re  and the intensity of the interactions were assessed using a non- 
param etric  approach (FIC index model) and a fully param etric  response surface approach 
(Greco model) of the Loewe additivity no interaction model (LA) as well as a non-param etric 
approach (P richard  model) and a param etric  surface response approach of the Bliss 
independence no interaction model (BI). Statistically significant synergy was found between each 
of the three azoles and terbinafine in all cases although with different intensity. A 27 to 64-fold 
and 16 to 90-fold reduction of geometric m ean of the azole and terbinafine M ICs, respectively 
was observed when they were combined resulting in FIC  indices lower than 1 down to 0.02. 
M IC-1 resulted in higher levels of synergy, which were m ore consistent between the two 
incubation periods than  M IC-2. The strongest synergy among the azoles was found with 
miconazole using the BI-based models and voriconazole using the LA-based models. The 
synergistic effects both on fungal growth and metabolic activity were m ore potent after 72 h of 
incubation. Fully param etric  approaches in combination with the modified colorimetric m ethod 
m ight prove useful for testing the in vitro interaction of antifungal drugs against filamentous 
fungi.
S. prolificans is a filamentous fungus, which 
causes various types o f human infections ranging from 
asymptomatic colonizations, and localized infections in 
immunocompetent individuals to disseminated infec­
tions usually in immunocompromised patients (7, 18). 
The mortality rate o f invasive infections is high (92%) 
despite antifungal chemotherapy with amphotericin B, 
miconazole, fluconazole or itraconazole (18). However, 
the effectiveness o f antifungal chemotherapy is 
uncertain since any success reported in the literature 
was associated with additional intervention such as 
surgery, immunomodulation or recovery o f host 
defense. Furthermore, in vitro susceptibility tests 
indicate a multi-resistant fungus due to the very low 
growth inhibitory activities o f conventional and new 
antifungal drugs (10, 12, 27). Therefore, new 
approaches for treating these infections are warranted. 
Promising results are coming up from the field o f in 
vitro combination o f antifungal drugs against fungi (3,
35, 41), especially after the recent findings of 
synergistic interaction between itraconazole and 
terbinafine against different fungi including S. 
prolificans (31, 32). Despite the fact that these two 
drugs were inactive alone, the in vitro combination of
them succeeded in inhibiting the fungal growth at 
concentrations achievable in plasma.
However, assessing the nature and intensity of 
drug interactions is still a debated area of 
chemotherapy. The in vitro interaction o f two or more 
agents is dependent both on the methodology which is 
used to generate the data as well as on the way the 
results are analyzed, resulting to variable as well as 
controversial conclusions (6, 20, 35).
Despite the considerable progress which has been 
made in producing reproducible results with the M-38P 
standard proposed by the NCCLS (33), the in vitro 
antifungal susceptibility testing o f filamentous fungi is 
faced with several problems regarding the choice o f the 
proper testing method, reading system, MIC endpoint 
and incubation period (11, 15, 34, 39). Different results 
might be obtained by choosing different combinations 
of these parameters. This is even more complicated 
when two drugs are combined in vitro. Spectropho- 
tometric and colorimetric modifications o f the NCCLS 
method have been described, quantifying more 
precisely the fungal growth and being able to detect 
small changes in metabolic activity o f fungi, 
respectively (26, 30). Based on these methods, the
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effects o f antifungal drugs either on the fungal biomass 
or on metabolic status of fungi can be measured.
However, even when the same methodology is 
used for testing the in vitro susceptibility to drug 
combinations variable conclusions might be inferred 
depending on the way data are analyzed. Many models 
and approaches have been described for the assessment 
o f in vitro drug interactions and extensive reviews have 
summarized them (5, 6, 20, 38, 43). The assumption of 
no interaction has a central position in these debates 
since synergy and antagonism are defined as departures 
from this. Thus, when the observed effect is more or 
less than the effect predicted from the no interaction 
theory synergy or antagonism is claimed, respectively. 
Among the various no interaction models, Loewe 
additivity (LA) and Bliss independence (BI) are the two 
major competitor candidates for reference models (20). 
LA is based on the idea that a drug cannot interact with 
itself while BI on the idea that two drugs act 
independently with the probabilistic sense of 
independence. Based on these concepts, various models 
have been described based on both parametric and non- 
parametric approaches o f these two reference models. 
These include estimates o f the intensity o f interaction 
and summary results incorporating statistically signi­
ficance levels.
Given that a synergistic interaction might have 
great impact on approaches for controlling infections 
caused by S. prolificans in clinical practice (19, 25), the 
unbiased assessment o f in vitro interaction o f antifungal 
drugs is crucial. In this study, the interaction between 
three azoles, voriconazole, miconazole, and itraco­
nazole, and an alyllamine, terbinafine, was tested in 
vitro against 5 clinical isolates o f S. prolificans. In order 
to reduce biases derived from factors related to the 
method of antifungal susceptibility testing as well as to 
theoretical and mathematical models for defining 
synergism, the in vitro interaction o f antifungal drugs 
were determined with a recently described spectro- 
photometric and colorimetric method (26), after 48 and 
72 h o f incubation based on two MIC endpoints and 
assessed using two parametric and two non-parametric 
models based on Loewe additivity and Bliss 
independence, described in the literature.
Ma ter ia ls  and M ethods
Isolates. Five Scedosporium prolificans strains from 
our private collection were used in this study namely 
AZN7898 and AZN7918 isolated from blood, AZN7901 and 
AZN7902 isolated from sputum and a reference strain 
AZN7906 (NCPF7108). The isolates were stored in 50% 
glycerol in water at -70oC. Candida parapsilosis (ATCC 
22019) and C. krusei (ATCC 6258) were used as quality 
control (QC).
Antifungal drugs. Three antifungal drugs belonging to
azoles namely, miconazole (MW 479.15) (Janssen Research 
Foundation, Beerse, Belgium), itraconazole (MW 705.64) 
(Janssen Research Foundation), voriconazole (MW 349.32) 
(Pfizer Central Research, Sandwich, United Kingdom), and 
the allylamine terbinafine (MW 291.44) (Novartis, Basel, 
Switzerland) were used in this study. Miconazole and 
voriconazole were dissolved in dimethylsulfoxid (DMSO) 
(Merck, Darmstadt, Germany) at final concentrations of 
25,600 mg/l and 6,400 mg/l, respectively. Terbinafine was 
dissolved in DMSO with 5% Tween 80 (Merck) and 
itraconazole in 0.1 M HCL/100% Aceton (1:1) (Merck) at 
final concentrations of 25600 mg/l and 12,800 mg/l, 
respectively.
Medium. The medium used was liquid RPMI 1640 
(with L-glutamine, without sodium bicarbonate) (GIBCO 
BRL, Life Technologies, Woerden, The Netherlands) 
supplemented with 0.165 M 3-N-morpholinopropanesulfonic 
acid buffer (Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany). The pH of the medium was adjusted to 7.0 ± 0.1 
at 22oC.
Inoculum. Each isolate had been grown for 7 days on 
Sabouraud dextrose agar with 0.5% chloramphenicol at room 
temperature and was then subcultured on the same medium 
for a further 5-7 days at 37oC. Conidia were collected with a 
swab and suspended in sterile water. After the heavy particles 
were allowed to settle the turbidity of the supernatants were 
measured spectrophotometrically at 530 nm (Spectronic 20D; 
Milton Roy, Rochester, N.Y., USA) and its transmittance was 
adjusted to 68-70% by diluting. Each suspension was diluted 
1:50 in RPMI 1640 to obtain 2x the final inoculum size 
ranging from 0.5 x 104 to 5 x 104 CFU/ml. Inoculum size was 
verified by plating 100 ml of serial dilutions of each inoculum 
onto a Sabouraud dextrose agar plate and incubated until 
growth became visible.
For the QCs, the transmittance of blastoconidia 
suspensions obtained from 1 to 2 day-old colonies was 
adjusted to 75-77% at 530 nm. The suspensions were diluted 
1/1000 and a final inoculum ranging from 0.5 x 103 to 2.5 x 
103 CFU/ml was used.
Susceptibility testing method. The in vitro 
interaction between the three azoles and the allylamine 
terbinafine was studied using a two-dimensional (12x8) 
checkerboard microdilution technique in sterile, 96-well flat- 
bottom microtitration plates described below. In order to 
choose the appropriate range of drug concentrations for the 
combination studies, the MICs of the individual drugs were 
determined in an exploratory study for each strain.
(i) Microtitration plates set up. For the combination 
studies, each drug was first serially diluted twofold in the 
corresponding solvents and then 100-fold in the medium 
according to the dilution scheme of NCCLS for water- 
insoluble drugs in order to obtain 4 times the final 
concentration. 50 ml of each drug concentration of the azole 
was added to columns 1 to 11 and then 50 ml of each 
concentration of terbinafine was added to rows A to G. In the 
wells of column 12, 50 ml of the medium containing 1% of 
the azole solvent was added and in wells of row H, 50 ml of 
the medium contained 1% of terbinafine solvent was added. 
Thus, column 12 and row H contained alone the azole and 
terbinafine, respectively and the well H12 was the drug-free 
well that served as growth control. The final concentrations
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after the addition of 100 ml of inoculum ranged from 64 to
0.06 mg/ml for miconazole, 32 to 0.03 mg/ml for itraconazole, 
16 to 0.015 for voriconazole, and 64 to 1 mg/ml for 
terbinafine. The microtitration plates were kept in -70oC until 
the day of the experiments.
(ii) Incubation and reading method. On the day of 
the test, microtitration plates were thawed and each well was 
inoculated with 100 ml of the inoculum suspension. After 
agitation for 15 sec, the microtitration plates were incubated 
for 72 h at 37oC. The growth in each well was quantified by 
using three methods: a spectrophotometric method after 48 
and 72 h of incubation (SP48 and SP72, respectively) where 
the optical density (OD) at 405 nm of each well was 
measured, a colorimetric method utilizing the dye MTT after 
72 h of incubation (COL72) where the conversion of the dye 
MTT to colored formazan derivative after 2 h of exposure by 
metabolic active fungi was measured at 550 nm and a 
modification of the latter colorimetric method after 48 and 
72 h of incubation (mCOL48 and mCOL72, respectively) 
where the dye MTT was added to the inoculum and therefore 
fungi was exposed to the dye for 48 and 72 h as described 
previously (26). The percentage of growth in each well was 
calculated as the OD of each well/OD of the drug free well 
after subtracting the background OD obtained from 
microorganisms free microtiter plates were proceeded as the 
inoculated plates. Thus, growth- and metabolic inhibitory 
effects of the drugs alone and in combination were estimated 
based on the results of spectrophotometric and colorimetric 
methods, respectively.
Drug interaction modeling. In order to assess the 
nature of the in vitro interaction between the three azoles and 
terbinafine against each S. prolificans strain, the data 
obtained using the three reading methods, as described above, 
were analyzed using four different models. The models were 
parametric and non-parametric approaches of the following 
two no interaction theories: the Loewe additivity and the 
Bliss independence. In the Loewe additivity theory 
concentrations of the drugs, alone or in combination, that 
produce the same effect, are compared while in the Bliss 
independence based models the estimates of the combined 
effect based on the effect of the individual drugs were 
compared with these obtained by the experiment.
(i) Loewe additivity is described by the following 
equation: 1 = dA/DA + dB/DB where dA and dB are the 
concentrations of the drugs A and B in the combination 
which elicit a certain effect and DA and DB the iso-effective 
concentrations of the drugs A and B when acting alone. The 
non-parametric approach is based on the fractional inhibitory 
concentration index model expressed with the following 
equation:
C comb C' combA BSFIC = FICa + FICb= ----A------ + —B-------
MICAalone MICBalone
where CAcomb and CBcomb are the concentrations of the drugs A 
and B in a combination and MICAalone and MICBalone the 
concentrations of the drugs A and B when acting alone (23). 
The SFIC was calculated for all combinations of the two 
drugs, which showed the same growth as the MICs. For each 
data set, among all SFICs, the FIC index (FICi) was 
determined as the SFICmin (the lowest SFIC) only when the
SFICmax (the highest SFIC) was smaller than 4; otherwise the 
FICi was determined as the SFICmax (23) (Fig. 1Ai). Two 
MIC endpoints were used for the evaluation of each data set. 
These were the MIC-1 and MIC-2 and were defined as the 
lowest drug concentration showing 25% and 50% of growth 
c mpared to the growth control, respectively. Based on these 
endpoints two types of FIC indices were determined, FICi-1 
and FICi-2, respectively. Off-scale MICs were converted to 
the next highest or lowest doubling concentration. Finally, 
the median and the range of FIC indices of the replicates 
were determined for both the MIC-1 and MIC-2. When the 
FIC indices in all four replicates were smaller than 1, 
significant synergy was claimed, when they were higher than
1 significant antagonism was claimed and in all other cases 
additivty or indifference was concluded. In addition 
isobolograms were plotted in order to visualize the departure 
from additivity (Fig. 1Aii).
The fully parametric surface approach described by 
Greco et al. (21) was used based on the following equation:
D a D b d a d b
where E is the OD (dependent variable) at the drug 
concentrations DA and DB (independent variables), Emax is the 
maximal OD observed in the drug-free control, IC50,A and 
IC50,B are the drug concentrations producing 50% of the Emax, 
mA and mB are the slopes of the concentration-effect curves 
(Hill coefficient) for the drugs A and B, respectively and a  is 
the interaction parameter which describes the nature of the 
interaction. This model was fitted directly to experimental 
data (the average OD among the replicates for all 
concentrations of the two drugs alone or in combination) with 
a non-weighted, non-linear regression analysis using the 
MODLAB program (MEDIMATICS, Maastricht, The 
Netherlands, www.medimatics.nl). Goodness of fit criteria 
included the 95% confidence interval (CI) of the fitted 
parameters, the R2, the sum of the squares, correlation and 
covariance matrices and the residual plots.
When the parameter a  was positive and 95% CI did 
not include 0, statistically significant synergy was claimed 
while when a  was negative and its 95% CI did not include 0, 
statistically significant antagonism was claimed. In any other 
case Loewe addittivity was concluded. The additivity surface 
was simulated by fixing all parameters of the Greco model to 
values obtained after the model fitted to experimental data 
except a  which was fixed at 0. The fitted experimental 
surface calculated by the Greco model was then subtracted 
from the additivity surface calculated as described above. The 
percentage above (synergistic combinations) or below 
(antagonistic interactions) the additivity surface was plotted 
in three-dimensional graph and a contour plot was 
constructed in order to determine the range of drug 
concentrations producing synergistic effects (Fig. 1B).
(ii) Bliss independence is described by the equation 
Ii = IA + IB - IA x IB where Ii is the predicted percentage of 
inhibition of the theoretical combination of the drugs A and B 
and IA, IB are the experimental percentages of inhibition of 
each drug acting alone, respectively. Since I = 1 - E where E 
is the percentage of growth and substituting to the former
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Figure 1. Assessment of the in vitro interaction between voriconazole (VCZ) and terbinafine (TB) against a clinical S. 
prolificans strain (AZN7898) based on Loewe additivity no interaction theory using the SP48 method. A. FIC index 
model (i). The checkerboard with the % of growth for each combination where are shown the combinations with more 
than 50% of growth (light gray area), the MICs-2 of VCZ and of TB and the iso-effective combination based on which 
the SFIC were calculated (dark gray area), the combinations with SFICs lower than 0.5 (underline wells) and the 
combination with lowest SFIC (0.20) (black well) which corresponded to the FICi-2. (ii). The corresponding 
isobologram with the additivity line (dashed line). B. Greco model. The three-dimensional (i) and the contour plot (ii) of 
the % of synergy with the following fitted parameters (± 95% CI): IC50TB = 5.33 ± 0.57, IC50VCZ = 2.63 ± 0.31, mTB = 
-0.51 ± 0.04, mVCZ = -1.1 ± 0.11, a  = 13.9 ± 1.6.
equation, the following equation is derived: Ei = EA x EB 
where Ei is the predicted percentage of growth of the 
theoretical combination of the drugs A and B, respectively 
and EA, EB are the experimental percentages of inhibition and 
growth of each drug acting alone, respectively. Interaction is 
described by the difference DE between the predicted and 
measured percentage of growth at various concentrations. 
Because of the nature of interaction testing using microtiter 
plates with twofold dilution of either drug, this results in a DE 
for each drug combination. Using a three-dimensional plot 
the DE depicted on the Z-axis, this results in a surface plot. In 
the non-parametric surface approach described by Prichard et 
al. (36, 37), the EA and EB are obtained directly from the 
experimental data while in the parametric surface approach 
(14, 20) these values are derived from fitting the Emax model 
to the concentration-effect curves of each drug alone. Thus, 
for the latter approach EA and EB are obtained by the 
following equation: EA,B = Emax x (D/IC50)m/[1+(D/IC50)m] 
where E, D, Emax, IC50 and m are the same parameters for
drug A and B as described above. The parameters of the 
model were obtained by a non-weighted non-linear regression 
analysis using the GraphPad Prism Software (San Diego, 
CA). Data were normalized by using the percentages, and the 
maximum and the minimum of the Emax model corresponding 
with 100% and 0%, respectively, were kept constant. The fit 
of the model was interpreted using the run test and the R2 
values. After the Emax model was fitted to the data, the 
parameters generated were used to calculate the no 
interaction surface for each replicate separately.
For each combination of the two drugs in each of the 
four independent experiments, the observed OD of growth 
obtained from the experimental data was subtracted from the 
predicted OD calculated as described above for each model. 
When the average difference was positive without its 95% CI 
among the four replicates overlapping 0, statistically 
significant synergy was claimed, when the difference was 
negative without its 95% CI among the four replicates 
overlapping 0, antagonism was claimed. In any other case
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Figure 2. Assessment of the in vitro interaction between voriconazole (VCZ) and terbinafine (TB) against a 
clinical S. prolificans strain (AZN7898) based on Bliss independence no interaction theory using the SP48 
method. A. The three-dimensional (i) and the contour plot (ii) of the % of synergy calculated with the non- 
parametric approach that resulted in 697% of synergy. B. The three-dimensional (i) and the contour plot (ii) of 
the % of synergy calculated with the parametric approach which resulted in 1118% of synergy with the 
following fitted parameters (± 95%CI) of the Emax model: IC50TB = 19.9 ± 6.7, mTB = -0.76 ± 0.21, IC50VCZ = 2.8 
± 0.7, mvcZ = -1.3 ± 0.37.
Bliss independence was concluded. The values thus obtained 
for each combination were used to construct a three­
dimensional plot. Peaks above and below the 0 plane indicate 
synergistic and antagonistic combinations, respectively while 
the 0 plane indicate no statistically significant interaction 
(Fig. 2). The contour plots were also constructed in order to 
visualize the drug concentrations producing an interaction.
Since the plot only shows the interactions for each 
separate combination of the concentrations, a value is needed 
to summarize the interaction surface. This was done by 
calculating the sum percentage of all statistically significant 
synergistic (SSYN) and antagonistic interactions (SANT). 
Interactions with <100% of statistically significant 
interactions were considered weak, 100-200% moderate, 
>200% strong.
R esults
Interaction between voriconazole and terb i­
nafine. The in vitro antifungal effects o f voriconazole 
and terbinafine were tested alone and in combination at 
concentrations o f 0.015 to 16 mg/l and 1 to 64 mg/l, 
respectively. Using the spectrophotometric method and 
reading after 72 h (SP72), 75% growth inhibition was 
achieved for all strains at concentrations o f 4 to 16 mg/l 
o f voriconazole and higher than 64 mg/l o f terbinafine. 
When the two drugs were combined the geometric 
mean (GM) of the MICs-1 decreased up to 27-fold and 
20-fold, respectively based on FICi-1. MICs-1 were 
then shifted down to 0.03 mg/l o f voriconazole and 2 
mg/l o f terbinafine (Table 1).
4
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Table 1. Susceptibilities (geometric mean and range in mg/l) of 5 S. prolificans strains against voriconazole (VCZ), 
miconazole (MCZ) and itraconazole (ICZ) alone and in combination with terbinafine (TB) based on the 75% 
growth inhibition endpoint (MIC-1) using the SP72 method
Com bination Isolate
MIC-1 Alone MIC-1 In combination
Azole Terbinafine Azole Terbinafine
VCZ and TB
MCZ and TB
ICZ and TB
7898 9.51 (8-16) >64 (>64) 0.71 (0.13-2) 9.51 (2-32)
7901 6.73 (4-8) >64 (>64) 0.25 (0.03-1) 6.73 (4-16)
7902 6.73 (4-8) >64 (>64) 0.5 (0.13-1) 8 (8)
7906 8 (8) >64 (>64) 1 (0.5-2) 9.51 (8-16)
7918 9.51 (8-16) >64 (>64) 1.19 (0.5-2) 11.31 (2-32)
7898 64 (32->64) >64 (>64) 1.19 (0.25-4) 2.83 (2-4)
7901 >64 (>64) >64 (>64) 2.83 (2-4) 2 (1-4)
7902 45.25 (8->64) >64 (>64) 2 (0.13-8) 2 (2)
7906 >64 (>64) >64 (>64) 2.83 (2-4) 1.41 (1-4)
7918 26.91 (8->64) >64 (>64) 0.84 (0.13-2) 2.38 (2-4)
7898 >32 (>32) >64 (>64) 1 (0.5-2) 16 (16)
7901 >32 (>32) >64 (64->64) 10.01 (4-16) 12.7 (8-16)
7902 >32 (>32) >64 (64->64) 4 (0.5-16) 8 (8)
7906 >32 (>32) >64 (>64) 3.17 (1-16) 8 (2-16)
7918 >32 (>32) >64 (>64) 4 (1-16) 10.08 (2-16)
A. Loewe additivity based models. (i) Non- 
param etric  approach. The median FIC indices for 
each strain regarding the growth inhibitory effects (SP 
methods) were lower than 0.75 down to 0.02 indicating 
synergy. This was significant in most o f the cases 
(Table 2). However, the degree o f synergy as well as 
the significance level was dependent on the MIC- 
endpoint and incubation period used, with reading of 
MIC-1 after 48 h o f incubation showing stronger 
synergy. Based on metabolic inhibitory effects strong 
synergy was found with the mCOL72 method. More 
variable results were obtained with COL method since 
FIC indices ranged from 0.02 up to 1.00 and 
discrepancies between FICi-1 and FICi-2 were found.
(ii) P aram etric  approach. The Greco model fit 
to the data well (median R2; 0.90, range; 0.83-0.96). 
The GM of IC50s and the median slope m was 5.9 mg/l 
(range 0.96-2342) and -0.61 (range -0 .16—1.46) for 
terbinafine and 4.2 mg/l (range 1.2-25) and -0.94 
(range -0 .45—1.79) for voriconazole, respectively. The 
interaction parameters a  were positive and the 95% CI 
did not overlap 0 indicating statistically significant 
synergy in all cases (Table 2). The interaction 
parameter a  ranged from 2.7-42 for all strains and 
methods except for one strain for which high a  values 
were obtained.
B. Bliss independence based models. When the 
interaction was determined based on BI, statistically 
significant synergy (P  < 0.05) was found using both 
non-parametric and parametric models. In most o f the 
cases more than 200% and up to 1582% of synergy was 
found indicating strong synergy (Table 2). Overall 
lower levels o f synergy were found with the COL72
method (median SSYN<165%). The SP methods 
resulted in higher levels o f synergy after 48h o f incu­
bation (median SSYN>195%) while mCOL methods 
after 72 h o f incubation (median SSYN >268%).
For the parametric approach, the Emax model fit 
well to the data [R2; 0.90 (0.74-0.99)]. The GM of the 
IC50s and the median slope m was 10.6 mg/l (range 1.6­
67.4) and -0.92 (range -0 .44—4.38) for terbinafine and 
2.9 mg/l (range 0.24-16.7) and -1 .2  (range -0 .13—5.2) 
for voriconazole, respectively. Antagonistic effects 
were not observed although the SP72 and mCOL48 
methods indicated some weak antagonistic 
combinations. The median absolute coefficient of 
variation o f the differences between observed and 
predicted ODs among the replicates o f all strains ranged 
from 41-232% (median 57%) for the SP methods, 68­
166% (median 123%) for the COL method and 44-83% 
(median 53%) for the mCOL methods with the 
parametric approach and 49-165% (median 88%) for 
the SP method, 86-180% (median 105%) for the COL 
method and 45-64% (median 51%) for the mCOL 
methods with the non-parametric approach.
Interaction between miconazole and terbi- 
nafine. The in vitro antifungal effects of miconazole 
and terbinafine were tested alone and in combination at 
concentrations o f 0.06 to 64 mg/l and 1 to 64 mg/l, 
respectively. Using the SP72 method, 75% growth 
inhibition was achieved for all strains at concentrations 
higher than 8 mg/l o f miconazole and higher than 64 
mg/l o f terbinafine. When the two drugs were combined 
the geometric mean (GM) of the MICs-1 decreased 54
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Table 2. In vitro interaction between voriconazole and terbinafine against S. prolificans
Loewe additivity based models Bliss independence based models
Method Time Isolate Non-parametric [median (range)] Parametric Non-parametric Parametric
FICi-2 FICi-1 a  ± 95% CI SSYN SANT SSYN SANT
Spectrophotometric 48 h 7898 0.13 (0.07-0.19) 0.10 (0.06-0.28) 13.9 ± 1.6 700% 0% 1118% 0%
7901 0.25 (0.08-0.75) 0.10 (0.05-0.13) 10.8 ± 1.8 428% 0% 742% 0%
7906 0.26 (0.13-0.38) 0.13 (0.06-0.25) 16.3 ± 4.5 457% 0% 566% 0%
7918 0.09 (0.04-0.13) 0.09 (0.04-0.09) 2479.8 ± 289.1 409% 0% 702% 0%
7902 0.14 (0.05-0.27) 0.09 (0.06-0.13) 42.2 ± 7.3 709% 0% 987% 0%
Median 0.14 0.10 16.30 457% 0% 742% 0%
Spectrophotom etr 72 h 7898 0.07 (0.05-0.31) 0.14 (0.13-0.75) 13.0 ± 3.4 1582% 0% 942% 0%
7901 0.32 (0.04-0.75) 0.13 (0.07-0.25) 32.4 ± 6.0 195% -3% 702% 0%
7906 0.38 (0.13-0.50) 0.28 (0.19-0.38) 8.4 ± 3.3 57% 0% 67% 0%
7918 0.08 (0.02-0.28) 0.27 (0.16-0.50) 1517.5 ± 334.8 770% -9% 520% -12%
7902 0.29 (0.13-0.31) 0.19 (0.08-0.25) 6.6 ± 2.1 185% 0% 579% -10%
Median 0.29 0.19 14.04 195% -2% 579% 0%
Colorimetric 72 h 7898 0.25 (0.02-0.63) 0.13 (0.04-0.16) 8.9 ± 4.0 165% 0% 442% 0%
7901 0.75 (0.50-1.00) 0.16 (0.13-0.16) 29.9 ± 16.8 0% 0% 23% 0%
7906 0.53 (0.07-0.75) 0.17 (0.07-0.19) 8.0 ± 3.0 34% 0% 72% 0%
7918 0.13 (0.08-0.25) 0.20 (0.04-0.31) 40.7 ± 16.5 254% 0% 49% 0%
7902 0.16 (0.08-0.50) 0.11 (0.04-0.19) 42.0 ± 12.2 619% 0% 903% 0%
Median 0.25 0.16 29.90 165% 0% 72% 0%
Modified 48 h 7898 0.25 (0.25-0.26) 0.25 (0.25-0.50) 1754.9 ± 947.1 299% -4% 373% -5%
Colorimetric 7901 0.25 (0.25) 0.25 (0.19-0.25) 33.7 ± 11.5 413% -5% 564% 0%
7906 0.25 (0.25) 0.27 (0.25-0.38) 2.7 ± 1.5 532% 0% 753% 0%
7918 0.25 (0.25-0.26) 0.13 (0.13-0.25) 9.9 ± 4.1 214% 0% 75% 0%
7902 0.26 (0.25-0.50) 0.27 (0.13-0.38) 8.2 ± 2.5 72% 0% 236% 0%
Median 0.25 0.25 9.9 299% 0% 373% 0%
Modified 72 h 7898 0.13 (0.08-0.13) 0.07 (0.06-0.07) 10.3 ± 7.6 279% 0% 56% 0%
Colorimetric 7901 0.25 (0.09-0.38) 0.13 (0.07-0.13) 5.0 ± 2.6 795% 0% 379% 0%
7906 0.31 (0.13-0.31) 0.13 (0.06-0.13) 3.9 ± 2.4 566% 0% 1072% 0%
7918 0.13 (0.07-0.13) 0.14 (0.07-0.14) 4.7 ± 2.9 579% 0% 513% 0%
7902 0.13 (0.07-0.25) 0.09 (0.06-0.13) 14.8 ± 5.0 464% 0% 468% 0%
Median 0.13 0.13 5.0 566% 0% 468% 0%
to 90-fold for both drugs, respectively based on FICi-1 
indices. MICs-1 were then shifted down to 0.125 mg/l 
o f miconazole and 1 mg/l o f terbinafine (Table 1).
A. Loewe additivity based models. N on-para- 
m etric approach. The median FIC indices for each 
strain regarding both the growth- and metabolic 
inhibitory effects were between 0.03 and 0.24 
indicating synergy, which was significant in all cases 
(Table 3). The degree o f synergy between 48 and 72 h 
was more consistent using the MIC-1 rather than the 
MIC-2 endpoint; for the latter endpoint weaker synergy 
was found after 48 h than after 72 h o f incubation. This 
was even more pronounced with the mCOL methods. 
MICs-2 o f the drugs in combination were lower than 
the lowest drug concentration using the COL72 method. 
Thus, the calculation o f the FICi for many replicates 
was impossible.
(ii) P aram etric  approach. The Greco model fit
to the data well [R2; 0.88 (0.76-0.93)]. The GM of IC50S 
and the median slope m was 22.1 mg/l (range 0.23- 
7.2x103) and -0.16 (range -0 .1 —0.53) for terbinafine 
and 4.2 mg/l (range 0.53-32.9) and -0.44 (range -0 .27­
-4.4) for miconazole, respectively. Relatively high 
IC50s o f terbinafine were obtained after 72 h of 
incubation. The interaction parameters a  were positive 
and the 95% CI did not overlap 0 indicating statistically 
significant synergy for each strain-method-incubation 
period however with different degrees o f synergy 
(Table 3). The interaction parameter a  ranged from 10­
2 .8  x 1 0 5 indicating very strong synergy with higher 
values obtained with the SP72 and mCOL72.
B. Bliss independence based models. Sta­
tistically significant synergy (P  < 0.05) was also found 
based on the parametric and non-parametric approach 
of BI since up to 1751% of synergy was found (Table 
3). For the former, the Emax model fit well to the data
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Table 3. In vitro interaction between miconazole and terbinafine against S. prolificans
Loew e additivity based m odels Bliss independence based m odels
Method Time Isolate Non-parametric [median (range)] Parametric Non-parametric Parametric
FICi-2 FICi-1 a  ± 95% CI SSYN SANT SSYN SANT
Spectrophotom etr 48 h 7898 0.13 (0.02-0.28) 0.04 (0.01-0.05) 302.1 ± 32.6 173% 0% 242% 0%
7901 0.11 (0.02-0.14) 0.05 (0.02-0.06) 3072.0 ± 441.7 243% 0% 396% -35%
7902 0.17 (0.14-0.28) 0.08 (0.01-0.28) 111.1 ± 17.5 163% 0% 206% -9%
7906 0.17 (0.09-0.28) 0.04 (0.01-0.13) 565.0 ± 110.7 160% -8% 284% -97%
7918 0.06 (0.03-0.15) 0.03 (0.02-0.08) 9462.1 ± 1194.5 460% 0% 615% 0%
Median 0.13 0.04 565.0 173% 0% 284% -9%
U-"Sa0+->O
-C0Ou-+->O<DOGO 7898 0.06 (0.02-0.09) 0.05 (0.03-0.08) 552.1 ± 77.6 57% 0% 135% -146%
7901 0.05 (0.02-0.08) 0.05 (0.03-0.06) 5516.6 ± 966.9 146% -6% 365% -144%
7902 0.06 (0.03-0.28) 0.06 (0.03-0.14) 1374.9 ± 242.9 10% -19% 78% -109%
7906 0.09 (0.03-0.13) 0.05 (0.02-0.07) 434.5 ± 124.9 67% -12% 138% -173%
7918 0.06 (0.03-0.16) 0.05 (0.03-0.27) 5464.7 ± 1082.9 392% -8% 505% -95%
Median 0.06 0.05 1374.9 67% -8% 138% -144%
Colorimetric 72 h 7898 0.06 (0.03-0.09) 0.04 (0.02-0.06) 817.5 ± 297.5 7% 0% 14% -16%
7901 0.19 (0.06-0.28) 0.03 (0.02-0.04) 180.1 ± 50.3 17% 0% 92% -95%
7902 0.05 (0.02-0.08) 0.05 (0.02-0.08) 128.2 ± 28.4 8% 0% 0% -75%
7906 0.03 (0.03) 0.05 (0.03-0.16) 55.5 ± 23.8 0% 0% 0% -97%
7918 0.08 (0.03-0.19) 0.04 (0.02-0.09) 633.2 ± 162.2 57% 0% 0% 0%
Median 0.06 0.04 180.1 8% 0% 0% -75%
Modified 48 h 7898 0.27 (0.27-0.28) 0.05 (0.04-0.13) 9.8 ± 2.2 556% -6% 567% -10%
Colorimetric 7901 0.16 (0.09-0.31) 0.05 (0.04-0.05) 44.3 ± 11.4 955% 0% 941% -21%
7902 0.27 (0.27-0.50) 0.04 (0.03-0.05) 34.1 ± 8.2 354% -5% 392% -34%
7906 0.38 (0.31-0.51) 0.04 (0.04-0.05) 18.5 ± 5.0 539% 0% 526% 0%
7918 0.27 (0.13-0.28) 0.31 (0.05-0.31) 3807.5 ± 1479.4 259% -9% 372% 0%
Median 0.27 0.05 34.1 539% -5% 526% -10%
Modified 72 h 7898 0.03 (0.03-0.04) 0.06 (0.06-0.13) 9505.2 ± 2824.2 487% 0% 518% -93%
Colorimetric 7901 0.03 (0.02-0.04) 0.09 (0.06-0.09) 6768.1 ± 2078.9 1051% 0% 1006% -136%
7902 0.03 (0.02-0.03) 0.06 (0.06-0.13) 7740.3 ± 1887.3 1751% 0% 1295% -89%
7906 0.03 (0.02-0.04) 0.13 (0.06-0.13) 7872.5 ± 3421.3 606% -8% 517% -103%
7918 0.06 (0.03-0.09) 0.08 (0.06-0.08) 534.6 ± 141.8 595% -31% 538% -26%
Median 0.03 0.08 7740.3 606% 0% 538% -93%
[R2; 0.88 (0.73-0.99)]. The GM of the IC50S and the 
median slope m were 11.4 mg/l (range 0.57-1028) and 
-0.35 (range -0 .10—0.86) for terbinafine and 4.43 mg/l 
(range 0.19-43.74) and -0.45 (-0.24--1.63) for 
miconazole, respectively. Higher levels o f synergy were 
found with the parametric approach than with the non- 
parametric based on the growth inhibitory activities. 
Among methods, mCOL72 and mCOL48 generated the 
highest levels o f synergy (median SSYN>526%) 
followed by the SP48 and SP72 (median SSYN<284%). 
Between the two incubation periods, stronger 
synergistic interactions were found after 48 h based on 
growth inhibitory effects and after 72 h based on 
metabolic inhibitory effects. By contrast the COL72 
method resulted in weak statistically significant 
synergistic interactions with 3 strains in the parametric 
approach showing no statistically significant synergistic 
interactions.
Weak statistically significant antagonistic 
interactions (SANT<100%) were observed in all 
methods for many strains. Particularly with the 
parametric approach even moderate antagonistic 
interactions were observed (200-100% SANT). These 
interactions were predominantly observed at the high 
concentrations o f miconazole and terbinafine i.e. 64 
mg/l where precipitation was obvious in the wells. The 
median absolute coefficient o f variation o f the 
differences between observed and predicted ODs 
among the replicates o f all strains ranged from 60­
124% (median 95%) for the SP methods, 142-227% 
(median 173%) for the COL method and 24-49% 
(median 40%) for the mCOL methods with the 
parametric approach and from 69-191% (median 123%) 
for the SP methods, 118-343% (median 236%) for the 
COL method and 23-56 % (median 36%) for the mCOL 
methods with the non-parametric approach.
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Table 4. In vitro interaction between itraconazole and terbinafine against S. prolificans
Loew e additivity based models Bliss independence based m odels
Method Time Isolate Non-parametric [median (range)] Parametric Non-parametric Parametric
FICi-2 FICi-1 a  ± 95% CI SSYN SANT SSYN SANT
Spectrophotometric 48 h 7898 0.13 (0.07-0.16) 0.19 (0.13-0.19) 4.3 ± 1.3 19% -20% 244% -45%
7901 0.52 (0.51-0.52) 0.13 (0.13-0.19) 9.3 ± 1.8 36% -25% 90% -27%
7902 0.07 (0.02-0.56) 0.13 (0.13-0.25) 203.8 ± 49.1 49% 0% 144% 0%
7906 0.16 (0.04-0.51) 0.14 (0.13-0.19) 3.3 ± 0.8 230% 0% 291% 0%
7918 0.51 (0.07-0.51) 0.13 (0.09-0.38) 25.1 ± 9.6 52% 0% 167% 0%
Median 0.16 0.13 9.3 49% 0% 167% 0%
Spectrophotometric 72 h 7898 0.13 (0.07-0.56) 0.14 (0.13-0.16) 25.9 ± 8.2 76% -31% 202% -178%
7901 0.75 (0.52-1.00) 0.31 (0.31-0.38) 57.2 ± 14.7 10% -85% 7% -98%
7902 0.02 (0.02-0.28) 0.19 (0.07-0.38) 182.9 ± 48.1 41% 0% 90% 0%
7906 0.13 (0.06-0.38) 0.16 (0.14-0.27) 8.1 ± 2.5 536% 0% 428% 0%
7918 0.51 (0.06-0.52) 0.14 (0.09-0.38) 457.6 ± 148.5 81% 0% 180% 0%
Median 0.13 0.16 57.2 76% 0% 180% 0%
Colorimetric 72 h 7898 0.07 (0.02-0.26) 0.16 (0.09-0.16) 202.9 ± 130.7 0% -46% 0% -109%
7901 0.13 (0.01-0.16) 0.26 (0.25-0.27) 5.2 ± 3.3 7% -83% 0% 0%
7902 0.13 (0.01-1.02) 0.19 (0.14-0.25) 29.1 ± 20.5 10% -53% 179% -3%
7906 0.04 (0.02-0.13) 0.13 (0.09-0.25) 23.7 ± 13.7 6% -209% 16% -404%
7918 0.16 (0.08-0.26) 0.16 (0.13-0.16) 69.9 ± 59.7 380% 0% 384% -4%
Median 0.13 0.16 29.1 7% -53% 16% -4%
Modified 48 h 7898 0.34 (0.19-0.50) 0.27 (0.27-0.28) 105.4 ± 39.1 25% -1% 69% 0%
Colorimetric 7901 0.14 (0.13-0.15) 0.20 (0.14-0.26) 802.1 ± 310.8 276% 0% 417% 0%
7902 0.27 (0.25-0.28) 0.20 (0.16-0.25) 23.9 ± 9.4 105% 0% 209% -14%
7906 0.20 (0.16-0.25) 0.23 (0.19-0.27) 81.6 ± 28.0 31% -14% 88% 0%
7918 0.11 (0.06-0.16) 0.08 (0.02-0.14) 795.3 ± 435.9 79% 0% 49% 0%
Median 0.20 0.20 105.4 79% 0% 88% 0%
Modified 72 h 7898 0.21 (0.14-0.28) 0.18 (0.04-0.31) 959.7 ± 542.4 146% -16% 529% -5%
Colorimetric 7901 0.04 (0.02-0.07) 0.15 (0.05-0.25) 5091.5 ± 3287.1 942% 0% 372% -16%
7902 0.30 (0.28-0.31) 0.05 (0.04-0.06) 404.7 ± 242.3 533% 0% 616% -51%
7906 0.28 (0.25-0.31) 0.06 (0.05-0.07) 2351.3 ± 1445.1 83% -13% 300% -33%
7918 0.04 (0.03-0.05) 0.07 (0.05-0.09) 7673.7 ± 389.4 263% 0% 1354% 0%
Median 0.21 0.07 959.7 263% 0% 529% -16%
Interaction between itraconazole and terb i­
nafine. The in vitro antifungal effects of itraconazole 
and terbinafine were tested alone and in combination at 
concentrations o f 0.5 to 32 mg/l and 0.06 to 64 mg/l, 
respectively. Using the SP72 method, 75% growth 
inhibition was not observed for all strains at high 
concentrations up to 32 mg/l o f itraconazole and 64 
mg/l o f terbinafine based on the results o f SP72. When 
the two drugs were combined the geometric mean (GM) 
o f the MICs-1 decreased up 64-fold for itraconazole 
and 16-fold for terbinafine based on FICi-1. MICs-1 
were then shifted down to 0.5 mg/l o f itraconazole and 
2 mg/l o f terbinafine (Table 1).
A. Loewe additivity based models. (i) Non- 
param etric  approach. The median FIC indices for all 
strains regarding the growth and metabolic- inhibitory 
effects ranged from 0.07 to 0.21 indicating synergy. 
This was significant in all cases with mCOL methods, 
but not with SP and COL methods since FIC indices up
to 1.02 were found for some strains (Table 4). The 
highest degree o f synergy was found after 72 h reading 
the MIC-1. The values o f the FIC indices represented 
the minimal values since the off-scale MICs o f both 
itraconazole and terbinafine alone did not allow the 
calculation of exact values.
(ii) P aram etric  approach. The Greco model 
fitted well to the data [R2; 0.88 (0.69-0.95)]. The GM of 
IC50s and the median slope m was 2.98 mg/l (range
0.15-93.6) and -0.68 (range -0 .15—1.7) for terbinafine 
and 404.4 mg/l (range 17.5-7 x 103) and -0.28 (range 
-0.16--26.7) for itraconazole, respectively. The a  
interaction parameters were positive and the 95% CI 
did not overlap 0 indicating statistically significant 
synergy for all strain-method-incubation period 
combinations (Table 4). The interaction parameter a  
ranged from 3.3 to 7.4 x 104 indicating very strong 
synergy. High a  values obtained with the mCOL72 
method. In some cases none o f the tested concentrations
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of itraconazole resulted in 50% of growth. In these 
cases the Greco model resulted in IC50s outside the 
range o f concentrations tested and this affected the fit. 
Therefore the IC50 of itraconazole was fixed to the next 
highest doubling concentration.
B. Bliss independence based models. Statisti­
cally significant interactions (P  < 0.05) were also found 
with the two approaches based on BI. High levels of 
synergy were found with mCOL methods (up to 1354% 
SSYN) followed by the SP methods (up to 536% 
SSYN). After 72 h o f incubation the levels o f synergy 
were higher than after 48 h. Strong statistically 
significant antagonistic interactions (up to -404%  
SANT) were found with COL method particularly with 
the non-parametric approach. The parametric approach 
resulted in higher % o f synergy than the non-parametric 
approach. For the former, the Emax model fitted well to 
the data [R2; 0.95 (0.77-0.99)]. The GM of the IC50s and 
the median slope m was 2.85 mg/l (range 0.23-155 
mg/l) and -0.52 (-0.11—1.22) for terbinafine and 
298.64 mg/l (range 5.2-5011 mg/l) and -0.43 (range 
-0 .06—0.99) for itraconazole, respectively. Statistically 
significant antagonistic interactions were found 
particularly with the parametric approach after 72 h of 
incubation, which were strong in some cases (>200%). 
The median absolute coefficient o f variation of the 
differences between observed and predicted ODs o f all 
strains ranged from 58-157% (median 106%) for the SP 
methods, 59-222% (median 106%) for the COL method 
and 51-69% (median 61%) for mCOL methods with the 
parametric approach and 57-287% (median 154%) for 
the SP methods, 51-195% (median 115%) for the COL 
method and 58-89% (median 71%) for the mCOL 
methods with the non-parametric approach.
Discussion
Strong synergistic interactions were found in 
vitro between terbinafine and three azoles, namely 
voriconazole, miconazole, and itraconazole, against 5 
clinical S. prolificans isolates based on antifungal 
growth- and metabolic inhibitory effects after 48 and 
72 h o f incubation. These results were confirmed by 
parametric and non-parametric approaches o f the 
Loewe additivity and the Bliss independence no­
interaction theories, respectively.
This confirms previous studies where terbinafine 
was found to interact synergistically with itraconazole 
for 90% of S. prolificans isolates (32) and 43% of 
Candida albicans (3), with voriconazole against 
Aspergillus species (41) and with fluconazole for 40% 
of C. albicans isolates (3) based on the FIC index 
model. However, the results obtained with the FIC 
index model are dependent on the MIC endpoints used 
particularly for filamentous fungi where they are not
clear established. In this study the results based on both 
MIC endpoints showed significant synergy with MIC-1 
resulting in higher levels o f synergy and more 
consistent between the two incubation periods com­
pared to MIC-2.
The interpretation o f the FIC index in concluding 
synergism or antagonism is a problem in it self. Since 
the determination o f  the MIC is sensitive to dilution 
errors, and 2 fold dilutions are used in determining 
MICs, the accuracy o f the MIC is usually taken as not 
more than within one dilution. Since the FIC indices are 
determined from two antifungals, the value of the FIC 
may also differ between experiments. In the 
interpretation o f a single FIC index therefore, a value of 
>4 is usually applied to conclude antagonism, and <0.5 
to conclude synergism (23). This is one o f the 
approaches we also took in interpreting the results. 
However, because we performed replicate experiments 
(4 times) for each strain-combination studied we were 
also able to interpret the results of the FIC index model 
for all replicates as one outcome (synergy, antagonism 
or additivity), thereby constraining the inter­
experimental error. Thus when the results of all four 
replicates were concordant, synergy or antagonism was 
claimed if  FIC indices were below 1 or above 1, 
respectively. In all other cases additivity was 
concluded. Another alternative approach would have 
been a more statistical approach, by using the mean of 
the four replicates and the 95% confidence interval; if  1 
does not include the 95% confidence interval synergism 
or antagonism could be concluded. However, because 
the distribution of the FIC indices is not normal we 
preferred the approach mentioned.
Assessing the nature o f drug interactions using 
the FIC index model faces several other problems 
except the choice of the FIC indices- and MIC- 
endpoints such as the lack o f a good summary and 
statistical interpretation o f the results, and the imprecise 
approximation o f the real FIC index when off-scale 
MICs are present. Therefore, the data were analyzed by 
a fully parametric approach described by Greco et al. 
(20). This model is based on the assumption that the 
concentration effect curves follow the Emax model 
(sigmoid curve with variable slopes), includes statistical 
significance levels o f the interactions and summarizes 
them with a non-unit, concentration-independent 
interaction parameter. This model does not require 
replicates to obtain statistical measures (although the 
mean with the standard error o f replicates can be 
included as weight factor) and is less sensitive to intra­
experimental errors compared to the FIC index model. 
The model fitted to the data well since narrow 95% 
confidence intervals for all parameters and low sum of 
the squares were obtained. Statistically significant 
synergy was found in all cases. The model resulted in 
high interaction parameters particularly when the IC50s
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of the individual drugs were off-scale. This indicates 
very strong synergy since a drug with poor activity 
(very high IC50) acquires activity when it is combined. 
However to obtain a reasonable fit, the IC50s had to be 
fixed to certain values in some cases. The value o f the 
interaction parameter for these cases might be uncertain 
because the extrapolation o f Emax model outside the 
range o f effects caused by a drug alone (i.e. 
itraconazole for which less than 50% inhibition was not 
observed at any concentration o f the drug alone) is very 
dangerous. The values o f interaction parameters found 
should then be regarded with extreme caution since the 
Emax model may not describe the concentration effect 
curve o f itraconazole appropriately in the whole range 
o f effects. However, results of previous studies have 
shown that the Emax model fitted well to concentration 
effect curves o f itraconazole against other filamentous 
fungi (i.e. Aspergillus species) (29). In addition, the 
Greco model fitted to the entire data set (21) where 
effects o f 0% up to 100% of inhibition were observed. 
Even though problems o f  fitting may arise when none 
o f  the tested combinations reduces the growth to 50%. 
Finally, results obtained with the Greco model, as for 
most o f  the regression analysis models, are dependent 
on various factors associated with the fitting procedure 
such as the initial parameters, the algorithms used for 
calculation the sum o f  the squares, variance models.
From the mechanistic point o f  view, the 
synergistic interaction between allylamines and azoles 
can be explained in a similar manner as the synergistic 
interaction between the antibacterials trimethoprim and 
the sulfonamides, which are acting at different steps o f  
the same pathway. Allylamines inhibit the squalene 
epoxidase, a non-cytochrome P-450 enzyme in the 
pathway of ergosterol biosynthesis whereas azoles act 
at a more distal point in the same pathway by inhibiting 
the 14a-demethylase o f lanosterol (16, 40, 47). Among 
the three azoles, miconazole showed the strongest 
synergy with FIC indices as low as 0.03 using the 
MIC-1. The strong synergy o f miconazole could be 
associated with its multiple mechanisms o f  action that 
probably involve alteration o f  fungal cell wall, 
alteration o f  the RNA and DNA metabolism, and 
intracellular accumulation o f  peroxides (4, 13) thereby 
increasing the sites o f potential interactions. Although 
sequential blocking o f  a biochemical pathway might 
often result in synergy (17, 44), the appropriateness of 
using Loewe additivity as no interaction model for 
analyzing interactions o f  drugs with dissimilar actions 
was questioned first by Bliss (8). Furthermore, it was 
found that Bliss independence o f the effects o f the two 
drugs acting in such ways can be achieved (46) even 
when the concentration effect curves o f  the two drugs 
followed the Emax model (24) despite Berenbaum’s 
critical arguments (6).
Even when Bliss independence was used as no 
interaction theory to analyze the interaction between the 
three azoles and terbinafine, strong statistically 
significant synergy was found in most o f the cases. 
However, weak or not statistically significant syner­
gistic interactions as well as strong statistically signi­
ficant antagonistic interactions were found. The latter 
was mainly due to precipitation at high concentrations. 
A good summary o f the results is lacking and replicates 
are required in order to obtain statistically significant 
results. Combinations with different interactions can be 
obtained and a full checkerboard design is required. 
Between the parametric and the non-parametric 
approach, higher levels o f synergy were found with the 
former, which was also less variable between the two 
incubation periods. The parametric approach could be 
applied in frugal experiments with significant results 
particularly when the concentration effect curves are 
well defined. It might reduce the intraexperimental 
errors particularly in single drug-containing wells. 
However, both models are sensitive to inter­
experimental variations. Precipitation at high 
concentrations affected more the results o f the 
parametric approach than those o f non-parametric 
resulting in strong statistically significant antagonistic 
interactions. Precipitation did not affect the results of 
the fully parametric Greco model since fully parametric 
approaches can fix experimental errors in total area of 
checkerboard by contrast with the semi-parametric like 
the parametric BI based model, which can do this only 
in the single drug containing wells. It would be 
interesting to compare all four models in interactions of 
different nature and degree using the same summary 
parameters and comparing the concentrations producing 
the synergistic effects.
Among the three azoles, the strongest synergy 
was produced with miconazole followed by 
itraconazole and voriconazole relying on Loewe 
additivity-based models and mainly on the Greco model 
since the calculation of the exact FIC indices for the 
interaction o f itraconazole and terbinafine was not 
possible due to off-scale MICs o f the former drug. 
Relying on Bliss independence-based models, 
voriconazole produced the strongest synergy followed 
by miconazole and itraconazole. This discrepancy, 
which might reflect different theoretical mechanisms, is 
caused by the different isobols obtained from the two 
models. As it was presented in Fig. 12 o f the review by 
Greco et al. (20), the isobols based on Bliss 
independence are dependent on the magnitude o f the 
slopes of the individual concentration effect curves. The 
smaller the slopes, the lesser Bliss synergistic 
interactions. Therefore, voriconazole with the largest 
absolute median slope resulted in the strongest synergy 
and itraconazole with the smallest absolute median 
slope resulted in the weakest synergy.
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Using spectrophotometric and colorimetric 
methods, the three azoles interacted synergistically with 
terbinafine not only by restricting the fungal biomass 
but also by reducing the metabolic activity of the fungi. 
However, lower levels of synergy were found with the 
standard colorimetric method compared to the 
spectrophotometric method and to the modified 
colorimetric method. This was more pronounced when 
the combinations were analyzed with Bliss 
independence-based models. Less and weaker 
statistically significant synergistic interactions were 
found with the standard colorimetric method (fungi are 
exposed for 3 h to the dye MTT after 72 h incubation 
with the drug) despite that the spectrophotometric 
method after 72 h resulted in strong statistically 
significant synergistic interactions for all the strains. 
This was caused mainly by the large variation between 
the replicates obtained with the standard colorimetric 
method resulting in less statistically significant 
interactions. Interestingly, the modified colorimetric 
method showed the lowest levels o f  interexperimental 
variability, thus increasing its potential for application 
in the in vitro combination studies o f  antifungal drugs.
The dynamic aspect o f  synergy between azoles 
and terbinafine was assessed by using measurements 
after 48 and 72 h o f incubation. The BI-based models 
resulted in higher levels o f  synergy after 48 h than after 
72 h based on the spectrophotometric methods while 
the opposite was observed with the modified 
colorimetric methods particularly for the miconazole- 
terbinafine and voriconazole-terbinafine interactions. 
This could be associated with the relatively higher 
interexperimetal variation observed after 72 h for the 
spectrophotometric methods and after 48 h for the 
modified colorimetric methods between the two 
incubation periods. The LA based models resulted in 
higher levels o f  synergy after 72 h than after 48 h 
particularly for the miconazole-terbinafine and 
itraconazole-terbinafine interactions. This could be 
explained with the growth curves o f S. prolificans 
recently published (28) where after 72 h the growth 
control inserts the second transition period while the 
drug containing wells might be in the log phase, which 
exhibits the highest growth rate. Therefore, at that time 
the synergistic effects are more pronounced and larger 
differences in growth between the single-drug and the 
drug-combinations containing wells could be observed.
The synergistic interaction between these three 
azoles and terbinafine might have great clinical impact 
for controlling infections caused by S. prolificans. Peak 
serum levels in humans have been reported for 
terbinafine up to 3.6 mg/l (2), for voriconazole up to 2.5 
mg/l (http://www.aspergillus.man.ac.uk), for 
miconazole up to 21.9 mg/l (13) and for itraconazole up 
to 1 mg/l (1). These levels are within the concentration 
range of these drugs, which produced the synergistic
effects when they were combined in vitro. Furthermore, 
successful outcome was reported in humans treated 
with itraconazole and terbinafine in invasive infections, 
which might be due to in vivo synergy between these 
two drugs (42, 45). Therefore, the combination therapy 
o f an azole with terbinafine could be beneficial for the 
management o f S. prolificans infections for several 
reasons such as (i) enhancement o f the antifungal 
effects o f the single drugs which in case o f S. 
prolificans can be absent like for itraconazole, (ii) 
reduction o f the required drug concentrations to 
produce the same effect as the drugs alone at levels 
achievable in serum, (iii) diminution o f the side effects 
and (iv) production o f fungicidal activities. Regarding 
the latter, although few of the combinations tested in 
this study appear to inhibit completely the growth at 
high concentrations, the fungicidal activity o f these 
combinations should be further explored.
Despite the in vitro synergistic interaction 
between azoles and terbinafine, the therapeutic synergy 
o f such combinations may be affected by 
pharmacokinetic and/or pharmacodynamic interactions 
that may take place in vivo (9, 22) diminishing, if  not 
reversing, the positive effects observed in vitro. 
Therefore, the effectiveness o f combination therapy 
should be tested initially in experimental infections in 
animal models. A murine model of scedosporiosis 
recently developed (J. Meletiadis, J. Curfs, J. F. G. M. 
Meis, and P. E. Verweij. Abstr. 40th International 
Congress o f Antimicrobial Agents and Chemotherapy, 
abstr. 1670, 2000) might help to test the in vivo 
interaction between azoles and terbinafine in an attempt 
to confirm the in vitro results.
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Assessing the in vitro Interaction of Antifungal Drugs: 
Comparison of Different Drug Interaction models
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Departments of Medical Microbiology, University Medical Center Nijmegen1 and Department of Medical Microbiology and 
Infectious Diseases, Canisius- Wilhelmina Hospitaf, Nijmegen, The Netherlands
The in vitro combination of various antifungal drugs [miconazole (MZ), itraconazole (IZ), 
fluconazole (FZ), am photericin B (AB), 5-flucytosine (FC), and terbinafine (TB)] was tested 
against 17 clinical fungal isolates including yeasts [3 Candida albicans (CA), 5 C. glabrata (CG), 
and 3 C. krusei (CK)] and filamentous fungi [3 Aspergillus fumigatus (AF) and 3 Scedosporium  
prolificans (SP)] with a m icrodilution checkerboard technique based on spectrophotom etric and 
colorimetric modifications of the NCCLS standards. The drug com binations-strains pairs were 
chosen in such a way to have interactions spanned from  strong synergy to strong antagonism 
based on the fractional inhibitory concentration index (FIC index) model. Thus, there were 
found 5 synergistic (MZ + TB with SP and FC + FZ with CA), 5 additive/indifferent (AB + IZ 
with AF and FC + FZ  with CK) and 6 antagonistic (FC + FZ against CG) interactions. The 
interactions were analyzed using standard  (the FIC  index model) and m odern concentration 
effect response surface approaches (fully param etric  model developed by Greco et al.) of drug 
interaction m odeling including non-param etric and param etric  models of two competing zero­
interaction theories, the Loewe additivity and the Bliss independence (model developed by 
P richard  et al.). Despite its simplicity, the FIC  index model resulted in variable conclusions 
depending on M IC endpoints determ ined and the in terpretation endpoints used. Using the M IC-
2 endpoints (lowest drug concentration showing 50%  of growth) problem s in calculating the FIC 
indices due to trailing phenom ena and fungistatic-fungicidal combinations were reduced. High 
reproducibility was achieved in in terpreting the FIC  indices when the cutoffs of 0.25 and 4 (for 
single experiments) and the cutoff of 1 (for replicates) were used for the upper and lower limits 
of synergy and antagonism , respectively. Although the fully param etric  Greco model did not 
describe precisely the entire response surfaces of antifungal drugs, it was able to differentiate 
synergistic from  antagonistic interactions with a non-unit, reproducible, concentration- 
independent interaction param eter including its uncertain ty  w ithout requiring replication. The 
assessment of antagonistic interactions with this model was problem atic. The Bliss independence 
based models resulted in mosaics of synergistic and antagonistic interactions raising questions 
about the mechanism of actions of antifungal drugs in combination. The levels of 150%  and -  
150%  of the sum of all statistically significant interactions can be used as cutoffs for synergy and 
antagonism. Sem i-param etric approaches need particu lar care since experim ental e rro rs are not 
elim inated from  the entire response surface.
Despite the considerable progress in antifungal 
therapy o f systemic mycoses, treatment options still 
involve several drawbacks such as the toxicity o f the 
widely used fungicidal antifungal drug, amphotericin B, 
the fungistatic properties o f the less toxic azoles, the 
development o f resistance to itraconazole, fluconazole 
and 5-flucytosine, and the emergence o f new pathogens 
resistant to conventional monotherapy (i.e. scedospo- 
riosis) (12, 34, 47). Thus, the introduction of new azoles 
with better pharmacokinetic profiles and potent 
antifungal activities (i.e. voriconazole, posaconazole) 
and the development o f new agents with novel 
antifungal actions (i.e. echinocandins, nikkomycins) 
have boosted the discussion about the potential of 
combination therapy in management o f invasive fungal
infections (13, 19, 24, 34, 40). More systemic drugs are 
now available with different mechanism of action 
increasing thus the possibility for synergistic 
interactions. This progress necessitates the provision of 
the in vitro antifungal susceptibility testing with new 
approaches for testing and analyzing combination of 
antifungal drugs.
Although antifungal drugs may interact 
differently under different conditions in in vitro systems 
(21, 27), variable results can be obtained even when the 
same in vitro methodology is used depending on the 
way that the nature and the intensity o f drug 
interactions are assessed (5, 6, 14, 34). The standard 
approach in the field o f medical microbiology is the 
calculation of the fractional inhibitory concentration
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index (FICi) (10, 18). Synergy or antagonism is 
concluded when the concentration o f the drugs in a 
combination showing the same effect as the MIC are 
lower or higher, respectively than the MICs o f the 
single acting drugs for more than 1 dilution step o f the 
assay. Despite the simplicity o f this model, there are 
several drawbacks o f this model to describe correctly, 
reliably and precisely the multi-dimensional 
phenomenon o f drug interaction. These include (i) the 
choice of the MIC endpoints particularly with the 
combination o f fungistatic and fungicidal drugs (ii) the 
choice o f endpoints for the interpretation of the FIC 
indices (iii) the sensitivity to intraexperimental errors 
particularly when a twofold dilution scheme is followed
(iv) the imprecise approximation o f the real FIC index 
when off-scale MICs are present (v) the lack o f a good 
summary o f the interactions (vi) the difficulty to 
interpret statistically the results (45). The multi­
dimensional (drugs + effect) nature o f the drug 
interactions has led to the development o f new models 
based on response surface approaches (7, 42, 44). One 
o f them is a fully parametric model described by Greco 
et al. which is an Emax based model and fits to the entire 
data set with a non-linear regression analysis (15). 
Many o f the above mentioned problems o f the drug 
interaction modeling are overcome since the nature and 
the intensity o f an interaction is summarized with a 
non-unit, concentration-independent interaction 
parameter including the uncertainty in the estimate.
However, both models mentioned above rely on 
the Loewe additivity (LA) zero-interaction theory. This 
theory is based on the simple idea that a drug by 
definition cannot interact with itself and therefore a 
combination o f a drug with itself is additive and its 
effect is that what is expected from the concentration 
effect curves. Opponents claim that the LA theory is 
limited to drugs that act similarly or have similar 
concentration-effect curves. Although many zero­
interaction theories can be found in the literature, the 
major competitor o f LA for a reference model is the 
Bliss independence (BI). The latter theory relies on the 
idea that two drugs that act independently at any aspect 
follow the law o f probability: the probability o f either 
or both two independent events (i.e. the action o f a drug 
which in case o f susceptibility tests corresponds to the 
percentage o f inhibition) to occur is the sum o f the 
probabilities o f each event to happen alone minus the 
multiplication o f them. Opponent arguments o f this 
theory consisted o f paradoxical cases when sham 
combinations o f the same drug are analyzed assuming 
the BI as zero-interaction theory and the fact that the 
equation o f the drug actions with independent events, as 
it is assumed in the BI theory, is questionable given the 
complexity o f systems like cells (6, 14).
Several models based on BI have been 
described elsewhere (14). One o f these is the non-
parametric model described by Prichard et al. (35, 36) 
as well as the parametric approach o f the latter model 
assuming that the concentration-effect relationship of 
each drug alone follows the Emax model (9, 14). Both 
models emphasize the multidimensional nature o f drug 
interactions and determine the interactions including 
statistically significant levels. Furthermore, they enable 
the presence o f mosaics o f synergistic and antagonistic 
combinations as opposed to the Greco model. However, 
both models lack a good summary, although various 
summary measures have been previously described (8, 
14, 36).
Controversial results on the nature as well as the 
intensity o f an in vitro interaction can be obtained using 
each o f the above-described models (14). Given the 
increasing interest of combination antifungal therapy, 
an unbiased, objective and comprehensive analysis tool 
for the assessment o f the in vitro combination of 
antifungal drugs is warranted. In order to compare all 
these models, 17 drug combination-fungus pairs 
including different antifungal drugs (miconazole, 
itraconazole, fluconazole, amphotericin B, 5- 
flucytosine, and terbinafine) and various species of 
yeasts (Candida albicans, C. glabrata, and C. krusei) 
and moulds (Aspergillus fumigatus and Scedosporium 
prolificans) were selected based on the FIC indices 
calculated from preliminary experiments. Thus, the 
collection consisted o f 6 synergistic interactions 
(FICi<0.5), 6 additive/indifferent interactions 
(0.5<FICi<4) and 5 antagonistic interactions (FICi>4). 
Data obtained from two dimensional checkerboard 
microdilution techniques based on a spectrophotometric 
(for yeasts) and a colorimetric (for moulds) 
modification o f the NCCLS standard for antifungal 
susceptibility testing, were analyzed with the four 
above mentioned models. Results concerning the 
parameters of concentration-effect curves o f the drugs, 
the nature and the intensity o f the interactions, as well 
as the drug concentrations, which showed the 
interactive effects estimated with each model, were 
compared to each other. Because the purpose o f this 
study was the drug interaction modeling o f antifungal 
agents, biological and clinical extrapolations o f the 
results were limited towards this direction.
M a ter ia ls  and  M ethods
Isolates. Six clinical isolates of filamentous fungi, 3 
Scedosporium prolificans, AZN7901 (SP1), AZN7902 (SP2), 
and AZN7906 (SP3) and 3 Aspergillus fumigatus, AZN5241 
(AF1), AZN58 (AF2), and AZN59 (AF3), and 11 yeast 
clinical isolates, 3 Candida albicans, AZN574 (CA1), 
AZN2308 (CA2), and AZN4518 (CA3), 3 C. krusei, AZN1- 
27 (CK1), AZN1-31 (CK2), and AZN1-32 (CK3), 5 C. 
glabrata, AZN608 (CG1), AZN1143 (CG2), AZN1-28 
(CG3), AZN2-50 (CG4), and AZN2-57 (CG5) were used in
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Table 1. Characteristics o f drug combination-strains pairs used in the interaction studies
FICInteraction . ..indices
Drug combination 
(concentration range in mg/l) Time Species
No. of 
Strains
Repli- Checker- ,* , , Method cates board
Synergy <0.5
Synergy <0.5 
Additive/ 0.5-4 
0.5-4 
Antagonism >4
indifferent
Additive/
indifferent
miconazole (64-0.06)
+ terbinafine (64-1) 
5-flucytosine (64-0.004)
+ fluconazole (128-0.125) 
amphotericin B (16-0.015) 
+ itraconazole (16-0.015) 
5-flucytosine (64-0.004)
+ fluconazole (128-0.125) 
5-flucytosine (64-0.004)
+ fluconazole (128-0.125)
72 h S. prolificans 3 4 12x8
48 h C. albicans 3 3 16x12
48 h A. fumigatus 3 3 12x12
48 h C. krusei 3 3 16x12
48 h C. glabrata 5 3 16x12
MTT
colorimetric
Spectropho-
tometric
MTT
colorimetric
Spectropho-
tometric
Spectropho-
tometric
this study. The isolates were stored in 50% glycerol in water 
at -70oC. C. parapsilosis (ATCC 22019) and C. krusei 
(ATCC 6258) were used as quality control (QC).
Antifungal drugs. Six antifungal drugs belonging to 
different classes of antifungal agents namely, the azoles 
miconazole (MZ) (Janssen Research Foundation, Beerse, 
Belgium), itraconazole (IZ) (Janssen Research Foundation), 
and fluconazole (FZ) (Pfizer, Capelle aan den IJssel, The 
Netherlands), the allylamine terbinafine (TB) (Novartis, 
Basel, Switzerland), the polyene amphotericin B (AB) 
(Bristol-Myers Squibb, Woerden, The Netherlands) and the 
pyrimidine 5-flucytosine (FC) (ICN, Pharmaceuticals, 
Zoetermeer, The Netherlands) were tested. In order to obtain 
stock solutions miconazole, itraconazole, terbinafine and 
amphotericin B were dissolved in 100% dimethylsulfoxid at 
concentrations of 25,600 mg/l, 12,800 mg/l, 25,600 mg/l and 
6,400 mg/l, respectively and fluconazole and 5-flucytosine 
were dissolved in water at concentrations of 512 mg/l.
Antifungal susceptibility testing method. The in 
vitro activities of drugs alone and in combination were tested 
in 96-well flat-bottom microtitration plates with a two­
dimensional checkerboard microdilution technique described 
previously (J. Meletiadis, J. W. Mouton, J. F. G. M. Meis, P. 
E. Verweij, submitted for publication) based on the standards 
proposed by the NCCLS for filamentous fungi (M-38P) and 
yeasts (M-27A) (28, 29). Briefly, serial twofold dilutions 
according to the dilution scheme for water insoluble and 
-soluble drugs of the NCCLS methods were prepared in the 
standard medium (liquid RPMI 1640 without sodium 
bicarbonate, with L-glutamine) (GIBCO BRL, Life 
Technologies, Woerden, The Netherlands) buffered with 
0.165 M 3-N-morpholinepropanesulfonic acid (Sigma- 
Aldrich Chemie GmbH, Steinheim, Germany) at pH 7.0 in 
order to obtain 4 times the final concentration. 50 ml of each 
drug concentration was mixed into the wells with 50 ml of 
each concentration of the other drug including the drug-free 
controls (medium with the drug solvent at the final 
concentration) for the two drugs alone and together in order 
to obtain a two-dimension checkerboard. Yeast and mould 
conidia were collected with a swab from 1-2 and 5-7 day-old 
cultures in Sabouraud dextrose agar, respectively and conidia 
suspensions were adjusted spectrophotometrically. The 
conidia suspensions were diluted in order to obtain two times 
the final inoculum, which ranged from 1 x 104 to 5 x 104
CFU/ml for mould isolates and from 1 x 103 to 2.5 x 103 
CFU/ml for yeast isolates in the standard medium. Then 
100 ml of conidia suspension were inoculated into each well. 
The final concentrations of the drugs after the inoculation, 
alone and in combination are shown in Table 1.
Interaction studies. The strain-drug combination 
pairs were chosen based on the results of previous 
experiments (Table 1) in such a way to have interactions that 
spanned from strong synergy to strong antagonism based on 
the fractional inhibitory concentration index (FICi) model. 
The growth was quantified spectrophotometrically at 405 nm 
for the yeast strains and at 550 nm colorimetrically using a 
modification of the MTT method described previously for the 
mould strains (25). The percentage of growth for each well 
was calculated compared to that of the drug-free well. All 
tests were conducted in replicates on different days.
Drug interaction modeling. Data obtained as 
described above were analyzed using four different models. 
The models were parametric and non-parametric approaches 
of the following two zero-interaction theories: the Loewe 
additivity and the Bliss independence. In the Loewe 
additivity theory, concentrations of the drugs that produce the 
same effect alone and in combination, are compared, while in 
the Bliss independence theory, the estimates of the combined 
effect based on the effect of the individual drugs were 
compared with the effects obtained with the experiment.
(i) Loewe additivity (LA) is described by the 
following equation: 1 = dA/DA + dB/DB where dA and dB are 
the concentrations of the drugs A and B in the combination 
which elicit a certain effect and DA and DB the iso-effective 
concentrations of the drugs A and B when acting alone.
FIC index model. The non-parametric approach is 
based on the fractional inhibitory concentration index model 
expressed with the following equation:
P comb p comb
A V“ 'RSFIC = FICa + FICb= ----A------  + — B-------
MICAalone MICBalone
where MICAalone and MICBalone are the concentrations of the
drugs A and B when acting alone and CAcomb and CBcomb are
the concentrations of the drugs A and B at the iso-effective 
combinations (18). Since each replicate experiment yields 
several SFICs, among all SFICs calculated for each replicate, 
the SFICmin and SFICmax were determined corresponding to
97
CHAPTER 3.3
the lowest and the highest SFIC, respectively. The reported 
SFIC (FIC index) was the SFICmin in all cases except when 
the SFICmax was higher than 4. In that case the SFICmax was 
reported as the FIC index (FICi) (18). Three MIC endpoints 
were used namely MIC-0, MIC-1 and MIC-2 defined as the 
lowest drug concentration showing 10%, 25% (or 20% for 
the yeast strains) and 50% of growth compared to the growth 
control, respectively. Thus, the following FIC indices were 
determined for each replicate, FICi-0, FICi-1 and FICi-2, 
respectively. Off-scale MICs were converted to the next 
highest or lowest twofold concentration. Since the FIC 
indices (FICis) are not normally distributed the median and 
the range of FICis among the replicates was calculated. 
Furthermore, the drug concentrations of the combination, 
which was corresponded to the FICi, was determined. This 
combination was actually the combination with the strongest 
effect (Imax).
Greco model. The fully parametric surface approach 
described by Greco et al. (15) was used based on the 
following equation:
DaD„
1 =
( E ) 1,mA IC ( E V 
VEm.-Ej V" U - E  j
- + a-
IC IClvMn ( e,!-e )
.5(1/mA + 1/mB)
(ii) Bliss independence (BI) is described by the 
equation Iind = IA + IB - IA x IB, where Iind is the predicted 
percentage of inhibition based on the experimental percenta­
ges of inhibition IA, IB of each drug acting alone, respectively. 
The latter equation is equivalent to Eind = EA x EB, where Eind 
is the predicted percentage of growth which describes the 
effect of a combination where the drugs are acting 
independently and EA, EB are the experimental percentages of 
growth of each drug acting alone, respectively. The 
difference DE between the predicted percentage of growth 
Eind and the experimentally measured percentage of growth 
(Eexp) describes the interaction at each combination of the 
drug concentrations. A three dimensional plot can then be 
constructed resulting in a surface plot.
In the non-parametric surface approach described by 
Prichard et al. (37), the EA and EB are obtained directly from 
the experimental data while in the parametric surface 
approach (9) these values are derived from fitting the Emax 
model to the concentration-effect curves of each drug alone. 
Thus, for the latter approach the Eind was calculated with the 
following equation:
E in d
(D a/IC 50,A )mA • (Db /I C 5 0,B )m"
[ 1 + /Da /IC 50,A )mA ] • [1 + (Db /IC50,b )m" ]
where E is the percentage of growth (dependent variable) at 
the drug concentrations DA and DB (independent variables), 
Emax is the maximal percentage of growth observed in the 
drug-free control, IC50A and IC50B are the drug 
concentrations producing 50% of the Emax, mA and mB are the 
slopes of the concentration-effect curves (Hill coefficient) for 
the drugs A and B, respectively and a  is the interaction 
parameter which describes the nature of the interaction. This 
model was fitted directly to all experimental data of a data set 
(percentages of growth for all concentrations of the two drugs 
alone or in combination) with a non-weighted, non-linear 
regression analysis using the MODLAB program 
(MEDIMATICS, Maastricht, The Netherlands, 
www.medimatics.nl). When the estimate of a  was positive 
and its 95% confidence interval (95% CI) did not include 0, 
statistically significant synergy was claimed while when a  
was negative without its 95% CI overlapping 0, statistically 
significant antagonism was concluded. In any other case 
Loewe additivity/indifference was concluded.
Goodness of fit criteria included the 95% CI of the 
estimated parameters, the R2, the sum of the squares 
(SumSq), correlation and covariance matrices. In order to 
check for any systematic deviation of the model from the 
data, residual plots were constructed and deviation from the 
normal distribution was tested with the Kolmogorof-Smirnof 
(KS) test.
In order to determine the drug combination which 
produced the highest effect (synergistic or antagonistic), the 
additivity surface was simulated by fixing all parameters of 
the Greco model to values obtained after the model was fitted 
to experimental data except a  which was fixed at 0. This 
surface was then subtracted from the fitted surface calculated 
by the Greco model. The drug model concentrations of the 
combination with the highest percentage of synergy or 
antagonism were reported.
where DA, DB, IC50,A, IC50,B, mA and mB are the same 
parameters as described above for drug A and B in the Greco 
model. The parameters of the model were obtained by a non­
weighted non-linear regression analysis of concentration 
effect curves of each drug alone using the GraphPad Prism 
Software (San Diego, CA). Data were normalized by using 
the percentages. The maximum and the minimum of the Emax 
model were kept constant during the fitting procedure at 
100% and 0%, respectively. The goodness of fit was 
interpreted using the 95% CI of the estimates, the run tests 
and the R2 values. The estimated parameters for each drug 
generated were subsequently used to calculate the zero­
interaction surface for each experiment.
For each combination of the drugs in each of the 
independent replicate experiments, the Eexp was subtracted 
from the Eind calculated with the non-parametric or the 
parametric model. When the mean difference was positive 
and its 95% CI did not include 0, statistically significant 
synergy was claimed for that specific combination of drug 
concentrations. When the mean difference was negative 
without its 95% CI overlapping 0, statistically significant 
antagonism was claimed for that specific combination of drug 
concentrations. In any other case Bliss independence was 
concluded. In the three-dimensional plots, peaks above and 
below the 0 plane indicate synergistic and antagonistic 
combinations, respectively, while the 0 plane itself indicate 
no statistically significant interactions.
Since the plots only show the interaction for each 
separate combination of concentrations, a value is needed to 
summarize the whole interaction surface for each strain. This 
was done in two different ways. In the first, the percentages 
of all statistically significant interactions were summed 
(SSSI). In the second, all statistically significant interactions 
were averaged and the mean percentage (MSSI) as well as its 
95% CI was calculated. When the MSSI was positive and its
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Table 2. Summarized results of the four drug interaction models based on species and drug combinations. The median
(min, max) for the 3 strains and the three replicates is presented
Species Drug LOEWE ADDITIVITY BASED MODELS
(No. of combi­ Non-parametric approach (FIC index) Parametric (Greco)
Strains) nations FICi-0 FICi-1 FICi-2 a b
SP (3) 
CA (3) 
AF (3) 
CK (3) 
CG (5)
TB + MZ 
FC + FZ 
AB + IZ 
FC + FZ 
FC + FZ
NDa 
0.17 (0.09, 0.25) 
1 (0.25, 2)
1 (0.5, 1)
8.5 (4.25, 9)
0.09 (0.06, 0.13) 
0.08 (0.05, 0.13) 
0.63 (0.27, 2)
1 (0.5, 1)
8.5 (4.25, 16.5)
0.03 (0.02,0.04) 
1.03 (0.28, 1.03) 
0.25 (0.08, 0.51) 
1 (0.5, 1.5)
8.25 (1.01, 32.5)
84.1 (0.2, 54 x 103) 
18.9 (1.2, 61.6) 
-0.14 (-0.30, 0.04) 
-0.2 (-0.5, -0.13) 
-0.22 (-0.51, -0.14)
BLISS INDEPENDENCE BASED MODELS
Non-parametric approach Parametric approach
s s s i  (%)c MSSI (% ± 95% CI)d s s s i  (%) MSSI (% ± 95% CI)
SP (3) 
CA (3) 
AF (3) 
CK (3) 
CG (5)
TB + MZ 1401 (1051, 1751) 
FC + FZ 347 (123, 440)
AB + IZ 30 (21, 39)
FC + FZ 70 (-56, 285)
FC + FZ -498 (-805, -282) ■
28.4 (14.9+1.8, 28.7±2.2) 870 (413, 1206) 
11.3 (7.2+7.1, 18.3+3.8) 639 (194, 871) 
1.2 (-0.1+14.4, 4.8+9.8) 137 (82, 207) 
13.9 (-13.9+17.1, 15.8+3.4) 102 (61, 152) 
-31.1 (-41.3+18.4, -27.4+12.6) -419 (-914, -214)
21.7 (9.2+3.4, 23.6+4.6)
15.2 (9.2+6.4, 20.2+2.8)
4.7 (4.3+9.4, 12.2+6.8)
6.8 (3.6+22.9, 7.9+7.8) 
-34.9 (-37.7+9.2, -30.6+24.6)
a ND, not determined.
b The 95% confidence intervals did not overlap 0. 
c Sum of all statistically significant interactions of a data set.
d Mean and 95% confidence interval of all statistically significant interactions of a data set.
95% CI did not include 0, statistically significant synergy 
was claimed for the entire data set. When the MSSI was 
negative without its 95% CI overlapping 0, statistically 
significant antagonism was concluded for the entire data set. 
In addition, the SSSI and the MSSI were calculated only for 
the statistically significant synergistic (SSYN and MSYN, 
respectively) and antagonistic (SANT and MANT, 
respectively) separately. Finally, the drug concentrations of 
the combination that yielded the highest synergistic or 
antagonistic effect (Imax) were determined.
Comparison of models. In order to compare the four 
models various parameters were chosen such as (i) the single 
drug parameters MIC-0, MIC-1 and MIC-2 of the FIC index 
model and the IC50 and the slope m of the Greco and the 
parametric BI-based model, (ii) the summary interaction 
parameters FICi-0, FICi-1 and FICi-2 of the FIC index 
model, a  interaction parameter of the Greco model and SSSI 
and MSSI of the non-parametric and parametric BI-based 
models and (iii) the interactive drug concentrations which 
yielded the most potent interaction as determined with each 
model.
Furthermore, different endpoints were used to 
determine synergy, zero-interaction (additivity, indifference, 
independence) and antagonism for each model. The 
percentage of agreement was calculated and the results were 
analyzed with the kappa test. A kappa value of 1 indicates 
absolute agreement (100%). Kappa values between 0.90-1 
indicate excellent agreement, 0.80-0.90 very good agreement,
0.61-0.80 good agreement, and <0.6 poor agreement
The concentrations of the drugs were transformed 
logarithmically in order to approximate normal distribution. 
The differences between the models for all drug-strain 
combinations were analyzed with analysis of variance 
(ANOVA) followed by Bonferroni ’s multiple comparison 
tests. In all comparisons, differences with P < 0.05 were 
considered statistically significant.
R esults
FIC  index model. The summarized results 
obtained with the FIC index model are presented in 
Table 2 for each species-drug combination. In the table, 
for all data sets for which the reported FICis were 
corresponded to the SFICmins (5. prohficans, C. 
albicans, A. fumigatus, and C. krusei), the SFICmaxs 
were lower than 2.5 (except for the third replicate o f the 
AF2 strain for which the SFICmax was 4) while for all 
data sets for which the reported FICis were 
corresponded to the SFICmaxs (C. glabrata), the 
SFICmins were greater than 0.5. This indicates that there 
were not both synergistic and antagonistic combinations 
within the same data set.
FIC indices varied from as low as 0.02 for 5. 
prolificans strains with terbinafine and miconazole to as 
high as 32.5 for C. glabrata stains with 5-flucytosine 
and fluconazole indicating strong synergy and 
antagonism, respectively. The results o f the median 
FICi-0, FICi-1 and FICi-2 were consistent for 3 of the 5 
combinations (5. prolificans, C. krusei, and C. 
glabrata). In contrast, for C. albicans and A. fumigatus, 
the value o f the FICi was dependent on the MIC 
endpoint chosen. For instance, using the FICi-0 for C. 
albicans one could conclude synergy (median FICi 
0.17), while using the FICi-2 indifference would be 
concluded (median FICi-2 1.03). Since some of the 
variation o f the results might be due to experimental 
errors, we looked at the variation between replicate 
experiments.
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Figure 1. Graphical representation with the analytical results of the four models. The FICi-0 (A), FICi-1 (B) and 
FICi-2 (C) of the FIC index model, the a  interaction parameters (D) of the Greco model and the % of SSSI of the 
non-parametric (E) and parametric (F) approach of Bliss independence. For all models except the Greco model the 
minimum, median and maximum among the replicates are presented for each strain with the three horizontal lines, 
respectively. For the Greco model the interaction parameter a  with its 95% CI is presented for each replicate of each 
strain. Squares and triangles correspond to positive and negative a  values, respectively.
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Fig. 1 shows that most o f the differences among 
the FIC indices of the replicates were within 3 log2. By 
using the FICi-1, better discrimination was obtained 
between synergistic, additive/indifferent and antago­
nistic interactions (Fig. 1) when the cut-offs o f 0.25 and 
4 were used for the upper limit of synergy and 
additivity/indifference, respectively. By using these 
endpoints for the interpretation of the results the highest 
reproducibility among the replicates was found (100%) 
(data not shown). Using the FICi-0, the interactions 
could be classified as synergistic or antagonistic when 
all replicates resulted in indices lower or higher than 1,
respectively while in additive/indifferent interactions 
one or more replicates resulted in indices o f 1.
Greco model. The fully parametric model was 
fitted to the entire data set o f each replicate. The results 
o f the interaction parameters a  are summarized in 
Table 2. Statistically significant synergistic interactions 
were found for S. prolificans and C. albicans strains 
indicated by the positive interaction parameters and 
lower limit o f their 95% CIs. Statistically significant 
antagonistic interactions were found for A. fumigatus,
C. krusei and C. glabrata strains since the interaction 
parameters a  and the upper limit o f their 95% CIs were
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negative. No additive interactions were found with the 
Greco model. As it is shown in Fig. 1, the model 
showed high reproducibility (98%) among the 
replicates since the results of all replicates were 
concordant with the exception of one replicate o f the 
AF1 strain, which resulted in a positive a  value by 
contrast with the other two replicates.
Regarding the goodness o f fit, narrow 95% CIs 
(<1log10) o f the fitted parameters were obtained and the 
R2 and the SumSq o f all fits ranged from 0.75 to 0.95 
(median 0.91) and from 0.3 to 7.4 (median 1.3), 
respectively. However, when the residuals of each fit 
were tested with the KS test statistically significant 
deviation from the normal distribution was found for all 
strains (P  < 0.05) except for the S. prolificans strains 
and two replicates o f the AF1 strain. The residual plots 
together with the three-dimensional graphs o f the 
response surface constructed by plotting the 
experimental data (experimental response surface) and 
data predicted with the Greco model (fitted response 
surface) revealed the areas where the model deviated 
from the data (Fig. 2).
For all fits with negative interaction parameters 
observed mainly with C. glabrata strains, the model 
deviated from the data at high concentrations of 
fluconazole and low concentrations o f 5-flucytosine 
(Fig. 2Ci and ii). For this area o f concentrations, the 
model yielded higher percentages of growth compared 
to the data at relatively lower concentrations o f 5- 
flucytosine while the opposite observed at relatively 
higher concentrations as it is shown in Fig. 2Ciii with 
the two groups o f residuals above and below the 0 
plane. For the fits with positive interaction parameters 
two patterns of deviation were found. In yeasts (i.e. C. 
albicans strains), the model deviated at intermediate 
concentrations o f fluconazole and low concentration of 
5-flucytosine (Fig. 2Bi and ii) where the fitted response 
surface was above and below, respectively o f the 
experimental data (Fig. 2Biii). In moulds (i.e. S. 
prolificans strains), despite the fact that the residuals 
did not deviate statistically significantly from the 
normal distribution, the Greco model deviated from the 
data at high concentrations o f the two drugs where the 
fitted response surface did not follow the same pattern 
o f curvature as the experimental response surface 
resulting in higher percentages o f growth (Fig. 2A).
Bliss independence based models. The results 
for all strains are summarized in Table 2 where the sum 
and the mean o f all statistically significant interactions 
(SSSI and MSSI, respectively) were used as summaries 
for each strain. S. prolificans strains showed the highest 
SSSI and the C. glabrata strains the lowest based on 
both the non-parametric and parametric approaches. 
The MSSI was statistically significant positive for the S. 
prolificans strains, but statistically significant negative 
for the C. glabrata strains. Between the two
approaches, the non-parametric approach resulted in 
stronger interactions for S. prolificans and C. glabrata 
strains, while the parametric approach did this for the 
remaining strains.
Although the absolute values o f the SSSI were 
different between the non-parametric and parametric 
approach, the nature o f the interaction determined with 
these two models was the same for most strains with the 
exception o f one C. krusei strain. As it is shown in 
Fig. 1, better discrimination between the different 
interaction groups (synergistic, independent, and 
antagonistic) was obtained with the parametric 
approach. When the MSSI was correlated with the 
SSSI, the former became statistically significant 
positive and negative when the SSSI was higher than 
100% and lower than -100% , respectively with the 
non-parametric approach. With the parametric 
approach, the same was found for the levels o f 150% 
and -150%  SSSI, respectively.
Regarding the goodness o f fit o f the Emax model 
for the parametric approach, the R2 ranged from 0.88 to 
1 (median 0.98) and the SumSq ranged from 0.01-0.06 
(median 0.27) for the concentration effect curves o f 5- 
flucytosine. For the concentration effect curves of 
fluconazole for all Candida strains except C. albicans, 
the R2 ranged from 0.85-1 (median 0.97) and the 
SumSq ranged from 0.01-0.35 (median 0.05). Low R2 
(0.47-0.98, median 0.64) and high SumSq (0.04-0.31, 
median 0.22) were found for C. albicans strains. For 
miconazole, terbinafine, amphotericin B and 
itraconazole the R2 and the SumSq ranged from 0.72-1 
(median 0.86) and 0.01-0.2 (median 0.05). Low R2 
(0.43-0.57) and high SumSq (0.17-0.32) were found for 
itraconazole against the AF2 strain. Run tests resulted 
in non-statistically significant deviation o f the Emax 
model for the concentration effect curves o f all drugs.
Although the SSSI and MSSI were used for each 
strain as summary parameters of the BI-based models, 
both models resulted in a mosaic of synergy and 
antagonism at different concentrations o f the two drugs. 
This mosaic is presented three dimensionally in Fig. 3. 
Synergistic combinations which are indicated with the 
volumes above the 0 plane coexist with antagonist 
combinations which are indicated with the volumes 
below the 0 plane for most o f the strains. The analytical 
results for each strain are shown in Fig. 4 where the 
sum and the mean of all statistically significant synergi­
stic (SSYN and MSYN) and antagonistic (SANT and 
MANT) interactions are presented separately. 
Based on the non-parametric approach, S. prolificans 
strains showed the largest SSYN (600-1800%) and the
C. glabrata strains showed the largest SANT (300­
800%) without showing both types o f interactions. The 
remaining strains showed both SSYN and SANT with 
the former being higher than the latter in most o f the 
cases as it is shown in Fig. 4A with the light gray bars
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Figure 2. Response surfaces of the experimental data (i) and the data predicted with the Greco model (ii) as well as the residual 
plots (iii). A. Combination of miconazole and terbinafine against a Scedosporium prolificans strain (SP3) for which the FICi-1 
and FICi-2 were 0.13 and 0.02 respectively. The interaction parameter a  ± 95% CI derived from the Greco model was 271 ± 120 
indicating very strong synergy. The normality test of the residuals resulted in non systematic deviation of the model (KS = 0.854, 
P  = 0.46). B. Combination of fluconazole and 5-flucytosine against a Candida albicans strain (CA2) for which the FICi-0, FICi-1 
and FICi-2 were 0.09, 0.09 and 1.03 respectively. The Greco model resulted in an interaction parameter of 37.08 ± 10 indicating 
synergy. The normality test of the residuals resulted in systematic deviation of the model (KS = 3.659, P  < 0.0001). C. 
Combination of fluconazole and 5-flucytosine against a Candida glabrata strain (CG2) for which the FICi-0, FICi-1 and FICi-2 
were 8.5 respectively. The interaction parameter a  ± 95% CI derived with the Greco model was -0.23 ± 0.10 indicating 
antagonism. The normality test of the residuals resulted in systematic deviation of the model (KS = 5.376, P  < 0.0001).
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Figure 3. Interaction surfaces obtained with the non-parametric (i) and the parametric (ii) approach of Bliss independence where 
the % of synergy (above the 0 plane) and antagonism (below the 0 plane) are shown. A. The combination of fluconazole and 
5-flucytosine against Candida albicans strain, (CA2), resulted in 347% SSSI and 18.3 ± 3.8% MSSI ± 95% CI with the non- 
parametric approach of BI and 871% SSSI and 20.2 ± 3.8% MSSI ± 95% CI with the parametric approach. B. The combination 
of itraconazole and amphotericin B against Aspergillus fumigatus strain, (AF1), resulted in 21% SSSI and 1.2 ± 11.6% MSSI 
with the non-parametric approach of BI and 82% SSSI and 4.3 ± 9.4% MSSI with the parametric approach. C. The combination 
of fluconazole and 5-flucytosine against Candida glabrata strain, (CG4), resulted in -740% SSSI and -27.4 ± 12.6% MSSI with 
the non-parametric approach of BI and 914% SSSI and 36.6 ± 12.6% MSSI with the parametric approach.
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Figure 4. Graphical representation of the analytical results of the non-parametric and parametric approach of 
Bliss independence (BI). The sum and the mean with the 95% CI of all statistically significant synergistic and 
antagonistic interactions are presented separately for each strain.
dark gray bars, respectively. Based on the non- 
parametric approach, S. prolificans strains showed the 
largest SSYN (600-1800%) and the C. glabrata strains 
showed the largest SANT (300-800%) without showing 
both types of interactions. The remaining strains 
showed both SSYN and SANT with the former being 
higher than the latter in most o f the cases as it is shown 
in Fig. 4A with the light gray bars dark gray bars, 
respectively. Using the MSYN and MANT, the same 
results were obtained, with the MSYN being 
statistically significant higher than the MANT for the S. 
prolificans strains and vice versa for the C. glabrata 
strains as it is shown in Fig. 4B.
Although the same conclusions were inferred 
with the parametric approach, the latter model resulted 
in some but weak SANT for S. prolificans strains (Fig. 
4C) and MSYN which was not statistically significant 
different from the MANT (Fig. 4D). However, the 
95% CI o f MSYN and MANT could not be calculated 
in some cases since only one combination showed the 
effect.
Com parison of the models. (i) Single drug 
param eters. The parameters o f the concentration effect 
curves o f the drugs acting alone that were used to 
determine the interactions with 1) the FIC index model, 
2) the Greco model and 3) the parametric BI-based 
model are summarized in Table 3 for each species and
drug. No specific parameters were estimated for the 
non-parametric BI model. Among the three MIC 
endpoints calculated with the FIC index model, 
statistically significant differences (P  < 0.01) were 
found between the MIC-2 and the other two MIC 
endpoints (ANOVA). These differences were observed 
mainly with the azoles and in particularly with 
fluconazole tested with the C. albicans strains where a 
8-fold difference between the median MIC-2 and MIC- 
1 was found. Overall, the IC50s estimated with the 
Greco model and parametric BI-based model were not 
statistically significant different from each other. The 
differences between the median IC50s of each drug- 
species combination were within 2 twofold dilutions 
with the exception o f the S. prolificans strains. For 
these strains the IC50s of terbinafine obtained with the 
Greco model were higher than those obtained with the 
parametric BI model. The IC50s estimated both with the 
Greco model and the parametric BI-based model were 
statistically significant different from MIC-0 and MIC- 
1 but not from MIC-2. The slopes estimated with the 
two latter parametric models were not statistically 
significant different.
(ii) Sum m ary interaction param eters. 
Statistically significant correlation was found among all 
summary interaction parameters (Table 4). All 
correlations between the FIC index model and the other
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Table 3. Single drug parameters. Median (range) among all strains and replicates of different parameters (MICs, IC50s in mg/l 
and slopes m) calculated with the FIC index model, the Greco model and the parametric Bliss independence (BI) model
Spp. Drug ■ FIC index model Greco model Parametric BI modelMIC-0 MIC-1 MIC-2 IC50 —m IC50 —m
CA FC 0.13 (0.06-0.25) 0.13 (0.06-0.13) 0.13 (0.06-0.13) 0.07 (0.06-0.08) 4.7 (2.7-7.2) 0.07 (0.05-0.07) 4.3 (1.6-7.1)
FZ 256 (16-256) 128 (16-256) 0.25 (0.0.06-1) 0.64 (0.06-0.36) 0.3 (0.2-0.4) 0.94 (0.19-2.96) 0.3 (0.2-0.5)
SP TB >64 >64 >64 33 (0.2-40)[x103] 0.09 (0.07-0.11) 51 (14-29 x 103) 0.3 (0.1-0.6)
MZ >64 >64 16 (8->64) 35 (15-222) 0.4 (0.3-0.5) 19 (11-33) 1 (0.5-1.5)
CK FC 16 (8-32) 16 (8-32) 4(2-16) 5.14 (3.23-15.21) 1.5 (1-3.7) 3.28 (1.44-11.2) 1.6 (0.9-5.0)
FZ 32 (16-64) 32 (16-64) 32 (16-64) 20.6 (13.8-52.1) 5.4 (4.3-34.7) 16.6 (10.7-38.7) 7.3 (2-19.6)
AF AB 1 (0.5-2) 0.5 (0.5-2) 0.5 (0.5-1) 0.40 (0.29-1.23) 4.3 (2-21.4) 0.39 (0.23-1) 5.6 (2.3-19.8)
IZ 32 (16->32) 32 (2->32) 8 (1->32) 1.87 (0.27-7.58) 0.7 (0.2-1.1) 5.41 (0.62-32.1) 0.5 (0.3-0.9)
CG FC 0.06 (0.03-0.25) 0.06 (0.03-0.25) 0.06 (0.03-0.25) 0.05 (0.03-0.15) 6.7 (1.9-296.6) 0.03 (0.01-0.13) 3.8 (1.7-8.2)
FZ 16 (16-64) 16 (8-64) 16 (4-64) 28.3 (17.5-128) 1.1 (0.7-2.1) 8.2 (2.1-54) 1.9 (0.7-8.1)
Overall 32 (0.031-256) 16 (0.031-256) 8 (0.03-128) 3.7 (0.03-40 x 103) 1.5 (0.07-296) 3 (0.013-102) 1.9 (0.13-19.8)
models were negative.
Among the summary parameters o f LA-based 
models, the strongest correlation was found between the 
interaction parameter a  and the FICi-1 (rs = -0.74) 
followed by FICi-2 (rs = -0.583). To determined 
whether the value o f the a  interaction parameters could 
predict the magnitude o f the FIC indices, combinations 
with negative and positive a  interaction parameters 
were analyzed separately. No statistically significant 
correlation was found for the a  negative interaction 
parameters and the corresponding FIC indices (the 
strongest correlation was with FICi-2, rs = -0.22). For 
the positive a  interaction parameters statistically 
significant correlation was found with the FICi-2 (rs = 
-0.63, P  = 0.009).
To explore further the relationship between a
interaction parameters and FIC indices, the a  
interaction parameters were plotted against the 
corresponding FIC indices from low to high a  values 
separately for interactions with negative (Fig. 5 A) and 
positive interaction parameters (Fig. 5B). Two patterns 
were detected. For negative interaction parameters, high 
a  values (close to 0) tended to correspond to high FIC 
indices (Fig. 5A). While for positive interaction 
parameters, small a  values (close to 0) tended to 
correspond to high FIC indices (close to 1) (Fig. 5B). 
Thus, although with the FIC index model the magnitude 
of synergy and antagonism is related with the degree of 
departure of the FIC indices from 1 (i.e. the larger the 
degree o f departure, the stronger interactions), with the 
Greco model this seems to hold only for positive 
interactions (i.e. the larger the degree o f departure o f a
Table 4. Correlationa between different summary parameters of parametric and non parametric approaches of
Loewe additivity and Bliss independence
Loewe additivty (LA) Bliss independence (BI)bCAreMeameaarpÎ.
rammmuS FIC index Greco Non-parametric Parametric
FICi-0 FICi-1 FICi-2 a SSSI MSSI SSSI MSSI
FIC index 
(LA)
FICi-0
FICi-1
1 0.943 
1
0.789
0.783
—0.544
—0.748
—0.879
—0.904
—0.777
—0.815
—0.916
—0.952
—0.903
—0.953
FICi-2 1 —0.583 —0.807 —0.726 —0.814 —0.799
Greco (LA) a 1 0.760 0.718 0.782 0.757
Non-para- SSSI 1 0.944 0.887 0.885
metric BI MSSI 1 0.801 0.816
Parametric SSSI 1 0.980
BI MSSI 1
a All correlations were significant at 0.01 level.
b For the correlation of the summary parameters obtained with LA- and those obtained with BI- based models the median 
parameter of the three replicates obtained with the LA-based models was used.
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Figure 5. Correlation between the FIC indices and the a  interaction parameters obtained with the Greco 
model. For interactions with negative interaction parameters (A) lower a  values corresponded to higher FIC 
indices while for interactions with positive interaction parameters (B) the opposite was observed.
interaction parameter from 0, the stronger the synergy) 
since for negative interaction parameters the opposite 
was observed (i.e. the larger the degree o f departure of 
a  interaction parameter from 0, the weaker the 
antagonism).
Given, that replicates are required to obtain a 
summary parameter for Bl-based models as opposed to 
LA-based models where each replicate resulted in a 
summary parameter, for the correlations between the 
BI- and LA- based models the median summary 
parameter of LA-based models among the replicates 
were used. Thus, between the summary parameters of 
BI-based models high correlation coefficients were 
obtained when the SSSI rather than the MSSI was used. 
Between the LA- and BI-based models, the interaction 
parameter a  o f the Greco model and the FICI-1 o f the 
FIC index model were highly correlated with SSSI of
both the parametric (rs = 0.782 and 0.953, respectively) 
and the non-parametric (rs = 0.760 and rs = 0.904, 
respectively). Statistically significant correlation was 
found between the BI-based models and the FIC index 
model even when combinations with positive and 
negative SSSI were analyzed separately.
(iii) Highly interactive drug concentrations. 
The concentrations o f drugs that showed the strongest 
synergistic or antagonistic interaction (Imax) determined 
with each model, are summarized in Table 5 for each 
species-drug pair. Although generally no statistically 
significant differences were found among the models, 
the Imax determined with the Greco model tended to be 
at high concentrations (median concentration 6 mg/l) 
closer to those determined with the FICi-1 (median Imax 
concentration 3 mg/l). The BI-based models showed the 
strongest interactions at lower concentration (median
Table 5. Median (range) drug concentrations in mg/l among all strains and replicates of the combination that showed 
the highest interactive effect as determined by each model
Spp. Drug
Loewe additivity Bliss independence
FICi-0 FICi-1 FICi-2 Greco Non-Parametric Parametric
CA FC 0.016 (0.008-0.031) 0.008 (0.004-0.016) 0.004 (0.004-0.004) 0.06 (0.03-0.06) 0.03 (0.02-0.03) 0.03 (0.03-0.03)
FZ 12 (1-32) 3 (1-4) 0.25 (0.25-0.25) 1.5 (0.25-4) 64 (8-64) 1 (1-2)
SP TB NDa 4 (4-8) 2 (2-4) 64 (64-64) 0.13 (0.03-0.25) 4 (4-8)
MZ ND 4 (4-8) 0.125 (0.016-2) 16 (4-32) 0.25 (0.13-0.25) 1 (0.25-4)
CK FC 0.004 (0.004-16) 0.004 (0.004-16) 0.004 (0.004-8) 8 (4-64) 0.25 (0.13-4) 0.008 (0.008-2)
FZ 32 (0.25-32) 32 (0.25-64) 16 (1-32) 32 (8-128) 2 (0.5-64) 1 (0.125-1)
AF AB 1 (0.25-2) 0.5 (0.016-1) 0.031 (0.016-0.125) 0.5 (0.5-1) 0.03 (0.03-0.125) 0.03 (0.03-0.03)
IZ 0.016 (0.016-2) 0.5 (0.016-8) 2 (0.125-8) 16 (0.06-16) 0.25 (0.125-1) 1 (0.125-4)
CG FC 0.031 (0.016-0.25) 0.031 (0.016-0.125) 0.031 (0.016-0.125) 0.03 (0.03-0.25) 0.02 (0.02-0.03) 0.02 (0.02-0.02)
FZ 256 (128-256) 128 (64-256) 128 (32-256) 64 (16-128) 16 (16-64) 16 (16-64)
Overall 0.63 (0.004-256) 3 (0.004-256) 0.25 (0.004-256) 6 (0.03-128) 0.75 (0.016-64) 1 (0.008-64)
a ND, not determined
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Table 6. Agreement in % (kappa value) between the four models using different endpoints for the definition of synergy 
(SYN), additivity/indifference (ADD), independence (IND) and antagonism (ANT)
Models and Interpretation endpoints Agreement in % (kappa value)
Greco model FIC index FICi-0 FICi-1 FICi-2
SYN; a±95%CI>0, ANT; a±95%CI<0 SYN<0.25, ANT>0.25 90% (0.66) 96% (0.91) 73% (0.38)
SYN; a±95%CI>0, ANT; a±95%CI<0 SYN<0.5, ANT>0.5 100% (1.00) 98% (0.96) 76% (0.50)
SYN; a±95%CI>0, ANT; a±95%CI<0 SYN<1, ANT>1 95% (0.87) 90% (0.78) 70% (0.40)
SYN; a±95%CI>0, ANT; a±95%CI<0 SYN<2, ANT>2 66% (0.36) 70% (0.45) 64% (0.36)
Non parametric BI FIC index FICi-0 FICi-1 FICi-2
SYN; SSSI>100% SYN; range FICi<1,
IND; 100%<SSSI<-100% ADD; range FICi incl. 1 93% (0.89) 82% (0.72) 69% (0.52)
ANT; SSSI<-100% ANT; range FICi>1
SYN; MSSI ± 95%CI>0 SYN; range FICi<1,
IND; MSSI ± 95%CI=0 ADD; range FICi incl. 1 85% (0.78) 76% (0.63) 56% (0.33)
ANT; MSSI ± 95%CI<0 ANT; range FICi>1
Parametric BI FIC index FICi-0 FICi-1 FICi-2
SYN; SSSI>150% SYN; range FICis<1, 76%
(0.0.64)IND; 150%<SSSI<-150% 
ANT; SSSI<-150%
ADD; range FICis incl. 1 
ANT; range FICi>1
93% (0.89) 94% (0.91)
SYN; MSSI ± 95%CI>0 SYN; range FICis<1,
IND; MSSI ± 95%CI=0 ADD; range FICis incl. 1 86% (0.91) 88% (0.81) 68% (0.52)
ANT ; MSSI ± 95%CI<0 ANT; range FICi>1
Greco model Non parametric BI
SYN; a  ± 95%CI>0 SYN; ESSI>100% 94% (0.88)
ANT; a  ± 95%CI<0 ANT; SSSI <100%
SYN; a  ± 95%CI>0 SYN; MSSI ± 95%CI>0 83% (0.62)
ANT; a  ± 95%CI<0 ANT; MSSI ± 95%CI<0
Greco model Parametric BI
SYN; a  ± 95%CI>0 SYN; SSSI >150% 94% (0.88)ANT; a  ± 95%CI<0 ANT; SSSI <150%
SYN; a  ± 95%CI>0 SYN;MSSI ± 95%CI>0 94% (0.88)
ANT; a  ± 95%CI<0 ANT; MSSI ± 95%CI<0
Parametric BI Non parametric BI
SYN; XSSI>150% SYN; XSSI>100%
IND; 150%<SSSI<-150% IND; 100%<SSSI<-100% 94% (0.91)
ANT ; SSSI<-150% ANT; SSSI<-100%
SYN; MSSI ± 95%CI>0 SYN; MSSI ± 95%CI>0
IND; MSSI ± 95%CI=0 IND; MSSI ± 95%CI=0 77% (0.64)
ANT; MSSI ± 95%CI<0 ANT; MSSI ± 95%CI<0
Imax concentrations 0.75 and 1 mg/l for the non- 
parametric and the parametric approach, respectively) 
closer to those determined with the FICi-0 (median Imax 
concentration 0.63 mg/l).
(iv) Agreem ent between the models. The levels 
o f agreement between the models based on the 
interpretation o f the results are summarized in Table 6 
together with the results o f the kappa test. Given that no 
additive interactions were found with the Greco model, 
for the comparisons with this model a unique cutoff was 
used for the determination o f synergy and antagonism. 
Furthermore, for the comparisons between the BI- and
LA-based models, the interpretation of median 
interaction parameter among the replicates was used for 
the Greco model while for the FIC index model synergy 
or antagonism was defined when all replicates resulted 
in FIC indices lower or higher than the chosen cutoff, 
respectively. In any other case additivity/indifference 
was concluded.
Between the Greco model and the FIC index 
model, the highest level o f agreement was found when 
the cutoff o f 0.5 was used for the interpretation of the 
results o f FICi-0 (100%) followed by FICi-1 (98%). 
Between the FIC index and the non-parametric BI­
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based model high levels o f agreement were found when 
the FICi-0 and the levels o f 100% and -100%  SSSI 
were used for the interpretation o f the results, 
respectively.
Between the FIC index and the parametric BI­
based model high levels o f agreement were found when 
the cutoff o f 1 for FICi-1 or FICi-0 and the level of 
150% and -150%  SSSI were used for the interpretation 
o f the results, respectively. The same results were found 
when the Greco model was compared with the BI 
models. Between the BI-based models higher levels of 
agreement were found with the SSSI (94%) using the 
above mentioned endpoints than with the MSSI (77%).
Discussion
Different drug interaction models were used in 
this study in order to analyze the in vitro interaction of 
different antifungal drugs against various fungal species 
using the microdilution checkerboard technique. 
Interactions that varied in nature and degree, as 
assessed with the standard model in the field of medical 
microbiology, the FIC index model, were included and 
head-to-head comparisons with three other models were 
made.
The first and major problem in determination of 
the FIC index is the choice o f the MIC endpoints for the 
two drugs alone and in combination (45). Although 
complete inhibition o f growth is the endpoint often used 
with antibiotics this is not possible in the case o f S. 
prolificans strains tested against terbinafine and 
miconazole since complete inhibition o f growth 
(MIC-0) is not observed at any concentration o f the 
drug alone or in combination. The interaction however 
was synergistic based on 75% (MIC-1) and 50% (MIC- 
2) inhibition o f growth. Even when the MIC-0 was 
defined as in cases o f C. albicans strains with 5- 
flucytosine and fluconazole, and A. fumigatus strains 
with amphotericin B and itraconazole, different FIC 
indices were obtained when the MIC-2 was used 
reversing the interpretation of the results from 
synergistic and additive/indifferent to additive and 
synergistic, respectively. These discrepancies were due 
to trailing phenomena observed with C. albicans strains 
when the drugs were tested alone. Trailing was reduced 
when the two drugs were combined (see Tables 2 and 
5) confirming previous study (16). MIC-0 was more 
sensitive to trailing than the other MIC endpoints. In the 
case o f A. fumigatus strains, the fungicidal action of 
amphotericin B at high concentrations of amphotericin 
B may cover the fungistatic action of itraconazole and 
vice versa at sub-MIC concentrations o f amphotericin B 
and high concentrations o f itraconazole. MIC-2 
endpoint was more sensitive to this effect than the other 
MICs. However, the discrepancies between FICi-0, -1
and -2 were mainly due to off-scale MICs of 
itraconazole alone and in combination when the MIC-0 
and MIC-1 were used, resulting in approximated FIC 
indices. The same phenomena were observed with S. 
prolificans strains where all MICs o f terbinafine and 
miconazole alone were higher than the highest 
concentration tested and with a C. glabrata strain where 
the MICs-2 o f fluconazole and 5-flucytosine in 
combination were lower than the lowest concentrations 
tested.
Another drawback o f the FIC index model is the 
summary parameter for each data set and the 
interpretation o f this parameter. According to the 
guidelines, among all SFIC indices calculated for each 
iso-effective combination, the SFICmin is reported as the 
FICi unless SFICmax exceeds 4. Synergy is claimed 
when the FICi is lower than 0.5 and antagonism when 
FICi is higher than 4. These cutoffs were chosen in this 
study in order to diminish the effect o f the 
intraexperimental error (± 1 dilution) o f antifungal 
susceptibility testing since a two-fold dilution scheme 
was followed (38, 39). The drawback o f this approach 
is that the SFIC of a single well attempts to describe the 
whole checkerboard without taking into account the 
interactions occurring at other concentrations and levels 
o f effect and without including its uncertainty. 
Furthermore, outliers can affect the results, particularly 
when checkerboards were abnormal and therefore 
subjective exclusion or inclusion of iso-effective wells 
was necessary.
In order to constrain the inter-experimental error, 
replicates were performed resulting in FIC indices in 
most o f the cases within 3 log2 (i.e. 0.25-1 or 1-4). For 
the interpretation o f the results, different endpoints 
were used in literature. Based on reproducibility o f the 
results, high reproducibility was found with FICi-1 
(100%) as well as the FICi-0 (94%) when the cutoffs of 
0.25 and 4 were used for the upper and the lower limit 
o f synergy and antagonism, respectively in order to 
interpret each replicate individually. These cutoffs are 2 
log2 below and above the additivity level 1 and can be 
obtained after taking into account 1 doubling dilution 
error (often observed with the NCCLS methodology) 
for both drugs, alone or in combination, at any direction 
o f the checkerboard. Although, different cutoffs can be 
found the literature (22, 30, 46, 48) the cutoffs 
recommended from the guidelines (18) and commonly 
used for the upper and lower limit o f synergy and 
additivity/indifference are the 0.5 and 4, respectively. 
These cutoffs although arbitrary are more stringent for 
defining antagonism than synergy since the cutoff of 
synergy (i.e. 0.5) is 1 log2 while the cutoff of 
antagonism (i.e. 4) is 2 log2 different than 1 (additivity). 
Therefore, from this point o f view is better to use the 
cutoffs 0.25 and 4 for the upper and the lower limit of
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synergy and antagonism, respectively as it is also illu­
strated in previous studies (3, 31).
However, by using stringent and arbitrary criteria 
to describe in vitro interactions, the problems of the 
inherent errors in laboratory tests might be pushed out 
o f sight but they are not disappeared. Furthermore, 
given that most o f the FIC indices are lying between 
0.5-1 (1, 2, 32, 46), large amount o f information about 
the drug interactions can be lost which might be in vivo 
important (4). There are several approaches to 
overcome these problems without losing important 
information such as smaller dilution steps, overlapping 
dilution series, continuous dilutions, more accurate 
techniques or replication (3, 4, 16). When replicates 
were analyzed, high reproducibility was found in the 
present study when synergy and antagonism was 
concluded if all replicates resulted in FIC indices lower 
or higher than 1, respectively and additivity or 
indifference when at least one replicate resulted in a 
FICi o f 1. In addition, the departure o f the FIC index 
from 1 can be evaluated statistically by checking if  the 
95% confidence interval overlapped 1 in which case no 
statistically significant interaction should be concluded.
In order to overcome the above mentioned 
drawbacks o f the FIC index model, another model 
based on Loewe additivity zero-interaction theory was 
used in this study; the fully parametric model described 
by Greco et al. (15). This model was initially developed 
to describe anticancer drug interactions and thenceforth 
found many applications to different data sets (9, 33,
41, 45). This model tries to describe the effect at each 
combination o f the two drugs including an interaction 
parameter, constant for the entire response surface, 
which indicates the departure from the additive surface. 
Thus, when this parameter is positive the experimental 
surface is below the additive one indicating synergy 
while when the parameter is negative the former is 
above the latter, indicating antagonism. This model 
enables us to check if  the model fits adequately to the 
data as well as if  the interaction is statistically 
significant. The model is based on the assumption that 
the concentration effect curves of each drug alone 
follow the Emax model (sigmoid curve) and that true 
concentration dependent interactions are rare. Since the 
Emax model describes adequately the concentration 
effect curves o f all antifungal drugs tested in this study, 
which has also been shown by previous studies (26), the 
appropriateness o f the Greco model to assess the 
interaction o f antifungal drugs was further explored.
The model fitted well to the data derived from all 
drug-combination-strain pairs based on the R2 and sum 
o f the squares. However, when the residuals were 
analyzed statistically and graphically, the model 
deviated systematically from the data. This deviation 
was statistically significant in all fits with negative 
interaction parameters (antagonistic interactions) and
was located at drug concentrations at which the 
experimental response surface was above the additive 
(antagonistic combinations). For this area, the Greco 
model did not follow the curvature o f the experimental 
response surface and it resulted in growth although 
experimentally no growth was observed. For the fits 
with positive interaction parameters (synergistic 
interactions), statistically significant deviation was 
found for the C. albicans strains. This deviation was 
due to the trailing phenomena observed with 
fluconazole, which also resulted in bad fit o f the Emax 
model when the latter was fitted to the concentration 
effect curves o f fluconazole for the C. albicans strains. 
In order to diminish the effect o f trailing, the 
concentration-effect curves for trailers could be 
normalized by setting as 0% the growth observed in 
concentrations at which the trailing is apparent. For the 
S. prolificans strains tested with miconazole and 
terbinafine, although a statistically significant deviation 
of the model was not found, residual plots and three­
dimensional graphs revealed the area where the model 
did not describe the experimental surface precisely. 
This area was located at relatively high concentrations 
where the largest bowing o f the response surface was 
observed (Fig. 2Ai). For this area the Greco model 
resulted in a more flat response surface (Fig. 2Aii).
The Greco model assumes that the concentration 
effect curves o f each drug at any level o f the other drug 
follow the Emax model with variable parameters (IC50 
and slopes) as is clearer shown in Fig. 2Cii. However, 
in the case of antagonistic interactions where the 
response surface concaves up and bell shaped 
concentration effect curves are apparent (see the 
concentration effect curve o f 5-flucytosine in the 
presence o f 128 mg/l o f fluconazole in Fig. 2Ci) the 
Emax model does not seem to hold true. These bell 
shaped curves are also observed, although less clear, in 
synergistic interactions as is shown in Fig. 2Ai where 
the response surface concaves down (concentration 
effect curve o f terbinafine in presence o f 8 mg/l of 
miconazole). This deviation o f the model is more 
pronounced with strong interactions and declines as the 
interaction parameter approaches 0. This deviation is 
not reported in previous studies where the Greco model 
was used because low (close to 0) interaction 
parameters were found in these studies and data about 
the goodness o f fit except the 95% CI are not presented 
in most o f them (9, 33, 41, 45).
Based on the results derived with the Greco 
model, no additivity was found which might indicate 
the sensitivity o f the model to detect even weak 
interactions. The results were very reproducible since 
all replicates except one were concordant. Although 
positive interaction parameters covered a broad range of 
values, from 1-10000, the negative interaction 
parameters were bounded in a narrow range from -0.04
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to -0.51 indicating possibly the inability o f the model to 
differentiate different degrees of antagonistic 
interactions as was also discussed above in relation to 
the difficulty o f the Greco model to describe the 
response surfaces.
One o f the assumptions o f the Greco model is 
that antagonistic combinations cannot coexist with 
synergistic ones in the same data set and if  such a case 
is found it is due to artifacts or experimental errors (43). 
However, Berenbaum summarized many types of 
interactions where both antagonism and synergy are 
present at different concentrations (6). These types of 
interactions cannot be described with the Greco model. 
Concentration dependent interactions was found for 
Candida albicans tested with the combination of 
fluconazole with fluphenazine where antagonism was 
observed at low concentrations of fluconazole and 
synergy at higher concentrations (17). These results 
were also supported by molecular studies on the 
mechanism of action. Similar phenomena were 
observed when itraconazole was combined with 
fluphenazine against itraconazole resistant Aspergillus 
fumigatus strains (J. Afeltra, personal communication). 
Since biphasic types o f interactions might really exist, 
two other models were used to analyze the interaction 
o f antifungal drugs, which can accommodate mosaics 
o f interactions.
These models are based on Bliss independence 
zero-interaction theory without any assumption about 
the shape o f the concentration effect curves o f the drugs 
(non-parametric approach) or with the assumption that 
the latter’s followed the Emax model (parametric 
approach). With these models, the type o f interaction 
was assessed for each combination o f the tested drug 
concentrations. Both models resulted in a mix of 
statistically significant synergistic and antagonistic 
combinations for most o f the data sets with the relative 
proportion ranged from purely synergistic for the S. 
prolificans strains to purely antagonistic for C. glabrata 
strains. The levels o f synergy or antagonism determined 
with the non-parametric and the parametric model were 
comparable in most o f the cases except for S. 
prolificans strains and for C. albicans and A. fumigatus 
strains where more antagonistic and synergistic 
interactions, respectively were found with the 
parametric approach. For the S. prolificans strains the 
antagonistic interactions were found at high 
concentrations o f the drugs where precipitation was 
obvious resulting in overgrowth in those wells. This 
affected the parametric approach since with this 
approach experimental errors are selectively eliminated 
with the fitting process only in the single drug 
containing wells and not in all directions o f the 
checkerboard. For C. albicans and A. fumigatus strains, 
the bad fit o f the Emax model to the concentration effect 
curves o f fluconazole and itraconazole, due to trailing
effects and in vitro resistance, respectively resulted in 
higher % of growth for each concentration o f the drugs 
present alone. Consequently the independent response 
surface determined with the parametric approach was 
shifted at higher levels compared to that o f the non- 
parametric approach resulting therefore in higher levels 
of synergy.
Although the few antagonistic combinations 
found in particular with the parametric approach for the 
S. prolificans strains, could be explained with 
precipitation at high concentrations o f the drugs, the 
presence o f both types o f interactions at different 
concentrations could raise points for discussion about 
the mechanistic explanation o f these observations. For 
instance, when itraconazole was combined with 
amphotericin B against Aspergillus fumigatus, 
antagonistic interactions were found at concentrations 
around the MIC of amphotericin B (2-0.5 mg/l) and 
synergistic ones at sub-MIC concentrations of 
amphotericin B (<0.5 mg/l) (Fig. 3Bi). Whether the 
antagonistic effects are related to the lack o f ergosterol 
due to sterol biosynthesis inhibition by itraconazole and 
the synergistic ones to the increased uptake of 
itraconazole inside the fungus due to damages o f cell 
membrane caused by low concentrations of 
amphotericin B, suggested by previous studies (20, 23), 
need to be confirmed with molecular studies. Then, it 
would also be possible to evaluate mechanistically the 
validity o f each o f the zero-interaction theories used in 
the present study to assess the interaction o f antifungal 
drugs. However, the same biphasic effect was observed 
also with the FIC index model, which resulted in lower 
FIC indices (synergy) based on the MIC-2 (which 
actually is observed at lower concentrations of 
itraconazole) and higher FIC indices 
(additive/indifference) based on the MIC-0 (which 
actually is observed at higher concentrations of 
itraconazole).
In order to summarize the results obtained with 
the Bl-based model for further comparisons and with 
any reserve about their legalization from the 
mechanistic point of view two approaches were 
followed. For each data set the sum and the mean 
together with its 95% CI o f all statistically significant 
interactions were calculated. The approach developed 
by Prichard et al. (36) where the volumes (% of 
interaction x the concentrations o f the two drugs) above 
and below the 0 plane were calculated, was not 
followed since the final results are unequally influenced 
by small in degree interactions occurred at high 
concentrations. Thus, based on the sum and the mean of 
statistically significant interactions, the latter was 
positive without its 95% CI overlapping 0, when the 
sum was higher than 100% and negative when the sum 
was lower than -100%  for the non-parametric approach 
while the same hold true for the parametric approach
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Figure 6. Graphical representation of the relationship between the interaction parameter a  and the FIC-2 index 
(assuming that FICA = FICB) defined by two models. The model 1 is the Greco model used in the present study 
which defined the following equation for the FICi-2-a relationship: FICi-2 = 1 -  a  x FICA x FICB. The model 2 
is an alternative model for the Greco model described first by Finney et al. (11) and defines the following 
equation for the FICi-2-a relationship: FICi-2 = 1 -  a  (FICA x FICB)1/2 Note the non-monotonic behavior of the 
Greco model by contrast with model 2. For negative interaction parameters, the model 1 has an asymptote at 0 
while the model 2 at -2.
based on 150% sum of statistically significant 
interactions. This suggests that these cutoffs may serve 
as cutoffs for statistically significant synergy and 
antagonism, respectively. Between the two approaches 
o f BI, higher reproducibility among the replicates was 
found with the non-parametric approach since the range 
o f the sum of statistically significant interactions was 
within 150% for most o f the strains.
Despite the pro and the con o f each model, the 
most important point is the nature o f an interaction 
determined with each model and discrepancy between 
them. Therefore a head to head comparison was 
performed including primary parameters (MICs, IC50s, 
slopes m) used for the calculation o f the summary 
interaction parameters (FICI, a , SSSI, and MSSI) of 
each model based on which the combinations were 
classified to different interaction groups (synergy, zero­
interaction, or antagonism). Non statistically significant 
differences among the MICs-2 determined with the FIC 
index model and the IC50s determined with the Greco 
and the parametric BI model (within 2 doubling 
dilutions) as well as between the slopes o f the 
concentration effect curves determined by the two latter 
models were found. This indicates that the Emax model 
could be used to determine the in vitro susceptibility of 
fungi and that fully parametric approaches do not affect 
the concentration effect curves o f the single drugs.
When the summary parameters o f each model 
were correlated, statistically significant correlation was
found for all models. A strong correlation was found 
between the FICi-1, the interaction parameter a , the 
SSSI o f both BI-based models and the MSSI o f the 
parametric BI-based model. For the FIC index and the 
Greco model, no statistically significant correlation was 
found between the FIC indices and the a  values, when 
the interactions with negative interaction parameters 
were analyzed separately. This might indicate the 
qualitative nature o f the Greco model for combinations 
with negative interaction parameters as discussed 
above. However, since the FIC index model is itself an 
approximation o f the intensity o f the interactions such 
an assumption needs further exploration. Negative 
correlation was found between the FIC index model and 
the other models since high FIC indices corresponded 
with low values o f the other summary parameters. 
However, this monotonic relationship was not found for 
the a  interaction parameters obtained with the Greco 
model since a biphasic correlation was found as 
depicted in Fig. 5.
This innate property o f the model is shown in 
Fig. 6 where hypothetical FIC indices calculated at the 
level o f 50% of Emax (i.e. FICi-2) were plotted against 
the interaction parameter a  according to the following 
equation FICi-2 = 1 -  a  x FICA x FICB. The latter 
equation is derived after rearrangement o f the Greco 
model given that the sum o f the first two terms on the 
right part o f the Greco equation is the FICi-2 and the 
term [E/(Emax-E )]05 (mA + mB) at 50% of effect equals 1
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independent o f the value of the slopes m. In the same 
graph the FICi-2-a relationship as defined by an 
alternative model introduced first by Finney et al. (11) 
is also plotted. This model was suggested by Greco et 
al. (14) in order to overcome the rise up at high 
concentrations observed with the first model. This raise 
up is more pronounced at a  values lower than -0.5 and 
therefore they were not observed in the present study 
since most o f the a  values were higher. This second 
model differs from the Greco model only in the third 
part o f the Greco equation in that this part squared. 
Although this model shows a monotonic relationship 
with the FIC index, as is show in Fig. 6, preliminary 
studies showed that it shares the same drawbacks, 
although to lesser extent, as the first model inferring the 
same conclusions. In the Fig. 6 is also depicted why 
narrow range o f negative a  interaction parameters 
found in this study since there is a minimum at -1  and a 
maximum at 0 for the a  values and why the degree of 
antagonism is reversibly related with the magnitude of 
the a  values as discussed above for the experimental 
data since increase of the FIC index is associated with 
increase o f the interaction parameter a  (closer to 0) for 
negative values as opposed for the positive interaction 
parameters.
The comparison o f the models based on the 
interpretations o f the results showed high levels of 
agreement between the Greco and the FIC index model 
when the cutoff o f 0.5 was used to interpret the FICi-0 
and the FICi-1. Although one might expect the cutoff of
1 to show the highest agreement, the cutoff of 0.5 is 
within the experimental error o f antifungal 
susceptibility methodology used in this study. This 
error affects more the results o f the FIC index model. 
From the same point o f view, the highest levels of 
agreement between the BI-based models and the FIC 
index model were found when the cutoffs o f 0.5 and 4 
were used to determine the upper limit o f synergy and 
additivity/indifference respectively when only the 
median FIC index among the three replicates rather 
than the FIC indices o f all replicates was used for the 
comparisons (data not presented). However, when all 
three replicates used to determine synergy (all FIC 
indices lower than 1) antagonism (FIC indices greater 
than 1) and additivity/indifference (in any other case), 
satisfactory levels o f agreement were found (45). For 
the BI models the corresponding levels of synergy and 
antagonism were 100% and -100%  SSSI for the non- 
parametric approach and 150% and -150%  SSSI for the 
parametric approach, respectively as discussed above. 
The latter resulted in higher levels o f agreement with 
the other models using both the SSSI and MSSI for the 
interpretation o f the results.
The drug concentrations, which showed the high­
est interactive effect (Imax), were not statistically 
significant different among the four models. The Imax
drug concentrations determined with Greco model were 
the highest and they were similar to those determined 
using the FICi-1 o f the FIC index model. The Imax drug 
concentrations determined with the BI models were 
relatively lower and similar to those determined using 
the FICi-0 o f the FIC index model. These conclusions 
confirm previous observations (14, 15) where the 
largest synergy was found at concentrations near but 
not exactly at the IC50s o f the two drugs and that the 
isobols are more bowed (stronger synergy) at 90% of 
pharmacological effect i.e. 10% of growth.
In conclusions, for the assessment o f the 
interaction o f antifungal drugs the FIC index model is 
easy and does not require sophisticated approaches. The 
FIC index based on MIC-2 (50% of growth) should be 
used in order to overcome problems coming from 
trailing effects and fungistatic-fungicidal combinations. 
However, interactions assessed based on other MIC 
endpoints might also be important to describe the 
concentration-dependent nature o f a drug combination. 
The cutoffs o f 0.25 and 4 for single experiments and 1 
when replicates are performed for the upper and lower 
limits o f synergy and antagonism respectively should be 
used for the interpretation o f the results. However, the 
drawbacks o f this model such as the monodimensional 
nature, lack o f good summary including statistical 
significance levels and the sensitivity to experimental 
errors remain.
For the BI models, the level o f 100% (for non- 
parametric approach) and 150% (for parametric 
approach) sum o f statistically significant interactions 
with any mechanistic reserve could be used to 
differentiate synergistic from antagonistic interactions. 
Particular care should be given in parametric 
approaches for the choice o f the model (especially with 
resistant and trailing strains) and because fitting process 
eliminates errors selectively in single drug 
concentrations and not in entire response surfaces. With 
the BI models, the multifactorial nature o f drug 
interactions is emphasized and statistically significance 
levels are included. However, replicates are required, 
the results are depended on the range o f concentrations 
tested, variation within the replicates can affect the 
levels and the nature o f statistically significant 
interactions and comparisons between different data 
sets are difficult.
The Greco model describes the interactions with 
a single concentration-independent non-unit interaction 
parameter, does not require replicates, includes 
statistically significant levels and it is reproducible and 
less sensitive to experimental errors. However, it does 
not describe precisely the response surface of antifungal 
combinations and therefore the interaction parameters 
may be approximations. Quantitative results might be 
difficult to obtain particularly for antagonistic 
interactions, and a non-monotonic relationship with the
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FIC index model exists. As it is pointed by Greco et al. 
the latter model is a model to assess drug interactions 
and therefore efforts to develop a model, which would 
describe precisely the response surface, should be 
continued.
Finally, the models could be evaluated from the 
biological point of the interactions if the mechanism of 
actions were fully understood, although this might be 
complicated in growth assays where population factors 
and in vitro parameters could affect the interaction (6). 
Therefore, drug interaction modeling should be focused 
on concentration effect response surface approaches. A 
comprehensive drug interaction model, which would 
describe the entire response surface and assess the 
interaction with a single parameter, is an attractive 
approach. However, even if  the concentration effect 
relationship of single drugs are well characterized and 
parameterized, the development o f such a model 
applicable to different interactions and tested against 
different microorganisms in various in vitro conditions 
is questionable. Therefore, different models might be 
required to assess the various combinations and 
possible interactions and to predict the clinical outcome 
o f combination therapy.
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GENERAL CONCLUSIONS
4.1 Sum m ary
Combination therapy might be an alternative 
chemotherapeutic approach for management of 
infections caused by filamentous fungi given the limited 
in vivo efficacy o f antifungal monotherapy. Among the 
benefits o f combination therapy are the enhancement of 
efficacy o f antifungal therapy, reduction o f appearance 
o f resistant strains and broadening o f the spectrum of 
antifungal activities. Drug levels that are required to 
produce an antifungal effect can be reduced to 
achievable serum levels and therefore side effects of 
highly toxic drugs might be diminished. In addition 
pharmacokinetic profiles o f antifungal drugs can be 
improved when pharmacokinetic interactions take 
place. Fungicidal activities might be produced and 
faster and better curative effects can be obtained. Since 
evaluation o f the efficacy o f combination therapy in 
clinical circumstances is not easy, in vitro testing of 
combination o f antifungal drugs could give information 
about the nature and the intensity o f drug interactions 
(1, 9). However, assessing drug interactions depends 
both on in vitro drug susceptibility testing as well as on 
the interaction model used for the analysis. Therefore, 
in this thesis two parameters of in vitro antifungal 
susceptibility testing o f filamentous fungi, the medium 
and the quantification o f fungal growth, were 
investigated (C hapter 2) and different drug interaction 
models were used for analyzing the in vitro 
combination o f various antifungal drugs (C hapter 3).
In C hapter 2.1, a microbroth kinetic system was 
developed in order to analyze the growth curves of 
three species of filamentous fungi (Rhizopus 
microsporus, Aspergillus fumigatus, and Scedosporium 
prolificans) in five different nutrient media. In general, 
five distinct phases could be distinguished in the growth 
o f  filamentous fungi, namely, the lag-phase, the first 
transition period, the log-phase, the second transition 
period, and the stationary-phase. The different growth 
phases o f filamentous fungi were barely distinguishable 
in RPMI 1640 in which the poorest growth was 
observed for all fungi even when the medium was 
supplemented with 2% glucose. R. microsporus and A. 
fumigatus grew better in Sabouraud and yeast nitrogen 
base medium than in RPMI 1640 with growth rates 3 to 
4 times higher. None o f  the media provided optimal 
growth o f  S. prolificans. The germination o f  conidia 
and spores as well as the elongation rates o f  hyphae 
were enhanced in antibiotic medium 3 and delayed in 
yeast nitrogen base medium.
In C hapter 2.2, a colorimetric method based on 
the reduction o f the tetrazolium salt dye 3-(4,5-Di- 
methyl -2 -Thiazyl) -2,5 -Diphenyl-2H-T etrazolium Bro - 
mide (MTT) was evaluated for the MIC determination 
o f  six different antifungal drugs (miconazole, 
voriconazole, itraconazole, UR9825, terbinafine, and
amphotericin B) against six different species o f  
filamentous fungi (A. fu.migatu.s, A. flavus, S. 
apiospermum, S. prolificans, Fusarium solani, and F. 
oxysporum). Furthermore, a new simplified assay that 
incorporates the dye MTT with the initial inoculum and 
in which the fungi are incubated with the dye for 48 h 
or more was developed. High levels o f agreement were 
found between the MTT and the NCCLS method for all 
drugs and species tested. Among the three genera tested 
and the two MIC endpoints used, the highest levels o f  
agreement were found with Aspergillus spp. (97%) and 
with the MIC-0 endpoint (97%). However, the 
percentage o f  hyphal growth as determined visually by 
the NCCLS method showed several discrepancies when 
they were compared with the percentages o f  MTT 
reduction. The new assay was easier to perform and 
more sensitive than the earlier MTT method showing 
comparable levels o f  agreement and reproducibility 
with the other two methods.
In C hapter 2.3, another colorimetric assay 
based on the new tetrazolium salt 2,3-bis{2-methoxy 
-4-nitro-5-[(sulphenylamino) carbonyl]-2H-tetrazolium- 
hydroxide} (XTT) was developed and optimized for 
testing the susceptibility o f various Aspergillus spp. to 
amphotericin B and itraconazole. This salt is converted 
by viable fungi to a water-soluble formazan in the 
presence o f  an electron-coupling agent. The 
combination o f 200 mg/ml o f XTT with 25 mM of 
menadione resulted in high production o f formazan 
within 2 h o f  exposure allowing the detection o f  hyphae 
generated by low inocula o f  102 CFU/ml after 24 h o f  
incubation. Under these settings the formazan 
production correlated linearly with the fungal biomass 
and less variable concentration effect curves for 
amphotericin B and itraconazole were obtained.
In C hapter 2.4, spectrophotometric reading 
was compared with the visual reading o f  the NCCLS 
method for antifungal susceptibility testing o f  25 
Aspergillus strains belonging to different species. 
Furthermore, results obtained with the XTT method 
were compared with those obtained with the NCCLS 
method. The intra- (between the observers) and inter- 
(between the experiments) experimental agreement o f  
the NCCLS and the XTT method exceeded 95% for 
MIC-0 for amphotericin B and MIC-0, and 1 for 
itraconazole. Between visual and spectrophotometric 
readings, high levels o f  agreement were found for 
amphotericin B (»97%) and MIC-1 (»92%) and MIC-2 
(»88%) for itraconazole. Poor agreement was found for 
MIC-0 o f itraconazole (51% after 24 h) since the 
spectrophotometric readings resulted in higher MICs-0 
than the visual. The agreement increased to 98% by 
shifting the threshold level o f  MIC-0 from 5% to 10% 
relative OD and by establishing an optical density 
larger than 0.1 for the growth control as validation 
criterion. No statistical significant differences were
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found between the NCCLS method and the XTT 
method with the levels o f agreement exceeding 97% for 
MIC-0 o f amphotericin B and 83% for MIC-0, 1 and 2 
o f itraconazole.
In C hapter 3.1, the in vitro combination of 
itraconazole and terbinafine was tested against 20 
clinical S. prolificans isolates using the modified MTT 
method described in Chapter 2. The results were 
analyzed based on the FIC index model and showed 
synergy for 18 out 20 strains. Although both drugs had 
poor activity alone, when they were used in 
combination up to 8-fold reduction o f the MICs o f the 
single drugs was observed and the antifungal activity 
occurred at concentrations achievable during treatment.
In C hapter 3.2, in order to generalize the results 
o f the previous study and to exclude methodological 
and analysis bias, the in vitro combination of 
terbinafine with three azoles, namely itraconazole, 
voriconazole and miconazole was tested against five 
clinical S. prolificans isolates using the 
spectrophotometric method described in Chapter 2.4, 
the colorimetric MTT and the modified method 
described in Chapter 2.2. In addition, the results were 
analyzed with parametric and non-parametric 
approaches of the Loewe additivity and Bliss 
independence zero interaction theories. Synergy was 
found in all cases with different intensity. Among the 
three azoles, based on Loewe additivity theory 
miconazole showed the strongest synergy while based 
on Bliss independence theory voriconazole did so. Less 
variable results were obtained with the modified MTT 
method. The fully parametric model described by Greco 
et al. (7) applied well to the data resulting in 
reproducible and easily interpretable results.
In C hapter 3.3, the appropriateness as well as 
the advantages and disadvantages o f each o f the four 
models used in the previous study were extensively 
explored by modeling the interaction o f various 
antifungal drugs against different fungal species. For 
this purpose combinations o f different interactions, 
spanning from strong synergy to strong antagonism, 
were chosen. Despite its simplicity, results o f the FIC 
index model depended on the choice o f MIC endpoints 
and interpretation endpoints. Furthermore it lacked of 
good summary. Although the model described by 
Prichard et al. (10) resulted in a concentration 
dependent mosaic of interactions, replicates were 
required for statistical evaluation o f the results, good 
summary was absent and the results were dependent on 
the concentration range used. The fully parametric 
model described by Greco et al., although it did not 
describe precisely the response surface o f antifungal 
combinations, was able to distinguish synergistic and 
antagonistic interactions and summarized the 
interaction with a non-unit concentration independent
interaction parameter including statistically significance 
levels without requiring replicates.
4.2 Sam env atting  (Sum m ary  in  Du tc h )
Combinatie therapie is een mogelijk alternatief 
voor de behandeling van infecties veroorzaakt door 
filamenteuze schimmels met het oog op de beperkte 
effectiviteit van monotherapie. De voordelen van 
combinatie therapie zijn onder andere versterking van 
de effectiviteit, vermindering van selectie van resistente 
stammen, en verbreding van het spectrum van 
antifungale activiteit. Hoge plasma spiegels die nodig 
zijn om een antischimmel effect te bewerkstelligen 
kunnen bij combinatie therapie verlaagd worden 
waardoor de bijwerkingen van deze vaak toxische 
middelen verminderd wordt. Daarnaast kunnen de 
farmacokinetische profielen verbeterd worden door de 
interacties die plaatsvinden. Fungicide activiteit kan 
door combinatie bewerkstelligd worden en daarmee tot 
snellere en betere curatieve effecten aanleiding geven. 
Aangezien de evaluatie van de effectiviteit van 
combinatie therapie bij patienten niet eenvoudig is, kan 
in vitro testen van combinaties van antifungale 
middelen informatie geven over de aard en intensiteit 
van de geneesmiddel interactie (1, 9). Echter, het 
bepalen van de geneesmiddel interactie is afhankelijk 
van zowel de methode van in vitro 
gevoeligheidsbepaling als het interactie model dat 
gebruikt wordt voor analyse. Derhalve werden in dit 
proefschrift twee parameters onderzocht die betrekking 
hebben op de methode van in vitro 
gevoeligheidsbepaling, namelijk het medium en de 
kwantificering van schimmel groei (hoofdstuk 2) en 
werden verschillende modellen vergeleken die de 
interactie van verschillende antifungale geneesmiddel 
combinaties beschrijven (hoofdstuk 3).
In hoofdstuk 2.1 werd een microdilutie kinetisch 
systeem beschreven waarmee de groeikarakteristieken 
van filamenteuze schimmels (Rhizopus microsporus, 
Aspergillus fumigatus en Scedosporium prolificans) en 
v ijf  verschillende media werden onderzocht. In het 
algemeen konden in de groei van deze filamenteuze 
schimmels v ijf  fases onderscheiden worden, namelijk 
de lag-fase, de eerste transitie periode, de log-fase, de 
tweede transitie periode en een stationaire fase. De 
verschillende groeifases van filamenteuze schimmels 
waren nauwelijks te onderscheiden in RPMI 1640 
waarin de groei van alle schimmels het minst was, zelfs 
als 2% glucose aan het medium was toegevoegd. R. 
microsporus en A. fumigatus groeiden 3 tot 4 maal beter 
in Sabouraud en yeast nitrogen base medium dan in 
RPMI 1640. Geen van de media ondersteunde de groei 
van S. prolificans optimaal. De ontkieming van conidia
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en sporen alsmede de elongatie snelheden van hyfen 
waren versterkt in antibiotic medium 3 en vertraagd in 
yeast nitrogen base medium.
In hoofdstuk 2.2 werd een colorimetrische 
methode, gebaseerd op de reductie van een tetrazolium 
zout kleurstof 3-(4,5-Dimethyl-2-Thiazyl)-2,5 
Diphenyl-2H-Tetrazolium bromide (MTT), geëva­
lueerd voor de bepaling van de minimaal remmende 
concentratie (MIC) van zes verschillende antifungale 
middelen (miconazol, voriconazol, itraconazol, 
UR9825, terbinafine en amfotericine B) tegen zes 
verschillende soorten filamenteuze schimmels (A. 
fumigatus, A. flavus, S. apiospermum, S. prolificans, 
Fusarium solani en F. oxysporum). Tevens werd een 
nieuwe gesimplificeerde methode geëvalueerd waarbij 
de kleurstof MTT aan het initiële inoculum werd 
toegevoegd en met de schimmels gedurende 48 uur 
geïncubeerd. Een hoge mate van overeenstemming in 
MIC tussen MTT en NCCLS methoden werd gevonden 
voor alle middelen en geteste soorten. Onder de drie 
geteste genera en twee MIC eindpunten, werd de 
hoogste mate van overeenstemming gevonden voor 
Aspergillus spp. (97%) met een MIC-0 eindpunt (97%). 
Echter, het percentage groei dat, conform de NCCLS 
richtlijn, visueel bepaald werd vertoonde discrepanties 
vergeleken bij de percentages van MTT reductie. Deze 
nieuwe methode was eenvoudiger om uit te voeren en 
gevoeliger dan de eerdere MTT methode, waarbij de 
mate van overeenstemming en reproduceerbaarheid 
vergelijkbaar was met de andere MTT methoden.
In hoofdstuk 2.3 werd een andere 
colorimetrische methode, gebaseerd op een nieuw 
tetrazolium zout 2,3-bis{2-methoxy-4-nitro-5-[(sulphe- 
nylamino) carbonyl]-H-tetrazoliumhydroxide} (XTT), 
beschreven en geoptimaliseerd voor de gevoelig- 
heidsbepaling van Aspergillus spp. voor amfotericine B 
en itraconazol. Dit zout wordt, in aanwezigheid van een 
electronbindende stof, door levende schimmels omgezet 
in het wateroplosbare formazan. De combinatie van 200 
mg/ml XTT met 25 mM menadion resulteerde in de 
hoogste productie van formazan bij een incubatie 
periode van 2 uur. Hiermee was het mogelijk hyfen, 
ontstaan uit een inoculum van 102 CFU/ml, te 
detecteren na 24 uur incubatie. Bij deze condities was 
er een lineair verband tussen schimmel biomassa en 
formazan productie en was de variabiliteit bij de 
concentratie-effect curven voor amfotericine B en 
itraconazol minimaal.
In hoofdstuk 2.4 werden spectrofotometrisch en 
visueel aflezen van de NCCLS methode met elkaar 
vergeleken voor gevoeligheidsbepalingen van 25 
Aspergillus stammen van verschillende species. Tevens 
werd de XTT methode vergeleken met de NCCLS 
methode. De intra (tussen waarnemers) en inter (tussen 
experimenten) experimentele overeenstemming van de 
NCCLS en XTT methode waren groter dan 95% voor
MIC-0 voor amfotericine B en MIC-0 en MIC-1 voor 
itraconazol. Tussen visueel en spectrofotometrisch 
aflezen werd een hoge mate van overeenstemming 
gevonden voor amfotericine B (»97%) en MIC-1 
(»97%) en MIC-2 (»88%) voor itraconazol. Matige 
overeenstemming werd gevonden voor MIC-0 voor 
itraconazol (51% na 24 uur) omdat de 
spectrofotometrische bepalingen hogere MIC-0s gaven 
dan de visuele. De overeenstemming nam toe tot 98% 
door de afleesgrens te verschuiven van 5% naar 10% 
relatieve OD en als validatie criterium een optische 
dichtheid van groter dan 0.1 te gebruiken. Er werden 
geen statistisch significante verschillen gevonden tussen 
de NCCLS methode en de XTT methode met een hoge 
mate van overeenstemming voor MIC-0 voor 
amfotericine B (97%) en voor MIC-0, -1, -2 voor 
itraconazol (83%).
In hoofdstuk 3.1 werd in vitro de activiteit van 
de combinatie van itraconazol en terbinafine getest 
tegen 20 klinische S. prolificans isolaten met de 
gemodificeerde MTT methode zoals beschreven in 
hoofdstuk 2. De resultaten werden geanalyseerd met 
behulp van de FIC index en synergie werd gevonden 
voor 18 van de 20 isolaten. Hoewel de activiteit van 
beide middelen apart gering was, leidde de combinatie 
tot een 8-voudige reductie van de MICs van de 
middelen afzonderlijk en waren de middelen actief bij 
een concentratie die binnen de therapeutische breedte 
ligt.
In hoofdstuk 3.2 werd, om de resultaten van de 
vorige studie te kunnen generaliseren en om bias 
gerelateerd aan methoden en analyse in vitro de 
combinatie van terbinafine met drie azolen te weten 
itraconazol, voriconazol en miconazol getest tegen vijf
S. prolificans stammen gebruik makend van de 
(gemodificeerde) colorimetrische methoden zoals 
beschreven in hoofdstuk 2.4. Tevens werden de 
resultaten geanalyseerd met parametrische en non­
parametrische benaderingen van Loewe additiviteit en 
Bliss onafhankelijke nul interactie theorieën. Van de 
drie azolen gaf de Loewe additiviteit aan dat miconazol 
de sterkste synergistische interactie liet zien terwijl de 
Bliss benadering suggereerde dat dit het geval was voor 
voriconazol. De minste variabiliteit werd bereikt met de 
gemodificeerde MTT methode. Het volledig 
parametrisch model, zoals beschreven door Greco (7), 
was goed toepasbaar op de experimentele gegevens en 
resulteerde in reproduceerbare en eenvoudig te 
interpreteren resultaten.
In hoofdstuk 3.3, werd de geschiktheid alsmede 
de voor- en nadelen van elk van de vier modellen die 
beschreven zijn in het vorige hoofdstuk in groter detail 
onderzocht door de interacties van verschillende 
antifungale middelen tegen verschillen schimmels te 
modelleren. Hiertoe werden combinaties van 
verschillende interacties geselecteerd variërend van
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sterk synergistisch tot sterk antagonistisch. Ondanks 
zijn eenvoud, waren de resultaten van het FIC index 
model sterk afhankelijk van de keuze van de MIC 
eindpunten en de interpretatie criteria. Verder konden 
de resultaten niet goed samengevat worden. Alhoewel 
het model van Prichard (10) leidt tot een concentratie 
afhankelijk mozaïek van interacties en meerdere 
herhalingen van experimenten nodig waren om deze 
statistisch te evalueren, konden de resultaten niet 
voldoende samengevat worden en waren de resultaten 
afhankelijk van de gekozen reeks van concentraties. Het 
volledig parametrisch model van Greco kon niet met 
precisie de oppervlakte respons van de antifungale 
combinatie beschrijven, maar met dit model konden 
synergistische en antagonistische interacties onder­
scheiden worden en kon de interactie samengevat 
worden in een non-unit concentratie onafhankelijk 
interactie parameter die zonder replica’s toegankelijk 
was voor statistische berekeningen.
4.3 IÏEPIAH'FH (SUMMARY IN GREEK)
H auvSvaafiévri Ospcrasia sivai cvck%ó|.icvo va 
aTtoxsXsi KaA.fi svaWtaKxiKfj xil|.icio0spU7üsuriKf| aycoyfj 
yia tt|v  KaTa7ioAi}j.r|or| Aoijxcó^scov tcou TtpoKaXoévxai 
UTio vi]|.iurosiösi<; puKtixcc ócóopcvtic xi]Q 
Trcpiopiopcvtic in vivo am m ;«;o ua r i k ó t  r| xac xtic 
avxijj.i)KrjxiaKf|<; jj.ovo0spa7tsia<;. Avajxsoa oxa ocpcA.ii 
Ti]q oi)v8i)aojj.svr|<; 0spa7tsia<; ouyKaxaXsyovxai r| 
svioxuorj xi]Q öpaotic xcov avxijj.i)Kr|xiaKö}v cpapjxdKOOv, r| 
(leiooorj xr|<; e|icpavior|<; avOeKxiKÓv oxeAexoóv Kat r| 
Sieépvvorj xoi) cpaofiaxo<; nic avxifit)KT|xiaKf|<; öpaotic. 
Oi ouyKsvxpóosu; xcov avxijj.uKr|xiaK©v cpapjxaKcov Ttou 
aTiaixoévxai yia va sivai ÖpuoxiKu fucopsi va pcioBoóv 
os smTtsSa Tiou sivai scpiKxa oxo aijia Kaï sxoi va 
Ttspiopioxoév oi Tiapsvépysisg loxupa xo^ikóv 
cpapjxdKcov. EthjiXsov, cpapjj.aKOKivr|xiKd xapaKxrjpioxi- 
Ka avxi|iuKtixiaKüJV cpapjxdKcov jxTtopsi va psAxicoOoév 
os 7ispi7ixcoor| Tiou Xapouv %épa cpapp.aKOKivr|xiKs<; 
aXAriAsTtiSpdosn;. Eivai svSsxójxsvo va TtpoKÓxpouv 
jj.i)kt|xokxóvs<; 8paosi<; Kaï va smxsuxOow ouvxojxóxspa 
Kaï KaXéxspa 0spa7tsi)xiKa aTioxsXsojxaxa. EjcsiSfj ópoq 
r| a7ioxijj.r|or| xr|<; a7ioxsXsojj.axiKÓxr|xa<; xr|<; ouvSuaojxs- 
vric XT|M-Sio0spa7isia<; os kaivikcc ouv0f|Ks<; 8sv sivai 
ewkoXtj, in vitro Tieipdfiaxa ouvSuaofióv avxifii)Kr|xi- 
atóóv cpapfiaKoov 0a fiTiopoéoav va Sóoouv TiXripocpo- 
pie<5 yia xo ei5o<; K a ï xr|v évxaor| xoov aAAr|AemSpdoecov 
fiexa^é xoov cpapfiaKoov (1, 9). Ooxóoo, r| a7ioxifir|or| 
xoov (papfiaKevxiKÓv aAAr|AemSpdoecov e^apxaxai xóoo 
a7tó xu; in vitro SoKifiéi; euato0r|oia<; óoo Kaï cwtó xo 
fiovxéXo aXXr|Xe7ii8paor|i; tiou xpiloi(.io7roisixai yia xr|v 
avaAuoi] xoov aTioxeXeofiaxcov. Fi’ amovc, xoix; X&fovq, 
oxr|v Tiapoéoa 8iaxpipf| epei)vr|0r|Kav Séo Tiapdfiexpoi 
in vitro SoKifióv ei)ato0r|oia<; vr|fiaxoeiSóv (ii)Kf|xoov, xo 
0pe7ixiKÓ vXiKÓ K a ï r| 7ioooxiKOTioir|or| xr|i; (ii)KT|xiaKf|i;
ava7ixi)§r|i; (ïcecpaXaio 2). EmjrXéov, xpT|oifiO7iotf|0r|Kav 
StacpopexiKa fiovxéXa cpapfiaKeimtóóv aXXr|Aem8pd- 
oeoov yia va avakoQovv in vitro ovvSvaofioi 8ia(pópoov 
avxi(ii)icr|xiaKÓv cpapfiaKoov (ïcecpaXaio 3).
Exo Ki:<p«/.aio 2.1, ava7crux0r|Ke éva niKpïic 
K i^jxaKcu; kivt|xikó oéoxrifia oe vypó vXikó yia va 
avaXi)0oév oi KafiTróXec; aiKiiotic xpuov eiSóv 
vr|(iaxoei8óv fii)Kf|xoov (Rhizopus microsporus, 
Aspergillus fumigatus, Kaï Scedosporium prolificans) 
oe Tiévxe StacpopexiKa OpeTixiKd vAira. TeviKa, 
(iTiópeoav va SiaivpiOoiVv jiévxe §excoptoxé<; cpaoeu; raxa 
xr|v aiKiioi] xoov (ii)Kf|xoov, r| AavOavouoa cpaorj, r| 
Tipóxri (iexaßaxiKf| 7tepio8o<;, r| Xoyapi0fitKf| cpaorj, r| 
8eéxepr| fiexaßaxtKf| 7tepio8o<; Kaï r| cpaor| 
oxaoijAÓxrjxai;. Oi StacpopexiKa; cpaoeu; ao^r|or|<; T®v 
vr|(iaxoei8óv p.i)Kf|xoov f|xav eXaxioxa SiaKpixéi; oxo 
0pe7ixiKÓ vXiKÓ RPMI 1640, oxo otioìo 7iapaxr|pf|0r|Ke r| 
cpxooxóxepri aiKiioi] yia óXoix; xoix; |.u)Kiixe.c aKÓ(ir| Kaï 
óxav Tipooxé0r|Ke oi)p.7iXf|poo(ia yXwKÓ^ rn; 2%. O R. 
microsporus Km o A. fumigatus avajrróxOilKav oxa 
OpsjixiKa DAiKÓ Sabouraud Kai Yeast Nitrogen Base 
KaÀmspa an ’óxi oxo RPMI 1640 jxs pi)0jj.oé<; aóctiotic 
3 sco<; 4 cpopsg i)\)/r|}ióxspoi)<;. Kavsva anó xa 0ps7txiKa 
i)XiKa 8sv i)7iooxf|pi£;s iKavoTtoirjxiKfj aé£;r|or| xoi) S. 
prolificans. H sKpMoxrjorj xcov koviSìcov Kaï xcov 
OTtopicov Ka0©<; Kai r| sTtijxiiKuvorj xcov ucpóv 
smxaxóv0r|Ks oxo 0ps7txiKÓ u/viKÓ antibiotic medium 3 
Kai smßpa8uv0r|Ks oxo Yeast Nitrogen Base.
Zxo Ki;cp('//v(/io 2.2, a^ioXoyf|0r|KS pia 
Xpco}xaxo}j.sxpiKii jj.s0o8o<; ßaoiojj.svr| oxrjv avaycoyfj 
svó<; akaioq xod xsxpa^oXioi), r| xP®ÖTlK1i 3-(4,5- 
8i(j£0i)X -2^^^^^^^,5 8i(psvó^2H- xsxpa^óXio ßpojxi- 
8io (MTT) yia xov TipooSiopiojxó xr|c; sMxioxrji; ava- 
oxaXxiKfji; 7ti)KvóxT|xa<; (MIC) s£;i 8iacpopsxiK®v avxi-
(ii)Kr|xiaK©v cpapjxaKcov (piKovaCoXti. ßopiKova^oXrj, 
ixpaKova^óXri, UR9825, xspjj.Tnvacpivr| Kaï ajxcpo- 
xepiKivrj B) svavxia os s£;i SiacpopsxiKa siSrj vrjjj.a- 
xosiSrnv jj.i)Kf|xcov (Aspergillus fumigtus, A. flavus, 
Scedosporium prolificans, S. apiospermum, Fusarium 
solani Kaï F. oxysporum). EmjiXéov, avajrróxOilKE 
Kaïvovpyia (/.ji/.ojioumcvii (iéGoSot; Kaxà xrjv ojioia ï] 
XpcooxiKii MTT Evocofiaxcövsxai oxo (/.p/iKo 
cvocp0a/4uo(.ia Kaï oi (.ivkiitcc sjicoa^ovxai (.ic xrjv 
XpcooxiKii yia 48 f] Kaï JiEpiooóxepsi; wpEt;. Y\|/t(M 
smTisSa oi)jjxpcovia<; ßps0T(Kav jxsxa^é xt(<; MTT Kaï xt(<; 
NCCLS (ie0ó8oi) yia óAa xa cpapjiaKa Kaï ei8r| fii)Kf|xcov 
Tiov eXéyx0r|Kav. Avajieoa oxa xpia yévr| tiov 
(ieXexf|0r|Kav Kaï xoix; 8éo xiüteoix; SeiKxóv MIC tiov 
Xpil o I |.i otto if] Oi] Kav. xa i)\]/r|Xóxepa eTiiTieSa owjACpcoviai; 
ßpe0r|Kav (ie xa ei8r| xoi) Aspergillus (97%) Kaï xov 
MIC-0 Seìkxt) (97%). Ooxóoo, xa Jiooooxa avà7rn>§r|<; 
xcov vcpwv óiuoq JipooStopioxriKav ojixikó (.ic xrjv 
NCCLS (ié0o8o fjxav apKexég cpopég oe aoupcpcovia 
óxav ouyivpiOriKav (ie xa Tiooooxa fiexaxpoTrrn; xr|i; 
XpoooxiKf|i; MTT. H Kaïvoépyia ja80o8o<; f|xav 
si)KoXóxspr| Kaï tiio si)aio0r|xr| aTio xr|v 7iaXaióxspr|
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fiéOoSo MTT Seixyovxai; Tiapópma emjteöa ov|Kp©via<; 
Kaï emvaAr|\j/ifióxr|xai; fie xu; aXkeq Svo fieOóSovi;.
I t o  Kj:<pa/.aio 2.3, avajrxóx0i]KT. ma u/jü] 
XP©(iaxofiexpiKf| jxé0o8o<; paoiofiévr| oe éva véo akaq 
tod xexpatJóXiov, to  2,3-Siq (2-^0ó§u-4-w po-5- 
[(oovkpsvuXajnvo) Kapji7tovvX]-2H-x£xpa^óXio vSpo- 
^siSio (XTT), Kaï P£Xxioxojroif|0T|K£ yia SoKifiét; svai- 
a0r|aia<; Siacpopcov siSwv Aspergillus arriv aficpoxspiKi- 
VII B Kaï iipaKovauó/ui. Avxó to  akaq fisxpaxpéjisxai 
anó i^évteq pw ajux oe (ita TtSaioSia/ami cpop|iaCdvT|
-
oi)v8uao|.ióc 200 fig/ml XTT fie 25 fiM fievaSióvr|i; eije  
mq aTioxéXeofia tt|v  7iapay©yr| cpopjxa^dvrn; fieoa oe 2 
©peg éK0eor|i; emxpéTiovxai; tt|v  avixyevor| v(p©v tiov 
TipoéKuyav aTio ap%iKÓ evo(p0aXfnofia 102 Kovi8i©v/m1 
fiexa aTio 24 ©peg emoaorn;. Kót© ütió avxég xu; 
oi)v0iiKe.c. r| 7iapay©yr| cpopjxa^dvrn; ovoxexi^óxav 
evOvypafifia fie tt|v  fivKr|xiaKr| piofidtja Kaï aTioKxr|- 
0r|Kav Xiyóxepo jierapXr|xé<; KajxjcóXei; ovyKévtp©or|<;- 
au^r|or|<;.
Zxo K£(paXaio 2.4, ovyKpi0r|Kav r| (paofiaxo- 
(p©xojiexpiKf| Kaï r| 07itikt| avayv©or| tt|i; NCCLS 
fieOóSov oe SoKipéc evaio0r|oiai; 25 oxeAex®v 
Aspergillus tiov avf|Kav oe StacpopexiKa eiSr| oe 
avTi(ivKT|TiaKa (papfiaKa. EmjtXeov, xa aTioxeXéofiaxa 
tiov a7ioKTT|0r|Kav fie xr|v XTT fiéOoSo ovyKpi0r|Kav fie 
avxa xr|i; NCCLS fieOóSov. H evSo7ieipa(iaxiKr| (fiexa^v 
x©v 7iapaTT|pr|T©v) Kaï Sia7ieipafiaxiKr| (fiexa^v x©v 
7ieipafiax©v) ovfi(p©via xr|i; NCCLS Kaï xr|i; XTT
-
- -
-
|.ie.Tpuciic avayv©or|<;, v\j/t|M, emTieSa ov|Kp©via<; 
ppé0r|Kav yia tt|v  afi(poxepiKivr| B (»91%) Kaï fie xovg 
SeiKxei; MIC-1(»92%) Kaï MIC-2 (»88%) yia -rr|v 
iTpaKova^óXr). Xajir|Xd emTieSa oujicp©via<; ppé0r|Kav 
fie xov MIC-0 SeiKxr| yta xr|v txpaKovatJóXr| (»51% fiexa
-
(pao(iaxo(p©xo(iexptKf|i; avayv©or|<; fjxav v\j/r|Aóxepoi 
aTio xovg avxioxoixovg xr|i; otitikth; avayv©or|<;. H 
ovfi(p©via av§f|0r|Ke oe 98% fiexaxom^ovxai; to ópio
-
7cvKvóxr|xa<; Kaï KaOiepóvovxai; fita otitikti 7rvKvóxr|xa 
fieyaAmepri tod 0.1 yia xr|v av§r|or| tod fiapxvpa 
(aé§T|or| fivicr|xa owiovoia avxifivicr|xiaKov) ©<; Kpm'ipio 
a^tomoxiai;. Mr| oxaxioxira aii|iavTua:c 8tacpopé<; 
ppé0r|Kav fiexa^v x©v fie0óS©v NCCLS Kaï XTT fie 
emjteSa ovjKp©via<; tiov ^eTiepvovoav to 97% yia tov 
MIC-0 SeiK-rri xr|i; afi(poxepiKivr|i; B kou 83% yta xovg 
SeiKxei; MIC-0, -1 Kat -2 xr|i; txpaKova^óXr|<;.
E to  K£(paXaio 3.1, o in vitro oimSoaoiióc rqc 
iTpaKova^óXrn; (ie tt|v  Tep(imva(pivr| 8oKi(iaoTT|Ke oe 20 
K^iviKa oteXexn S. prolificans %pr|oi(i07i0i©VTai; rr|v 
xp07i07i0ir|jiévr| fiéOoSo MTT tiov 7iepiypa(pr|Ke oto 
Ke(paXaio 2.2. Ta aTiOTeXéofiata avató0r|Kav (ie paor| 
to  fiovtéAo tov KXaofiaxiKoé SeiKtri avaotaXtiKÓv
ouyKevtp©oe©v (8eiKTT|<; FIC) Kaï ppé0r|Ke ovvépyeia 
oe 18 a7tó t a  20 oteXéxil- Av Kaï ra  Séo avTi(ivKT|TiaKa 
(papfiaKa eixav fiiKpi| 8paor| fióva tovi;, ótav 
Xpr|oi(iO7ioif|0r|Kav oe ovvSvaojió, 7iapaTT|pf|0r|Ke (ié%pi 
Kaï OKTOTiXaoia (iei©or| t©v Sbiktóv MIC tiov 
emTijyxavav t a  (papjiaKa fióva tovi; Kaï avTi(ivKT|TiaKr| 
Spaori e|X(pavioTT|Ke oe oDyKevtpóoeu; jiov f|Tav 
OepaTievTiKa etpiKtéi;.
Eto K£(paXaio 3.2, yta va yeviKevOoév ta  
aTioteXeofiam tt|<; 7ipor|yoT3|xevr|<; (leXérrn; Kaï va 
aTioKXeiotei tvxóv avaXvtiKÓ Kaï fieOoSoXoyiKÓ 
ovoTT|(iaTiKÓ ocpaXfia, 8oKi(iaoTT|Ke o in vitro 
ouvSuao|ió<; tt|<; Tep|xmva(pivr|<; (ie tpelg a^óXsq, rr|v 
iTpaKova^óXri, rr|v popiKova^óXr| Kaï rr|v p.iKova^óXr|, 
oe 5 K^iviKa oteXéxil S. prolificans xpiloifiOTioióvrni; 
tt|v  (pao(iaTO(p©TO(ieTpiKf| fiéOoSo tiov 7iepiypa(pr|Ke 
o to  KecpaXaio 2.4, rr|v xpc)|-iaTO|.ieTpudi péOoSo MTT 
Kaï tt|v  Tp07i07i0iT|(iévr| fiéOoSo MTT tiov Tiepiypa- 
(pr|Kav o to  KecpaXaio 2.2. EthtiMov, t a  a7toreXéojxaTa 
avaA,é0r|Kav (ie 7tapajxerpiKé(; Kaï (ir| TiapajietpiKéi; 
7tpooeyyioeu; t©v 0e©pi©v «ttji; TipooOetiKrn; Kata 
Loewe» Kaï «ttji; ave^apTrjoiai; Kata Bliss» yta rr|v 
aTiovoia <pap|.iaKe.i)TUviic aXXr|Xem8paor|i;. Zvvépyeta 
Ppé0r|Ke oe óXeq tu; Tiepmtóoeu; Sia(popeTiKr|i; ója©<; 
svTaoscoq. Msm^v t©v tpuóv a^oXóv, (ie pdot| rr| 
0e©pia tt|i; TipooOetiKrn; Kata Loewe, r| |.uKovaCóAii 
Tiapovoiaoe tt|v  lo^Dpóiepii ovvépyeia ev© (ie Paor| rr| 
0e©pia tt|i; ave^aprrjoiai; Kata Bliss, r| popiKova^óXr| 
Tiapovoiaoe tt|v  lo^Dpóiepii ovvépyeia. Me rr|v 
Tp07i0Ti0ir|(iévr| fiéOoSo MTT a7ioKTT|0r|Kav aTiote- 
XéojAata fie piKpóiepec SiaKVfiavoeu;. To 7iXf|p©i; 
TiapajietpiKÓ fiovtéXo tiov 7iepiypa(prr|Ké aTio tov Greco 
Kaï tovi; ovvspyaxsi; xov (7) éSsi^s iKavo7ioir|TiKr| 
scpapjioyfj oxa 8s8ojiéva 8ivovxa<; STiavaXruj/ijia Kaï 
svKoXa spjirjvsvoijia aTioxsXéojiaxa.
Ixo  Ks;<p«/v«io 3.3, s^sxdoxrjKav Sis^oSiKa r| 
Kaxa/v/vii>vóxiixa Ka0©<; Kaï xa 7iXsovsKxf|jiaxa Kaï 
jisiovsKxiijiaxa x©v xsooap©v jiovxéX©v tiov xptfijio- 
7ioif|0r|Kav oxrjv Tiporiyovjisvrj jisXéxrj, TipoxvTio- 
Tioi©vxa<; xrjv aXXriXsTriSpaorj 8ia(póp©v avxijivKrjxi- 
aK©v (papjiaK©v svavxia os öiaxpopsxiKa si8r| jivKf|x©v. 
Fi’ avxó xo Xóyo eTitléx0r|Kav ovvSvaojioi p.e Sta- 
(popexiKéi; aXXr|Xem8paoeii; c.Kxc.ivóiir.ve.c aTio ioxupf| 
ovvépyeia fiéxpi loxupó avxay©viop.ó. Flapa xr|v 
a7iXóxr|xa xov, xa aTioxeXéofiaxa xov fiovxéXov xov 
8elKXT| FIC e^apxióxav anó xr|v e7itloyf| x©v SeiKxóv 
MIC Kaï x©v opi©v tiov xPTl0 i|-l07I0lli()llKav Tia TITV 
epfir|veia x©v a7ioxeXeop.ax©v. EmTipóoOexa, xo 
fiovxéAo xov 8elKXT| FIC oxepeixo KaXf|<; ovvo\j/r|<; x©v 
a7ioxeXeo(iax©v. Atio xr|v aXXr| TiXevpa, av Kaï xo 
fiovxéAo tiov 7iepiypa(pT|Ke aTio xov Prichard Kaï xovg 
ovvepyaxei; xov (10) eije ayq aTioxéXeojia éva fi©oaïKÓ 
aXXrjXsmSpdosmv avakoya jis xrjv ovyKsvxp©or| xov 
(pappaivou. aTiaixovvxav s7iavaXr|7ixiKd Tisipajiaxa yta 
oxaxioxiKa acio/voyi'ioiua anoxsAiojiaxa, sXsras KaXrj 
ovvo\)/T| x©v a7ioxsXsojiax©v Kaï xa aTioxsXsojiaxa
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Figure 1. Factors that may contribute to clinical resistance.
e£,apxiovxav ano xi]v Ttepioxfj xow cuyKevxpoiceow Ttou 
Xpi]oi(j.o7ioii]0i]K8. To 7tA,f|pox; TiapafxexpiKo fiovxeAo 
nov avamvxQi]Ks ano xov Greco Kai xoug ow epyaxeg 
xou, av Kai 8ev 7repieypa\[/e eTtaKpipo'ig xi]v eTtupaveia 
a7toKpiGi]<; xow avxifiuKiixiaKow GuvSuacfiGW, fjxav 
iKavo va Siaxoipioei auvepyaxiKeg Kai avxayowicxiKeg 
aXX.i]}i87ii8pdo8ii; Kai va cuvo\[/icei xig aXA,i]A£7ii8pdoeii; 
(ie (iia Tiapafiexpo a)Jti])te7ii8paGi]<;, xcopig fiovaSa, 
ave£,apxi]xi] xow auyKsvxpoiGeow GUfiTtepiXafipdvovxag 
oxaxioxiKa oi](iavxiKa eTtuteSa xcopig va aTtaixowxai 
87iavaX.i]7ixiKa Tteipafiaxa.
4.4 F uture  P erspec tiv es
The need for standardized and clinically 
relevant antifungal susceptibility testing (AST) of 
filamentous fungi became obvious as a result o f an 
increase in the incidence rates o f opportunistic fungal 
infections and in the number o f available antifungal 
drugs. Ideally, the ultimate role of susceptibility testing 
is to correlate the in vitro results with the in vivo 
activity thereby predicting the outcome of therapy with 
an antifungal agent in a reproducible way (5). However, 
clinical outcome may be affected by various factors 
related to the host, drug, and fungus and interactions 
between them (Fig. 1) (14). Therapeutic failure might 
be the result o f clinical resistance, which is associated 
with a variety o f factors shown in Fig. 1 and/or of 
microbiological resistance (intrinsic or acquired during 
therapy), which is associated with the fungal pathogen 
and described by the minimal inhibitory concentration 
(MIC) determined with the in vitro susceptibility testing 
methodologies (3).
Since MICs are not physical or chemical 
measurements, the results o f in vitro drug susceptibility 
testing are a function o f the condition o f methodology 
used. Although some parameters have little effect on 
the results o f AST, their effect may increase when all 
these parameters are combined simultaneously (4, 11). 
Furthermore, given the significant morphological and 
physiological variation o f filamentous fungi, species- 
specific adjustments of AST might be required in order 
to obtain reliable results. This is illustrated by the poor 
and differential growth of different mould genera in 
RPMI 1640 medium. However, to optimize AST for 
moulds, truly microbiologically resistant strains are 
required. Although, resistance could be explored using 
clinical data or data obtained from animal models, an 
objective view o f microbiological resistance could be 
obtained based on molecular studies where resistance 
would be associated with particular mechanisms at this 
level.
In addition, MICs are parameters that describe a 
static situation where the concentration o f drug remains 
constant over time. In vivo the concentration o f drugs 
fluctuates over time in a different way depending on the 
site of infection (2). The fungus is exposed to different 
concentrations at each time point. This changes the 
antifungal activity o f the drugs. Therefore, 
pharmacokinetic data should be taken into account for 
assessing the in vivo antifungal activity (12). This can 
be done with in vitro pharmacodynamic models where 
the human pharmacokinetics are simulated or in animal 
models, where host factors are also accounted, by 
establishing pharmacodynamic indices associated with 
the MICs (e.g. time that the drug concentration exceeds 
the MIC, the ratio of the maximal drug concentration to
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the MIC, the ratio o f the area under the curve to the 
MIC) (8).
In such systems, precise quantification o f even 
small amounts o f fungal growth is required in order to 
describe the concentration dependent effect accurately. 
The colorimetric methods described in this thesis 
provide sensitive, reproducible, easy to perform, and 
rapid assays for precise quantification o f filamentous 
growth and objective MIC determination. This potential 
is considered by the subcommittee o f the European 
Committee on Antimicrobial Susceptibility Testing for 
reference methodology for in vitro AST of filamentous 
fungi. Based on these assays the entire concentration- 
effect curves o f antifungal drugs can be characterized 
and modeled, providing more information about the 
action o f antifungal drugs. Particularly for amphotericin 
B, for which the concentration-effect curve is very steep 
using twofold dilutions, a wider range o f dilutions (1.5- 
fold or arithmetically increased dilutions) would give 
more information about the antifungal action and might 
enable the separation o f resistant strains from 
susceptible ones, a critical problem of the current in 
vitro AST methodology.
The real time monitoring o f filamentous growth 
described in this thesis would enable not only the 
automation o f AST but also the modeling o f antifungal 
effects on filamentous fungi; possibilities which were 
precluded with visual determination o f growth. With 
this system the filamentous growth can be studied 
kinetically and the effect of antifungal drugs 
pharmacodynamically. In addition pharmacodynamic 
studies like the assessment o f post antifungal effects in 
filamentous fungi are facilitated with this system (13). 
Furthermore, the effect o f drugs alone or in 
combination, simultaneously or sequentially admi­
nistered, can be studied from the perspective o f the 
growth curves.
In vitro combination o f antifungal drugs is an 
area o f AST where more focus is needed, given the 
clinical implications o f the results obtained from 
combination studies. Although the Loewe additivity has 
fewer drawbacks as a reference zero interaction theory, 
the Bliss independence cannot be implicitly excluded. 
The differences between these two theories might 
reflect differences in mechanism o f action o f the drugs. 
Such conclusions require precise description of 
response surfaces o f each drug interaction excluding the 
noise, derived from experimental variations. This in 
combination with molecular studies on mechanisms of 
action of antifungal drugs would help to establish a zero 
interaction theory.
Fully parametric models are an attractive 
approach for analyzing drug interactions since they 
provide a quantitative measure o f the intensity of 
interaction including statistical analysis, reduce the full 
data set o f an experiment to a smaller set o f parameters
and facilitate prediction o f the response under new 
conditions. Furthermore, they are appropriate for 
complex situations such as three or four drug 
combinations, they have the potential to explain all the 
characteristics o f a complex system and they tend to be 
tolerant of a wider spectrum o f experimental designs. 
Finally, they are objective, rigorous, and consistent with 
modern statistical concepts and they can be used as the 
pharmacodynamic component o f composite pharmaco­
kinetic/pharmacodynamic models (6).
However, further investigation is required to find 
the best model for the interaction o f antifungal drugs 
given the inability o f the Greco model to describe 
precisely the response surface o f antifungal agents 
against fungi. Although, more than one model might be 
required to describe such interactions, the choice o f the 
best model would be difficult and to a certain degree it 
would be arbitrary. A good model should allow each 
agent’s individual concentration-effect curve to be 
different and accommodate more than two agents. It 
should describe synergy and antagonism in different 
regions of the concentration-effect surface and follow 
the correct course even in regions for which there are no 
data. Furthermore, it should closely follow the overall 
average data without following random fluctuations and 
include a data variation model for fitting data with 
modern statistical approaches.
Finally, the system of real time monitoring of 
fungal growth, the colorimetric methods in combination 
with modern approaches o f drug interaction modeling 
would equip the in vitro AST of filamentous fungi with 
powerful tools for thorough understanding of 
interactions o f antifungal drugs enabling the 
pharmacokinetic-pharmacodynamic modeling for 
filamentous fungi. In vitro data could be used to explore 
the benefits of combination therapy and to optimize the 
dosing regimens with an ultimate goal, to cure patients 
with opportunistic infections caused by filamentous 
fungi.
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